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ABSTRACT
This thesis looks at the condition under which sympathetic neurons (SCG) develop in order 
to understand the causes of selective vulnerability during ageing and therefore shows how 
pre-treatment in vivo with NGF at a specific point during development affects SCG 
neurons.
In summary, results show that following pre-treatment in vivo there is an increase in 
neuronal number, with differential effect on different subpopulations of neurons (MCA 
versus iris projecting neurons). MCA-projecting neurons (a vulnerable subpopulation of 
SCG neurons) increase in growth and innervation of specific target tissues following NGF 
pre-treatment in vivo, showing a maintained plasticity after termination of development and 
therefore a potential target site for future therapeutics.
NGF pre-treatment in vivo also increases neuronal survival time throughout life, showing 
that the limited supply of NGF in real life prime neurons to a reduced potential.
The results on survival also show a difference in the mode of action between the two major 
survival pathways (PI3-K and ERK), with PI3-K being the predominant in adult life and 
ERK acting mainly in early life. This shows a double survival mechanism which is plastic 
and capable of shifting predominance according to factors such as NGF stimuli and/or 
ageing.
Furthermore if the NGF pre-treatment in vivo is applied after termination of development, 
neurons show plasticity by developing an ‘addiction’ or dependance to NGF; pre-treatment 
termination results in death of the neurons.
Preliminary results show increase in Akt activity which is downstream of PI3-K, and is 
activated in NGF-dependent survival of SCG neurons (Pierchala et al., 2004). Biological
consequences of Akt activation are survival, increase in cell number and growth, which are 
all characteristics relevant also to cancer-cell growth.
Further preliminary results show an inhibition of GSK-3p pathways, which is downstream 
of Akt and is determinant for cytoskeletal rearrangement, glucose metabolism and cell 
survival; regulation of GSK-3p has been widely studied in relation to Alzheimer’s disease. 
In conclusions this research shows that sympathetic neurons are plastic and by priming 
tiiem with NGF, at a critical point during development, their survivability is increased. 
These results support the existence of a sensitive mechanism for adjusting neuronal 
capacity to resist cell death in response to neurotrophic factor deprivation.
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CHAPTER I
GENERAL INTRODUCTION
1.1 Anatomy and biology of superior cervical ganglia (SCG)
The SCG are positioned on each side of the neck and are an extension of the cervical 
sympathetic chain. SCG results form fusion of the upper four cervical spinal nerve ganglia, 
typically 3cm in length and spindle-shaped. It lies deep to the carotid sheath at the angle of 
the mandible; anterior to the lateral mass of the atlas and axis and is separated from them by 
the prevertebral fascia. The SCG receives preganglionic efferent fibres from the thoracic 
part of the sympathetic trunk; its branches have a complex distribution to supply blood 
vessels, glands and pilomotor muscles of the head and neck (see figure 1).
According to the neurotrophic hypothesis neurons are initially overproduced and their 
number subsequently refined by cell death through competition for trophic factors, which 
are synthesized in restricted amounts in target tissues. Sympathetic neurons transport NGF 
from their target tissues (Hendry et al., 1974) to the cell body where they influence the 
expression of neuronal genes and hence production of new proteins. Analysis of mutant 
mice with targeted disruptions of the genes for NGF and its tyrosine kinase receptor, TrkA, 
confirm the importance of NGF and TrkA for sympathetic neuron survival (Smeyne et al., 
1994).
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Figure 1.1: Anatomy and location of the superior cervical ganglia (by Young and Young, 1987).
1.2 Ageing and the nervous system
What is ageing at the molecular level and what are the cellular mechanisms that contribute 
to the characteristics we label ageing? Which changes can be avoided, compensated for, or 
postponed? Those, and many others, are the questions scientists and gerontologists 
normally ask themselves, and despite decades of research there is no clear answer as yet.
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What we know is that the nervous system plays a central role in ageing and therefore we 
asked ourselves: how does ageing affect the nervous system? In order to tackle this issue we 
need to step back and understand the basics of the developing nervous system. Despite the 
basic plan of the brain being virtually identical from person to person, during early life the 
fine details of the networks are influenced by electrical activity which determines a slightly 
different design for each one of us. Several variables are responsible for such differences, 
but the one we are focusing on in this research is a definite extra cellular environmental 
stimulus affecting the development of specific groups of sympathetic neurons.
1.3 Phenotypic plasticity
The field of biogerontology has been classified as the one that best defines ageing in 
sufficient detail to be able to design experiments (Hayflick, 2000). It is therefore the 
appropriate terminology to define this research approach, which aims to explain the specific 
mechanisms of cellular ageing and phenotypic plasticity. Phenotypic plasticity in this 
particular project focuses on the conditions under which neurons develop in order to 
understand the causes of selective vulnerability during ageing. Selective vulnerability is 
most readily remembered and appreciated in the context of neurodegenerative disorders 
such as amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease (AD), 
where specific populations of neurons tend to be affected by degeneration more than others. 
AD specifically might be defined as a faster than normal deterioration of the capacity for 
plasticity (Teter and Ashford, 2002). Neuroplasticity is related to both a substrate of 
learning and memory as well as to responses to neuronal attrition and injury (compensatory 
plasticity); which involves modulation of structural and functional processes of axons, 
dendrites and synapses. The processes manifesting plasticity include: synapses (electrical,
18
biochemical, structural), neurite (axon, dendrite), neuron cell bodies, anterograde (toward 
distal neurites) and retrograde (from distal neurites) transport, cell interactions (neuron- 
glia), and neural networks. Signal of plasticity include intemeuronal (anterograde and 
retrograde, transsynaptic and extra/parasynaptic) as well as intracellular signaling (Cotman 
and Nieto-Sampedro, 1984; Neill, 1995). This study is concentrating in neuron-target 
interactions, neurite, neuron cell body, retrograde and pathway signaling as well as neuronal 
survival.
1.4 Nerve growth factor (NGF) and other neurotrophic factors (NT)
One of the molecules playing a major role in plasticity of sympathetic neurons is nerve 
growth factor (NGF). NGF was discovered 50 years ago as a molecule that promoted the 
survival and differentiation of sensory and sympathetic neurons (Levi-Montalcini and 
Hamburger, 1951; 1953). The mature, fully processed form of biologically active NGF 
appears to be similar in all tissues and consists of a dimer of 13-kDa polypeptide chains, 
each of which has three intrachain disulfide bridges (McDonald et al., 1991; Taiwo et al., 
1991). NGF is normally produced in the mouse submandibular gland in response to stress 
(Fahnestock et al., 1991), and is part of the neurotrophin family of molecules sharing a high 
degree of structural homology and including brain-derived neurotrophic factors (BDNF), 
neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) (Butte et al., 1998; Ibanez, 1994; 
Robinson et al., 1995; 1999). NGF has two known receptors, TrkA and p75 (Bothwell, 
1995; Kaplan and Miller, 1997). TrkA is a single-pass transmembrane protein that serves as 
a receptor tyrosine kinase (RTK) for NGF signaling (Loeb et al., 1991). Sympathetic 
neurons express both TrkA and p75 and nonneuronal target cells of sympathetic and 
sensory neurons throughout the body produce NGF during development. These includes
19
targets in the skin, vascular (middle cerebral artery, MCA) and other smooth muscle cells, 
iris cells, various endocrine tissues, such as the testis the ovary, pituitary, thyroid, 
parathyroid, and endocrine salivary glands. Most of these cells produce NGF throughout 
adult life and their production is modulated in response to neuronal stimuli (Levi- 
Montalcini et al., 1995; 1996). See figure 2.
SURVIVAL
PI3-K PI-4,5-P
I-3,4,5-P3
PDK1
Bcl-X
14-3-3
Bcl-X.
Figure 1.2: Diagram o f NGF and PI3-K survival pathway.
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1.5 NGF and ageing
Intrinsic age-related reduction of retrograde NGF signaling may contribute to degenerative 
changes, the consequences of failing in NGF signaling can be both direct, by inducing cell 
atrophy, and indirect, by increasing the vulnerability of the atrophic neurons to other insults; 
for this reason the ageing nervous system is peculiar in its highly selective nature of 
neurodegenerative phenomena affecting differently different groups of neurons (Cowen, 
2002). In order to define and understand the determinants of selective vulnerability in 
neurodegenerative disease as well as in normal ageing, it will be important to determine 
neuron number according to specific classes of neurons, based on morphology and 
phenotype. However, how neurotrophic signaling contributes to adult neuronal plasticity 
and whether impairments in the system contribute to age-related neurodegeneration, is 
equally important.
Morrison and Hof (1997) studied how ageing tends to affect specific regions of the nervous 
system and subgroups of neurons; subset of neurons in the entorhinal cortex or gut neurons 
of the enteric nervous system (Cowen et al., 2000). Two supporting evidence for the 
selective vulnerability theory (Cowen, 2002) are first the concept of antagonistic pleiotropy 
described by Kirkwood and Austad (2000) where phenotype and patterns of gene 
expression that are advantageous in early life become disadvantageous during ageing. A 
specific example linked to my research is the adaptation of MCA neurons to low level of 
NGF during early development, which in later life renders MCA neurons more vulnerable 
to cell death.
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Secondly that lifespan maybe linked to the survival of key groups of cells, which, according 
to Wolkow et al. (2000) and Cowen (2001), might be neurons. Wolkow et al. (2000) 
showed that altered gene expression in particular neurons can affect lifespan.
Gavazzi and Cowen (1996) proposed a simple explanation of ‘neurotrophic hypothesis of 
ageing* where the availability of NGF in different target tissues would determine selective 
vulnerability of sympathetic neurons, this was contrasted by results of equal axonal 
degeneration between iris and pineal gland compared to MCA (Cowen et al., 1996; and 
Kuchel et al., 1999 respectively), suggesting that there is no differential reduction during 
ageing of NGF synthesis or protein level.
Changes in neuronal plasticity contribute to neurodegeneration; in fact neuronal plasticity 
can be defined as the responsiveness of a neuron to its surroundings including the capacity 
to respond to injury. Decreased plasticity of ageing sympathetic neurons has been shown in 
‘in vivo’ studies, including regeneration, collateral sprouting and synapse formation 
(Fawcett, 1992; Kuchel, 1993; Kuchel and Zigmond, 1991).
Plasticity in mature neurons is also shown by maintained responsiveness to NGF. 
According to Andrews and Cowen (1994) ageing sympathetic nerves sprout in response to 
NGF, even though signs of degeneration were present, indicating a high degree of plasticity. 
Little is known about why particular groups of neurons are more vulnerable than others to 
degeneration which is characterized by loss of synapses, dendrites, and axons. Cooper and 
Soffoniew (1996) looked at increased vulnerability of spatial cholinergic neurons to partial 
loss of target neurons in aged rats, finding an increased vulnerability with age. Several 
studies looked at selective vulnerability as an effect of neurotrophins (NT) availability on 
the recovery of nucleus basalis (Eriksdotter-Nilsson et al., 1989; Dekker and Thai, 1992;
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Dekker and Thai, 1993; Casamenti et al., 1994; Dekker et al., 1994; Chu et ah, 2001), 
substantia nigra (Camarata et al., 1992; Anglade et ah, 1997; Yurek and Fletcher-Tumar,
2001), motor neurons(Greeson et ah, 1992; Bergeron et ah, 1998), enteric neurons 
(Chalazonitis et al., 1998; Esteban et ah, 1998; Souberyre et ah, 2001; Chalazonitis et ah, 
2001),
According to Cowen et al (2003) a characteristic of the ageing nervous system is a 
differential selective vulnerability between particular groups of neurons. In this study they 
used SCG projecting to the MCA and the iris; MCA projecting neurons are more vulnerable 
(Thrasivoulou and Cowen, 1995), while iris neurons seem to be more protected (Gavazzi et 
ah 1996) from atrophic changes during old age. Cowen et al. (2003) studied receptor 
expression of TrkA and p75 on those two populations of SCG neurons and found that for 
both receptors during early postnatal life messenger RNA increases, on the other hand 
differentiations between receptors occur in mature adulthood and old age, where TrkA 
remain stable while p75 expression decreases. Furthermore they looked at iris and MCA 
projecting neurons and their expression of NT receptors and mRNA which has a substantial 
increase, in p75 and TrkA, in iris for both young and old rats. Conversely no effect on either 
age was detected in MCA projecting neurons. They suggested that lifelong exposure to low 
levels of neurotrophin combined with impaired plasticity of neurotrophin receptor 
expression is associated with vulnerability to age-related atrophy.
The hypothesis is that during postnatal life, levels of extrinsic neurotrophic factors set the 
activity of a neuronal maintenance program, which in turn in later life determines 
vulnerability to age-related neurodegeneration (‘developmental conditioning’).
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1.6 Ageing and selective vulnerability
Selective vulnerability during ageing has been observed in superior cervical ganglia (SCG) 
by Gavazzi et al. (1996), they looked at SCG neuronal projection to MCA which are 
characterized by loss of axons and dendrites, and, probably, neuron cell death, compared to 
SCG neurons projecting to the iris characterized by survival and continuing growth in old 
age. The two groups of neurons are physiologically and morphologically distinct. 
Differential behaviour of these two types o f neurons could be associated with the type of 
innervations, which is ‘multi-unit’, for MCA (characterized by a slower response to stimuli) 
and ‘single-unit’ for iris (rapid response). Furthermore MCA- and iris- projecting neurons 
differ significantly in the neurotrophic factor expression in their target tissues and in their 
neurotrophic uptake characteristics. According to Andrews et al. (1996) phenotypic 
adaptation of these subpopulations of neurons is an adaptation to their particular function. 
According to Morrison and Hof (1997) ageing is not associated with widespread losses of 
neurons in either the central or peripheral nervous system (Cowen and Gavazzi, 1998). 
Gatzinsky et al. (2004) looked at the role of NGF uptake in selective vulnerability to cell 
death in ageing sympathetic neurons, and concluded that neuronal vulnerability is 
associated with life-long low or high levels of NGF availability; MCA projecting neurons 
showing a 37% loss with ageing and no significant loss in iris-projecting neurons.
1.7 The neurotrophic hypothesis
The original neurotrophic hypothesis first proposed by Purves, (1988) states that structure 
and connections of developing and mature neurons are governed by their ongoing 
interactions with target tissues. The hypothesis arose from work on NGF (Levi-Montalcini 
et a l, 1975), which is the founder member of the neurotrophin family of secreted proteins.
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NGF, in the peripheral nervous systems (PNS), provides trophic support to sympathetic 
neurons. Neurons compete for a limited supply of neurotrophic factors, and therefore targets 
and neurotrophic availability regulate the population of innervating neurons (Korsching, 
1993). According to Davies et al. (1987) neurotrophin levels in target tissues increase 
rapidly when growing axons reach their targets and this coincides with the time when 
neurons become responsive to neurotrophins (Miller et al. 1991, and Wyatt and Davies 
1993). Furthermore in accordance with Davies (1996) results in the developing peripheral 
nervous system many neurons die shortly after their axons reach their target fields, this 
might be due to the fact that target fields requirement and size determines the number of 
neurons surviving. In fact, once neurons grow into their targets they either form a synapse 
and begin to establish the functional connections that characterize the mature nervous 
system, or they die. Studies on timing of neuronal death have shown that sympathetic 
neurons become dependent on the supply of two neurotrophins, NGF and NT3, at the time 
or just before they begin to innervate their targets (Crowley et al., 1994; Wyatt et al., 1997; 
Francis et al., 1999). Neurons, when they reach the target tissues, become dependent on the 
trophic factor supplied by the target tissues for survival and differentiation. During 
neurogenesis there are initially more neurons sending axons to the target tissues than there 
are cells in the tissue, this initial overabundance is believed to ensure that all target cells 
receive innervation from axons, and competition of numerous neurons ensures that only 
those neurons that make functional connections will persist into the mature nervous system. 
Thus, although initially there is a lot of trial and error in proper matching between neurons 
and their targets, in adulthood no cells will be uninnervated and no surviving neurons will 
fail to make synapses. Neurons in the developing brain go through a period when they are
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dependent on trophic factors in order to survive, and their targets go through a period when 
they can produce and secrete those factors. Different regions of the brain, or different kinds 
of neurons, become sensitive to one or a few neurotrophic factors, and make receptors for 
those factors, and their targets produce only one or few such factors, in limiting amounts 
(Davies, 1996; Bibel and Barde, 2000).
1.8 Superior cervical ganglia (SCG) dependence on NGF
While SCG neurons are dependent during perinatal development on NGF for survival and 
growth during early postnatal life they become independent of NGF for survival but remain 
NGF dependent for growth (Easton, et al., 1997; Orike, Thrasivoulou et al., 2001; Orike, 
Middleton et a l, 2001). Because of the continued dependence of sympathetic, sensory and 
hippocampal neurons on neurotrophins for growth during adulthood, it is believed that 
specific trophic factors are instrumental in helping responsive neurons recover from injury 
or disease (Diamond et al., 1992; Crutcher, 2002).
Synaptogenesis is a complex process involving a diverse set of molecular signals between 
the neuron and its target; the target cell send signals to the neuron that induces the growth 
cone to stop growing and convert into the stationary structure of the nerve terminal, that 
develop synaptic vesicles, active release sites, voltage-dependent calcium channels, and all 
the necessary machinery for production and release of neurotransmitter, as well as reuptake 
of transmitters and recycling of vesicle membrane.
Neuron sends signal to its target that induces the target cell to produce appropriate 
receptors for transmitters and neuropeptides, to consolidate the receptors at high density at 
the same location as the nerve terminal, and to assemble all the necessary signal 
transduction and second messenger pathways necessary for proper postsynaptic response to
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transmitter; for the most part the nature of the molecular signals in the nervous system 
remains mysterious, and therefore constitutes an area for much research (Vrbova et al., 
1999).
1.9 Signaling and survival pathways
Neurotrophins bound to receptors are then internalized by retrograde transport to the 
perikarya, where they provide signals in the key processes affecting neuronal survival and 
differentiation. SCG neuronal responsiveness to trophic factors is mediated by the trk 
tyrosine kinase family and the low-affinity p75 receptors whose expression may change 
during development (Bothwell, 1995). Recent studies have suggested the role of PI3-K in 
SCG survival.
Belliveau et al. (1997) showed that NGF promotes sympathetic neuron survival by acting 
via TrkA. Ligand binding triggers dimerization and autophosphorylation on tyrosine 
residues forming docking sites for the adaptor protein, She, PLCy, and SHP, resulting in 
activation of several signaling pathways:
■ Shc/Grb2/Gabl-dependent activation of phosphoinositide 3-kinase (PI3-kinase) 
(Holgado-Madruga etal., 1997);
■ Shc/Grb2/Sos-dependent activation of Ras, leading to activation of ERK/MAP-kinase;
■ PLCy -mediated generation of DAG and inositol triphosphate (Kaplan and Miller, 1997). 
Genetic studies on Caenorhabditis elegans (Hekimi et al, 1998) shows PI3-kinase as a 
central element in controlling lifespan; this is evident in the homology of the insulin-like 
signaling pathway that contributes to cell survival in mammalian neurons and to longevity 
regulation in C. elegans, Drosophila and other organisms. PD-K and the Forkhead family
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are homologous to age-1 and daf-16, and IGF-1 is orthologous to daf-2. According to 
Feldman et al. (1997) and Gorio et al. (1999) the pathway resembles that of survival and 
growth responses to neurotrophic factors present in central and peripheral neurons (Cowen
2002); with the only exception that down regulation of age-1 in C. elegans results in an 
increase in lifespan while a decrease of PI3-K in mammals results in a decrease of cell 
survival.
Numerous studies have considered the importance of class IA PI3-K for a multitude of 
cellular functions including cell survival, growth, proliferation, intermediary metabolism, 
and cytoskeletal rearrangements (Vanhaesebroeck and Waterfleld, 1999; Shepherd et al., 
1997).
PI3-K catalyze the phosphate to transfer to the 3’-OH position of inositol lipids, producing 
phosphatidylinositol-4,5-biphosphate(PIP2), and phosphatidylinositol-3,4,5-triphosphate 
(PIPj), which act as second messengers by recruiting proteins containing pleckstrin 
homology (PH) domains to the plasma membrane to assemble signaling complexes 
(Vanhaesebroeck et al., 2001). In vitro experiments have shown an intrinsic protein serine 
kinase activity of class I PI3-K (Vanhaesebroeck et al., 1999). The form of IA PI3-K is 
typically a heterodimer with an 85-kDa regulatory subunit (identified as p85a and p85p) 
and a 110-kDa catalytic subunit (pi 10a, pi 1 Op, and pi 108), and is regulated by a range of 
mechanisms acting via the various modular domains of the subunits. P85a and p85p are 
products of different genes and several splice variants of p85a exist; a third gene product 
p55y has also been identified. The pi 10a and p isoforms are widely expressed, whereas the 
8 is expressed predominantly in leukocytes. The functional consequences of this protein in 
vivo are different (Foukas et al., 2004; Hunter, 1995). Phosphorylation of the sole PI3-K
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phosphorylation site Ser608, by p85a, plays a role as a shutoff switch in growth factor 
signaling and contributes to the differences in functional properties of different PI3-K 
isoforms in vivo.
Crowder and Freeman (1998) first looked at the potential survival signals mediated by PI3- 
K to test the Akt functions during NGF mediated survival in rat SCG neurons; Akt is an 
effector protein kinase of PI3-K. PI3-K and Akt are both necessary for the survival of NGF- 
dependent sympathetic neurons. Furthermore in a wide range of tumour types PI3-K is over 
activated, causing Akt phosphorylation, which in turns triggers a cascade of responses, from 
cell growth and proliferation to survival and motility.
Akt, which is also known as PKB (protein kinase B) encodes a serine/threonine kinase that 
has an amino-terminal PH domain, a central catalytic domain and a short carboxy-terminal 
regulatory domain. There are three members of the Akt family (Aktl, Akt2, and Akt3); and 
Akt is activated by a dual regulatory mechanism that requires both translocation to the 
plasma membrane and phosphorylation at Thr308 and Ser473 (Andjelkovic et al., 1997; 
Bellacosa et al., 1998). The generation of PIP3, on the plasma membrane, following by PI3- 
K activation, recruits Akt by direct interaction with its PH domain. At the membrane level 
3-phosphoinositide-dependent protein kinase-1 (PDK-1) phosphorylates AKT at the 
Thr308, but maximal activation is obtained by phosphorylation of Ser473 by PKK-2 (Alessi 
et al., 1997). Although models of Akt activation are fairly clear, there is very little insight 
into how Akt is down regulated after activation (Andjelkovic et al., 1996; Maira et al.,
2001). The main biological consequences of Akt activation are survival, proliferation 
(increased cell number) and growth (increased cell size). Akt effect on survival pathway is 
by stopping PTEN (phosphatase and tensin homologue deleted from chromosome 10)
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mediated apoptosis (Li et ah, 1998). The tumour suppressor PTEN is a dual-specificity 
phosphatase that plays a functional role in cell cycle arrest and apoptosis (Di Cristofano and 
Pandolfi, 2000; Simpson and Parsons, 2001). Constitutive activation of Akt is common 
event in cancer cell that have lost PTEN function because of either chromosomal deletion 
or mutation (Wang et al., 1998). Activated Akt protects cells from apoptosis by 
phosphorylating and inactivating proapoptotic substrates such as BAD, procaspase-9, and 
forkhead family transcription factors (Nakamura et al., 2000) Akt also prolongs cell 
survival by delaying p53-dependent apoptosis through Mdm2 phosphorylation (Zhou et ah,
2002). Expression of exogenous PTEN in mutant cells restores the endogenous pattern of 
Akt phosphorylation and therefore sensitivity to apoptosis induced by various proapoptotic 
stimuli (Frisk et al., 2002). A recent study in Drosophila, by Stocker et al. (2002), reports 
that phenotype of PTEN loss in flies (lethality) is rescued by a PH-domain mutant Akt that 
lacks the ability to bind PIP3; indicating that Akt might be the only important effector of 
PIP3, even though there are still no evidence of the same effect in mammals.
Akt also affect proliferation by preventing degradation, regulating the activity of the 
glycogen synthase kinase-3p (GSK-3J3) (Diehl et ah, 1998). GSK-3P was the first substrate 
of Akt to be identified, and its phosphorylation by Akt is inhibitory (Cross et ah, 1995), 
resulting in binding of the phosphorylated N-terminal residues of GSK-3p to its phosphate- 
docking motif which in turn inhibits phosphorylation of substrates (Dajani et ah, 2001; 
Frame et ah, 2001). Inhibition of GSK-3p plays a role in inhibiting apoptosis in neuronal 
cells. Ding et ah (2000) found that over expression of a GSK-3p inhibitor protein promotes 
neuronal cell survival in response to inhibition of PI3-K. Furthermore, selective and potent 
small-molecule inhibitors of GSK-3p have recently been developed, termed SB-415286 and
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SB-216763 (Coghlan et al., 2000) and these together with lithium (GSK-3{3 inhibitor) have 
been shown to protect both central and peripheral nervous system neurons in culture from 
death induced by reduced PI3-K pathway activity (Cross et al., 2000). The proteins that 
GSK-3p phosphorylates to induce apoptosis remain to be defined. GSK-3J3 is of medical 
importance being involved in metabolic control, animal development, and oncogenesis 
(Harwood, 2001).
In addition to its role in proliferation, there is growing evidence that Akt also affects cell 
growth. Recent studies showed the protein mTOR (also known as FRAP1) as the central 
regulator of cell growth; it is a serine/threonine kinase functioning as molecular sensor 
regulating protein synthesis according to availability of nutrients, mTOR is a direct target of 
Akt (Nave et al., 1999).
Summarizing NGF is necessary for survival during early stages of survival and perturbation 
of NGF levels later in life results in phenotypic changes, affecting SCG growth; Campenot 
(1977) demonstrated that local NGF regulates the advance of sympathetic neuron growth 
cones.
In addition to NGF there are other neurotrophic factors affecting neurons, including: Brain- 
derived neurotrophic factor (BDNF), glial cell derived neurotrophic factor (GDNF), insulin­
like growth factor (IGF), and insulin (Sofroniew et al., 2001; Hallbook ,1999).
BDNF doesn’t seem to affect directly SCG neurons survival (Huang and Reichardt, 2001; 
Brady et al., 1999); even though the BDNF-activated trkB/IRR (insulin receptor-related 
receptor), elicit activation of a signaling cascades, resulting in a PI3-K survival response, in 
SCG neurons (Kelly-Spratt et al., 2002).
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Members of the GDNF family of ligands do play essential early roles in development of 
SCG (Huang and Reichardt, 2001). According to results from a study carried out by Durbec 
et al., 1996), the requirement for GDNF precedes the dependence of SCG neurons on NGF 
and TrkA; mice lacking c-ret, the tyrosine kinase activated by GDNF, were shown to lack 
all neurons in the SCG without any obvious phenotype in the sympathetic chain at the trunk 
level. According to Tsui-Pierchala et al. (2002), NGF-dependent ret phosphorylation 
regulates soma size and metabolism but not survival of adult rodent SCG neurons. 
Sympathetic neurons are known to possess insulin receptors of the peripheral type (similar 
to those of hepatic and fat cells, rather than the brain type which shows dual specificity for 
both insulin and insulin-like growth factor (IGF-1)) for both insulin and IGF-1 (Karagiannis 
et al., 1997). According to Zackenfels et al. (1995), insulin and IGFs have a role in the 
control of neuron and neurite outgrowth in sympathetic neurons. According to Bitar et al. 
(1997), IGF-1 is not only implicated in development, survival and maintenance of 
sympathetic and sensory neurons, but neurons are affected during the course of diabetes. 
Diabetes caused a decrease in IGF-1 and its receptor proteins in SCG neurons, while insulin 
partially prevented such depletion. Similar results in the central nervous system where 
according to Fukudome et al. (2003) IGF-1 greatly promoted dendritic growth and survival 
of Purkinje cells in mammalian cerebellum. IGF-1 seems to up-regulate, among others, the 
signaling pathways involving PI3-K.
Ookuma et al. (2003) showed a different effect in the insulin-like ageing pathway of 
c.elegans, by identifying a target of DAF-16, the transcriptional regulator that extends 
lifespan when the insulin-related pathway is down regulated.
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Dillin et al. (2002) looked at the age specific timing requirements for insulin/IGF-1 
signaling in C. elegans; concluding that life-span regulation can be dissociated temporally 
from phenotypes.
1.10 Chapter division
The thesis aims to tackle several of the topics mentioned above in detail and some other 
topics are only forming a basis of preliminary results for further research. Chapter II expose 
the methodology used to develop the research; while chapter III is the first research chapter 
and studies the characterization of age-related neuron cell loss (cell counting) in vivo and 
how subpopulations with different phenotypes (MCA versus iris) are affected with age, 
before and after the in vivo pre-treatment regime, as well as when pre-treatment in vivo 
have been applied late (i.e. late treatment group). Neurite growth have also been measured 
(retrograde tracing and axonal arborizations) across ages and following either early or late 
pre-treatment in vivo with NGF. Furthermore this research looked at the effect of pre­
treatment in vivo on nerve fibre degeneration (nerve density was measured using imaging 
and data analysis by counting the number of intercepts per millimetre (I.D. per mm)), 
specifically using subgroups of sympathetic neurons in the SCG: MCA and iris; initially 
three more targets have been considered: skin, sweat glands and SCG ganglia, but due to 
lack of initial results the last three targets have been abandoned.
Chapter IV looked at mechanisms mediating neuronal vulnerability to age-related 
neurodegeneration and considered the survival and mortality patterns in vitro before and 
after pre-treatment in vivo across ages, as well as when treatment have been applied late. 
Furthermore the effect of pre-treatment in vivo have been studied on subpopulation of 
neurons (MCA and iris), to observe possible alterations of survival and mortality pattern.
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External neurotrophic factors may have an effect on survival of SCG neurons: insulin, IGF, 
BDNF, GDNF, those have been studied in vitro before and after pre-treatment in vivo with 
NGF.
In chapter V the signaling pathways affecting growth and survival in adult and ageing 
neurons have been studied by investigating effects of age and treatment. The research 
concentrated on the effect of inhibition of survival pathways (such as PI3-K and Erk) across 
ages with early or late pre-treatment in vivo with NGF. Furthermore p-Akt and GSK-3p 
upregulation was observed after early and late pre-treatment in vivo, and form preliminary 
results for further research. Chapter VI aims to analyze and discuss the entire research 
results into a broader biological context.
1.11 Aims
This PhD research intend to look at the developmental conditioning, by altering NGF 
availability to sympathetic neurons, at a critical time, at 3 weeks old, before maturation; the 
effect of the conditioning is then observed at different stages of maturation. Two major 
target tissues, MCA and iris, are considered in order to determine how selective 
vulnerability is affected by a developmental conditioning in early age. The research 
objectives focus on manipulation of trophic factor availability, using NGF and NGF 
specific antibodies during early postnatal life or after termination of development at three 
months old in rat SCG neurons.
Developmental conditioning affects survival and growth, based on the suggestion that high 
NGF levels are associated with neuronal protection against age-related degeneration. Key
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regulator of signaling pathway are studied, PI3-K, Erk, Akt, GSK-3p in order to see the 
effect of exogenous factor during early postnatal life.
1.12 Hypothesis
The main hypothesis is that altering NGF availability during early postnatal life will 
increase survival and neuronal plasticity and decrease age-related neuron cell loss and fibre 
atrophy, in adult and ageing neurons. Treatment after the termination of development is not 
expected to have similar effects. Changes in NGF availability are predicted to affect some 
subgroups of sympathetic neurons (those projecting to the MCA) more than others (those 
projecting to the iris).
I hypothesize that increased plasticity resulting from altered availability of NGF will occur 
as a consequence of changes in the signaling pathway (mainly PI3-K).
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CHAPTER II
MATERIAL AND METHODS
2.1 Animals
The rat {Sprague Dawley) is a standard mammalian model organism, widely used in 
neuroscience, ageing, and developmental studies. It has been studied and used 
extensively because it is easily obtainable, relatively inexpensive, readily maintained 
and cared for, and for having several characteristics similar to humans, being a mammal. 
Male rats have been regularly used in our laboratory for other studies and are kept in 
groups of 3 per cage and fed ad libitum on a dry pellet diet at constant 12hr light/dark 
cycle and temperature was controlled at 17°C. The average lifespan of a rat is 2 years, 
weaned at 3 weeks, and reaches maturity at about 3 months old. All animals were raised 
in the Royal Free Hospital School of Medicine comparative biology unit, all rats were 
subject to regular veterinary inspection and all the experimental procedures used were 
licensed by the Home Office.
2.2 Experimental design and in vivo pre-treatment regime
A target sample size of nine male animals per group per-treatment was judged to be the 
minimum required for this study. The age groups used are:
1. Two ‘acute’ groups (examined immediately after treatment, at about seven 
weeks old);
2. Four ‘eight months’ groups (examined 6 months after termination of treatment);
3. One ‘eighteen months’ group;
4. One ‘twenty-four months’ group;
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5. One ‘late treatment’ group (i.e. treated after development);
6. One ELISA group (group size and treatment regime are explained in section 
2.6).
There are two acute groups in order to provide a repetition to consolidate the data; the 
eight month group has been also repeated once. One more eight months group was 
prepared for examination of loss of subpopulations of neurons, this was analysed either 
in vitro (on dissociated cultured neurons in absence of external growth factor support), 
or ex vivo on frozen sections of SCG (using cell counting following retrograde tracing).
Two sub-populations of SCGs are examined: one projecting to the iris, characterised by 
single-unit innervation and considered the less susceptible to external insult (Cowen, 
1993; Gavazzi and Cowen, 1996), and one projecting to the middle cerebral artery 
(MCA), characterised by a multi-unit innervation and regarded as being the more 
vulnerable of the two.
The treated tissue used from the animals was either superior cervical ganglia (SCG) for 
in vivo and ex vivo experiments, or iris and middle cerebral artery (MCA) for ex vivo 
experiments. Initial experiments were carried out with skin and sweat glands as well, 
but lack of significant data caused us to abandon these last two tissues.
The in vivo treatment is a manipulation of trophic factor availability, using exogenous 
growth factor (Nerve Growth Factor or NGF, 2.5S, Murine; from Promega) and specific 
antibodies (anti-NGF, kindly supplied by Dr Robert Rush at Flinders University, 
Australia) during early postnatal life; treatment started at three weeks old or after 
maturation in the case of the late treatment group which is starting at three months old.
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Animals have been subsequently examined, either immediately after treatment (i.e. 
acute group) six months after termination of the treatment (8 months group), 16 months 
after treatment (18 months group) and 22 months after treatment (24 months group). 
The NGF antibodies (anti-NGF) were kindly supplied by Dr. R. Rush who published 
several articles on the effect of anti-NGF on SCG neurons (Zhou and Rush, 1996; Zhou 
et al., 1994; Lees et ah, 1981). Anti-NGF injections produced pain and localized 
inflammation, therefore to assess such effect a second control was introduced, pre- 
immune serum. The control for NGF was cytochrome-C and for the initial acute group a 
further untreated control was included, and showed no difference compared to 
cytochrome-C.
The only information available on similar administration of NGF is from Tria et al. 
(1994) where they have carried out some studies on pharmacokinetics of murine NGF. 
The treatment used in this experiments consists of three subcutaneous injections per 
week of 4.5pg of NGF, anti-NGF, or cytochrome-C (used as a control in all the groups), 
for a duration of four weeks (0.09 pg/gm). NGF has been dissolved in sterile water and 
proper concentration for injection has been diluted in PBS; cytochrome-C has been 
diluted in PBS as well. Initially two different concentration of NGF have been tested in 
order to understand the most suitable (see figure 2.1).
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Figure 2.1: NGF dose trial of in vitro serum free cell culture following high (4.5 pg) versus low (1.5ug) doses of 
murine NGF subcutaneous injections on SCG neurons. High dose is symbolized with the solid black diamond 
line; low dose is a black empty diamond; control is a solid grey square line.
More specifically we characterized (1) neuron cell loss and nerve fibre degeneration 
(using morphometry on ex vivo tissues), (2) loss of subpopulations of neurons (using 
cell counting following retrograde tracing and in vitro dissociated neurons), (3) in vitro 
survival and growth of adult and ageing SCG neurons including subpopulations of 
neurons and the factors and pathways involved (using dissociated cell culture) in serum- 
free medium.
As the treated rats may constitute a model for studying ageing in SCG neurons we also 
started to consider further mechanisms (factors, and intracellular signalling pathways) 
mediating neuronal vulnerability to age-related neurodegeneration.
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2.3 Bilateral surgical sympathectomy
Rats were scarified, a mild incision was made and tissue retracted. The stemomastoid 
muscle was cut at the insertion and reflected medially to expose the sternohyoid and 
omohyoid muscles. These were reflected medially to expose the bifurcation of the 
common carotid artery which was exposed and retracted laterally to expose the superior 
cervical ganglion (SCG). SCGs were carefully removed making sure to remove all 
lobes of the ganglion up to the post ganglionic internal and external carotid trunks.
2.4 Retrograde neuronal tracing with FluoroGold
Rats were anaesthetized with halothane and their heads fixed firmly in a stereotactic 
head frame. For MCA projecting neurons, a mild-line incision was made in the scalp 
and tissue retracted to expose the cranium. The temporalis muscle was gently teased 
away at its superior aspect where it is attached to the temporal bone and undermined to 
expose the temporal bone beneath. After retracting the temporalis muscle, a small hole 
was drilled into the temporal bone, lateral to the sagittal suture with a dental burr. A 
small cut in the dura mater overlying the MCA allowed a small piece of foam pre­
soaked in 2pi of 2% FluoroGold (from Fluorochrome, Inc.) to enter and was placed over 
the MCA under the dura mater. A small piece of antibiotic gauze was placed over the 
dura mater, the temporalis muscle was returned to its original position and the operation 
site sutured. For iris-projecting neurons an injection in the anterior chamber of each eye 
with lpl of 2% FluoroGold was performed under anaesthesia as above.
2.5 Immunostaining
Growing SCG neurons used for growth assay were fixed for 20 minutes in 4% 
performaldide and washed 2 times in sterile PBS, immunostained using, as primary
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antibodies, mouse monoclonal Tuj (neuron-specific tubulin-1; from Biochem) 1:500 
overnight and washed twice in PBS and as fluorescent secondary, goat anti-mouse IgG 
conjugated to FITC (Molecular Probes Alexa Fluor 488) at a concentration of 1:400 for 
1 hour all at room temperature and washed twice in PBS. Antibodies proper 
concentration was reached using a diluant of Hepes containing 1% goat serum, 0.1% 
sodium azide ,0.1%  DL-Lysine and 0.1% triton when used for GSK-3P measurements, 
after Tuj staining, BUGS (courtesy of Dr. P. R. Gordon-Weeks) antibodies were applied 
for 2 hours and washed twice with PBS. BUGS is an affinity purified rabbit polyclonal 
against a glycogen kinase-3 p phosphorylation epitope on MAP IB. In neuronal cultures 
BUGS labels cell bodies and axons and, when they reach a certain length, the staining of 
axons is graded with growth cone having the highest levels; it was used routinely at a 
concentration of 1:200 on cultures with goat anti-rabbit fluorescent secondary 
(Molecular Probes Alexa Fluor 568) at 1:400 concentration for 1 hour following by two 
washes in PBS. SCG neurons on coverslips used for measuring phospho-Akt where 
stained using mouse monoclonal primary antibodies at a concentration of 1:200 for 2 
hours following by two washes in PBS, and fluorescent goat anti-mouse secondary 
antibodies (Molecular Probes Alexa Fluor 568) concentrated 1:400 for 1 hour and 
washed twice.
Iris and MCA whole mounts where immunostained with Tyrosine Hydroxylase (TH 
rabbit pAb, polyclonal antibodies). The whole mounts where first fixed for 2 hours in 
4% performaldide, and then washed twice for 10 minutes in Hepes buffer. Half an hour 
wash in 0.1% Triton and goat serum and 3% Hepes buffer in order to increase 
antibodies penetration into the tissues. TH was applied in concentration of 1:50 
overnight; followed by three times ten minutes washing in PBS (was used in these last 2 
sets of washing in order to create affinity with the mounting Citiflour which PBS
based). The secondary antibodies used are goat anti rabbit Alexa red, in concentration of 
1:200 for an hour and an half, followed by three times ten minutes wash in PBS and 
mounting in Citiflour.
2.6 Cell-Death ELISA
Potential criticism in the treatment regime might be that by treating SCG neurons during 
development with NGF we might be killing the vulnerable neurons, and therefore using 
a subset of the entire population for these studies. In order to overcome this problem we 
decided to test levels of apoptosis at different times during treatment by using a cell- 
death detection ELISA kit (Promega, UK), a photometric enzyme-immunoassay for the 
quantitative and qualitative in vitro determination of cytoplasmic histone-associated- 
DNA-fragments (mono- and oligonucleosomes) after induced cell death. The kit used 96 
plates and is a 3 hours procedure; the samples, solutions and reagents were prepared 
according to the ‘Roche Applied science protocols’. The data analysis was as follows:
- average of the value from the double absorbance measurements o f the samples 
(measured using a luminescence microplate reader Dynex Technologies, MRX);
- subtracted the background value of the immunoassay from each of these 
averages;
- calculated the specific enrichment of mono- and oligonucleosomes released into 
the cytoplasm from these values using the following formula:
o enrichment factor = mU of the sample (dying/dead eells)/mU of the 
corresponding negative control (cells without CAM treatment)
■ mU = absorbance [1 O'3 ]
Three groups of six animals per treatment, as well as an untreated control were set aside, 
resulting in three repeats and 2 replicates per treatment. One group was treated with
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either NGF or CYT-C (Cytochrome-C) for one week and tested. The second group was 
treated for four weeks, standard regime, and tested and the third group, composed of 
four animals, was not treated at all.
2.7 Imaging, morphology, densitometry and physical dissector
Nerve fibre degeneration was measured using morphometry on ex vivo tissues (i.e. 
MCA and iris), neuronal outgrowth was measured on in vitro dissociated cultured SCG 
neurons; GSK-3p and p-Akt activation was estimated by densitometry. Neuronal cell 
loss was calculated on preparations of ex vivo tissue, 15pm thick frozen sections of 
SCGs.
Animals scarified for neuronal cell loss calculation were killed by carbon dioxide 
asphyxiation at 48 to 72 hours after tracing operations were performed. Animals were 
perfused with 150 to 300ml (depending on age and size) of 4% paraformaldehyde (PFA) 
in PBS through the left ventricle after placing a haemostat on the thoracic aorta. SCG.s 
were dissected, taking care to preserve the rostral pole of the ganglia where the majority 
of neurons are found, the ganglia are subsequently pinned to a silgar block and fixed for 
two hours on a shaker. Following fixation ganglia have been washed in phosphate- 
buffered saline (PBS), kept at 4°C overnight in 15% sucrose PBS and frozen at -70°C in 
moulds with O.C.T. cryoprotectant until sectioning using a cryostat (Bright Instrument 
Company Ltd.) and all sections were positioned on Superfrost slides (Polysine, Manzel- 
Glaser). The area of every section was traced and measured and complete average 
volumes for each ganglion calculated. The total number of neurons per ganglia was 
counted on a Nikon fluorescence microscope and a x20 planapo objective and 
estimated using the average volume data calculated from the completely sectioned 
ganglia as follows:
Total number= (average volume of whole ganglion / volume of counted section) x mean 
number of labelled neurons counted per section.
The physical disector (Gundersen, 1986) method was used for correction of 
overestimation of cell numbers in order to be able to count the number o f neurons cell 
body every fourth section and use the adjacent section as a look up one, following the 
physical disector method used in Williams and Rakic (1988).
Microscopical image analysis for acquisition of images and subsequent analysis of in 
vitro tissue was achieved using the established methods of image analysis Cowen and 
Thrasivoulou (1992) using the Kontron, KS400 computer programme with an attached 
Zeiss AxioCam. Image analyser interfaced to a NIKON fluorescence microscope via a 
low light video camera. An image was taken in, with standardised optimal gain setting 
and integration time of the camera. The measurements taken for tissues analysis (i.e. 
MCA and iris) were:
■ Nerve density (expressed as area % of the field covered by nerves);
■ Intercept density (measured as the number of nerve bundles that transacted a 
grid of lines and expressed as intercepts per mm);
The measurements taken for neurite growth are:
■ PI = cell body;
■ P2 = perimeter at half-maximum radius;
■ P3 = circumference;
■ TNL = total neurites length;
■ AREA P 1 P 3  = area covered by neurites;
■ AREA CELL;
■ Pid 1 = number of intercepts at half-radius;
■ GV cell = integrated grey value o f the whole cell (for measuring growth of 
BUGS and p-Akt);
■ GV mean = mean grey value per pm2 for whole cell.
Densitometry for measuring growth BUGS and p-Akt differential activation due to pre­
treatment in vivo have been analysed using KS400 programmed written appositely (see 
figure 2.2).
Figure 2.2: Example of BUGS immunostaining (left red panel) and Tuj (right green panel) on the same 
cultured SCG neuron.
2.8 Cell culture and survival/mortality counting
SCG were dissected, dissociated and cultured as described by Orike et al. (2001). 
Dissected SCG were collected in Hanks' balanced salt solution (HBSS- Gibco BRL, 
UK; cat.no. 14170-088). The SCG were desheathed carefully under a dissecting 
microscope to remove all surrounding connective tissue, ganglia were than cut into 8 to 
12 pieces (depepnding on the age o f the donor). The pieces o f  ganglia were treated with 
enzymes; first they were incubated in 2ml HBSS + lOmM HEPES buffer (Sigma, UK; 
cat. no. H0887) containing 800iu collagenase (Sigma, UK; cat.no. C9891) and 12mg 
bovine serum albumin (BSA; Sigma, UK; cat.no. A8806); secondly, after two washes in
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HBSS, the pieces of ganglia were incubated in 2ml HBSS containing HEPES and BSA 
as before plus 2mg trypsin (Sigma, UK; cat.no. T2271); following by two washes in 
HBSS. Times of incubation veried according to the age of the tissue: collagenase 
between 20 and 35 minutes, and trypsin between 30 and 45 minutes. Neurons were than 
dissociated with sequential mechanical trituration in a small volume (0.5ml) of culture 
medium (Ham’s F-14, Imperial Labs, UK, pH 7.4) supplemented with 2mM glutamine, 
0.35% BSA, 60ng/ml progesterone, 16g/ml pultrescine, 400ng/ml L-thyroxine, 38 ng/ml 
sodium selenite, 340ng/ml tri-iodothyronine, 60g/ml penicillin, lOOg/ml streptomycin 
and lOmg cytosine arabino-furanoside (all Sigma, UK). Trituration was performed using 
fire-polished glass pipettes with a bore diameter at the tip of 0.05-0.1mm. A maximum 
of two ganglia were triturated at any one time. Two factors are critical in the production 
of viable dissociated neurons, firstly the ganglia pieces have to be of the right size to fit 
the bore of the pipette quite tightly, thus being subject to some shearing stress as they 
passed through the tube; secondly a maximum of 2 or 4 triturations were performed 
following by removal of cells by decanting the supernatant medium. Fresh medium was 
then added and a further 2 or 4 triturations were carried out before the cells were again 
removed. These sequential triturations were repeated as many times as it took to remove 
the majority of the neurons, which again varied according to the age of the donor. 
Before plating, the decanted supernatant aliquots cantaining dissociated cells were 
pooled and non-neuronal cells removed by differential sedimentation (Davies, 1986). 
Differential sedimentation consists of allowing the cell suspension to sedimentate for 1 
hour through a dropping funnel containing Ham’s F-14 medium plus 10% heat- 
inactivated horse serum (Gibco). Separate 5ml fractions were removed and a 0.5ml 
sample from each was examined under phase contrast microscopy for the presence of 
non-neuronal cells. Fractions containing neurons only were pooled , and spun at lOOOrcf
fro 3min. After removal of the supernatant, neurons were gently resuspended in culture 
medium and counteded in a small droplet of medium of known volume. From the 
counts estimates the total number of dissociated neurons , and hence the approximate 
proportion of the total numbers of SCG neurons dissociated from each ganglion.
Neurons were cultured on coated coverslips (19mm round coverslips; Coming) in 
culture plates (NUNC, Coming) in serum-free medium with no addition of growth 
factors and the density of plating was kept constant at about 500 cells per coverslip. 
Coverslips were first treated with acetone, ethanol and 1 molar hydrochloric acid, and 
then marked specifically for counting survival/mortality of neurons. Coating of 
coverslips was performed in two phases, a primary coating with 0.5mg/ml poly-d-lysine 
(Sigma, UK; cat.no. P6407) overnight and a second with 20pg/ml laminin (Sigma) for 4 
hours.
The survival/mortality data were gathered by counting one horizontal strip of 
microscope fields on the coverslip starting from the mark on one side to the opposite 
side (see Figure 2.3), the strip contains about 70 to 100 cells, counting intervals were of 
about 12 or 24 hours depending on whether it was a mortality or a survival assay 
respectively; the number of live (phase-bright) cells was recorded using a Nikon 
Eclipse inverted microscope TE300 with phase optics and a motorised stage controlled 
by joystick with electronic coordinates. Cultured neurons survived from a minimum of 
one week to about 3 weeks after dissociation.
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Box visible only from the ocular
piece on the microscope
Mark indicating
i9mm diameter
start of counting
Fig. 2 J :  Characteristic o f  the coversiips used for grow ing neurons and mode o f counting for survival/mortality 
assay; the grey arrow indicates the direction o f counting.
2.9 Survival vs. mortality plotting and analysis
Mortality and survival are both important because they explain different cellular 
changes. Mortality isolates only one of the two important components of ageing; the 
physiological degeneration even in the absence of age-specific changes in mortality, the 
other important element is the effect of treatment which is explained better with the 
survival plots. Biologists, ecologists and gerontologists have used estimates of age- 
specific mortality as a critical component in studies of various biological processes. In 
organisms performance and physiological conditions progressively deteriorate, and 
therefore mortality rates progressively increase, with age. However the analysis of age- 
specific mortality rates has some statistical challenges caused by sampling error, 
Promislow et al. (1999) presented simple maximum likelihood models that effectively 
remove biases even at relatively small sample sizes, they state that the most powerful 
approach, used commonly in medical survival analysis, but infrequently by population 
biologists, is that of maximum likelihood estimation (MLE). In my experiments 
physiological changes due to age don’t represent potential statistical error as we divide 
experiments in age groups, although we have to be careful when comparing mortality of
treated cells with that of controls. Inter-experimental variation due to cell culture 
changes between experiments is also taken into consideration. Therefore two different 
plotting regimes have been used in order to distinguish specific effect of treatment on 
neuronal lifespan, the survival curve and the mortality plot.
The survival curve is produced using changes in neuronal number with time, and is 
calculated as the percentage of N at t* compared to the percentage of N at to (where N 
represents the number of live cells at every count in one horizontal strip of the coverslip; 
t* is the counts on the day and to is the first count 12 to 15 hours after plating). The 
formula is as follows:
% survival = (tx x 100)/to
The mortality plotting is considered as the percentage of mortality calculated as the 
logarithm of the age-specific mortality minus the logarithm of the age-specific survival 
(Tatar, 2001). The formula is as follows:
% u< = LN qt 
q, = -LN p, 
pt = %NL/ %N(L-1)
where:
u, = mortality rate;
q, = age-specific mortality;
p, = age-specific survival which is equal to 1 - q,;
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LN = natural logarithm;
tx = the count on a specific day ;
L - 1 = the count of the previous day;
to = the count at time 0 (i.e. first day of counts).
The comparison between the survival curve and the mortality plot is particularly 
interesting when looking at the specific effect of treatment at different stages of the life 
of the cell in vitro and the time when mortality increases, reaches a plateau, and start 
increasing again to reach a final plateau; we have described this triphasic behaviour as a 
curve divided into three ‘phases’. Phase one (day 1 to day 3-5), phase two (day 3-5 to 
day 11-15), phase three (day 11-15 to day 25 or more).
2.10 Signalling pathway in culture
Neurotrophins and other external factors, including NGF, brain-derived neurotrophic 
factor (BDNF), and insulin suppress neuronal apoptosis, while glial-derived 
neurotrophic factor (GDNF) and IGF-1 promotes apoptosis in SCG neurons.
NGF suppresses neuronal apoptosis through the receptor tyrosine kinases (Trk) A by 
activating the Erkl/2 and PI3-K pathways. PI3-K activates the serine/threonine kinase 
Akt, a component of many receptor signal transduction pathways, which amongst other 
can prevent cell death by deactivating GSK-3p.
In the Erk pathway NGF phosphorylates and activates MAP-kinase which suppress 
apoptosis by inhibitory phosphorylation of BAD (Hetman and Xia, 2000). 
Pharmacological inhibition and external growth factor interaction have been employed 
in this study to describe the signalling pathway activated in survival mechanisms 
following in vivo treatment. The pharmacological inhibitors of PI3-K used in culture is 
50pM of LY294002 (Vlahos et o l , 1995), while U0126 (Duncia et ol., 1998) was used
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at the same concentration for Erk/MAPK inhibition. A pilot experiment with several 
doses (see figure 2.4) o f LY294002 was carried out in order to adopt a physiological 
level o f the pharmacological inhibitor and at the same time avoid cell apoptosis due to 
toxicity rather than PI3-K inhibition.
NGF SURVIVIAL
10uM
25uM
50uM
100uM
Days in cu ltu re
Figure 2.4: Trial of in vitro serum free cell culture following NGF pre-treatment in vivo on 8 months SCG 
neurons and application of differential doses of PI3-K inhibitor (LY 294002) in culture; n=500.
Inhibitors were applied at plating time and the first count was carried out between 5 and 
12 hours after plating, and repeated at 24 hours intervals until termination o f  live cells. 
External growth factor experiments have been carried out in order to understand 
whether survival is activated by external factors, such as BDNF, insulin, GDNF and 
IGF-1 (see figures 4.18 and 4.19 in chapter 4). External factors concentration has been 
maintained at physiological levels (5 0 jiM ), and mode o f application as well as plating 
density was kept constant.
All data sets have been statistically tested with ANOVA analysis o f variance followed 
by Bonferoni post oc test.
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CHAPTER III
THE ROLE OF EARLY LIFE PRE-TREATMENT WITH NGF OR NGF 
ANTIBODIES ON SELECTIVE VULNERABILITY TO CELL DEATH AND 
NEURITE OUTGROWTH IN ADULT AND AGEING SYMPATHETIC NEURONS
3.1 Introduction
The mechanisms underlying selective vulnerability, in ageing and in neurodegenerative 
diseases, remain obscure; there is evidence that development does affect later life 
neurodegeneration (Gatzinsky et al., 2004; Gardner et al., 2005). Gatzinsky el al (2004) 
first related neurotrophic factors (NT) levels in targets to local pattern of age-related 
SCG neurodegeneration, in this study a significant difference in neuronal number 
between ages has been detected, with a decreased neuronal number with increasing age. 
When neurons grow into their targets they either form synapses, begin to establish the 
functional connections that characterize the mature nervous system, or they die 
(Heumann et al. 1984; Shelton and Reichardt, 1984; Johnson et al., 1987; Davies, 
1996). These processes are regulated by molecular crosstalk between the ingrowing 
neurons and cells of the target tissues, and particularly by target-derived proteins called 
‘trophic factors; this model is called the neurotrophic hypothesis (Oppenheim, 1989; 
Haverkamp and McManaman, 1990; Sohal et al., 1991; Co wen, 1993; Johnson and 
Oppenheim, 1994; de la Rosa and de Pablo, 2000). The hypothesis states that neurons, 
at about the stage that their neurites reach the target tissue, become dependent on 
trophic factors supplied by the target tissue, for survival and differentiation. The targets 
are thought to make limited quantities of these factors, not enough to sustain all the 
neurons that grow into the region, thus neuronal axons must compete for the limited
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supply of trophic factor. The neurons that by chance obtain a threshold amount of the 
factor will survive and prosper to form synapses, the others will die. An 
‘overabundance’ of neurons is formed during neurogenesis, and they send in more 
axons to the target tissue than there are cells in the tissue. This is in order to ensure that 
all target cells receive innervation from axons, while the limited supply of factors from 
the target tissue ensures that only those neurons that make functional connections will 
survive into the mature nervous system. Furthermore the overabundance of neurons is 
also necessary in order to establish proper matching between neurons and their targets, 
which initially is characterised by trial and error mode.
In the experiments described here, the focus is on the effect of exogenous NGF on SCG 
neurons applied systemically in vivo before termination of development (i.e. ‘early’ pre­
treatment in vivo), or after termination of development (i.e. ‘late’ pre-treatment in vivo). 
It is therefore important to identify the characteristics of development of SCG neurons 
and how they are affected by NGF as well as the mode of action of NGF.
In mammals soluble peptide growth factors play indispensable roles in inter and intra 
cellular communication; NGF in particular is the molecule that regulates the survival 
and maturation of developing neurons in the peripheral nervous system (Huang and 
Reichardt, 2001). NGF biology does not only centre around the concept of target- 
derived neurotrophic factors where NGF is released by postsynaptic targets and acts on 
presynaptic neurons to build and/or maintain functional contacts. This is not the sole 
role of NGF actions, NGF and its receptors are produced throughout adult life and 
during ageing by many different cell types. According to a review from Sofroniew et al.
(2001) the dynamically regulated expression of NGF and its receptors suggests multiple 
functions of NGF signaling, many of which are poorly understood. During neuronal
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development NGF promotes survival and maturation of neurons expressing TrkA and 
p7 5 NTR (c onover and Yancopoulos, 1993; Snider, 1994), by participating in the 
classical target-derived neurotrophic relationships which is evident, according to 
Crowley et al. (1994), in the experiments where the NGF gene is knocked out resulting 
in loss of most sympathetic neurons. Smeyne et al. (1994) also found a depletion of 
SCG in TrkA knockout mice. Gene disruption of p75NTR causes changes in sympathetic 
innervation, specifically of the pineal gland and sweat glands (Lee et al., 1994), as well 
as on the number of sympathetic neurons (Brennan et al., 1999). NGF signaling through 
p75NTR might either restrain the normal survival and development of sympathetic 
neurons, or alternatively p75NTR disruption may allow NT-3 to signal through TrkA to 
enhance neuronal survival (Clary and Reichardt, 1994); this remain a controversial issue 
and further studies are needed to clarify the interaction. To summarize the effect of 
NGF on developing neurons, firstly neurons are not continuously dependent on the 
supply of a single target-derived factor throughout life and a multitude of molecules 
from different sources influence developmental survival and maturation (Davies, 1994). 
Secondly, according to Enokido et al. (1999) transiently required growth factors may 
derive from sources other than the final region, such as local interactions around the cell 
bodies or intermediate targets that axons encounter and than grow past to final 
destinations (Wang and Tassier-Lavigne, 1999). Thirdly, NGF signaling can also 
mediate axon sprouting, as well as growth cone turning and local guidance (Campenot, 
1977, Gallo et a l,  1997; Patel et a l, 2000; Rice et a l,  1998; Tuttle and O’Leary, 1998). 
Fourth, NGF can induce the death of certain developing neurons by signaling through 
p75NTR in the absence of TrkA, as in the retina (Frade and Barde, 1998; Frade et al., 
1996).
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Finally, if neurons survive successfully the stages of cell birth and migration, neurite 
extension to appropriate targets, avoiding apoptosis at each stage, then they may form 
synapses with their target tissue. Synaptogenesis involves diverse set of molecular 
signals between the neuron and its target, and sometimes involving glial cells as well. 
After synaptogenesis started, target cells send signals to the neurons that induce the 
growth cone to stop growing and convert into stationary structure of the nerve terminal, 
which develops synaptic vesicles, active release sites, voltage-dependent calcium 
channels, production and release of neurotransmitter, and reuptake of transmitters and 
recycling of vesicle membrane. The neurons send signals to their targets inducing them 
to produce appropriate receptors for transmitters and neuropeptides, to consolidate the 
receptors at high density at the same location as the nerve terminal, and to assemble all 
the necessary signal transduction and second messenger pathways necessary for proper 
postsynaptic responses to neurotransmitters (Van den Pol et al., 1998).
3.1.1 Role of receptors and signaling pathways
Almost two decades ago Yan et al. (1988) reported the potential functional significance 
of NGF receptors of spinal motoneurons and how they can bind, internalize, and 
retrogradely transport NGF.
A decade ago numerous studies reported axonal regeneration such as Gold et al. (1993) 
documenting axonal regeneration over long distances following axotomy in the 
C57BL/01a mouse mutant. Nowadays neurotrophins prevention of cell death in the 
peripheral nervous system is well-established; and according to studies carried out by 
Tucker et al. (2001), the physiological involvement in nerve growth of mixed nerves is 
also dependent upon neurotrophins during development.
NGF in vivo treatment also influences neuronal growth; according to Emanueli et al.
(2002) endogenous NGF stimulates neurovascularization and vascular endothelial cell
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proliferation in mice. Furthermore Mills et al. (2003) showed the link where intergrin- 
linked kinase (ILK) is an important effector in NGF-mediated neurite outgrowth. ILK is 
a, PI3-K dependent, serine-threonine kinase that regulates adhesion, migration, 
differentiation, and survival (Giancotti and Ruoslahti, 1999; Dedhar, 2000; Wu and 
Dedhar, 2001). Stimulation of ILK after exposure to NGF results in activation of AKT 
and inhibition of GSK-3p (Delcommenne et a l, 1998; Attwell et al., 2000; Dedhar, 
2000; Persad et al., 2000). Therefore to summarise the importance of these findings 
NGF seems to affect growth which in turn is linked with neurovascularization via a ILK 
mediated pathway which is a PI3-K dependent causing activation of Akt and inhibition 
of GSK-3p (refer to chapter VI).
The aim is to investigate how ‘early’ and ‘late’ pre-treatment with exogenous NGF 
affects selective vulnerability, and specifically changes in neuronal numbers, growth, 
and peripheral innervation.
The hypotheses investigated in this chapter are firstly that there will be changes in the 
numbers of neurons in the adult and aged SCG following pre-treatment with NGF, and 
changes in the ratio of vulnerable versus protected neurons. Secondly, I hypothesise that 
growth of adult and aged SCG neurons in vitro will be affected by pre-treatment 
(example neurons immunostaining in figure 3.1).
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Figure 3.1: Example of neurons immunostained with Taj for growth assay.
3.2 Results
3.2.1 Investigation o f a possible side-effect o f NGF pre-treatment in vivo on neuron 
survival
NGF is also known to cause inflammation, and there was the possibility that pre­
treatment in vivo might be causing neuronal toxicity and therefore partial neuronal 
death during treatment; this would have caused a subset o f  neurons survived to 
treatment rather than the entire population. In order to avoid such possibility animals 
have been treated for either one week or four weeks (the latest is equivalent to the full 
treatment) and the SCG removed and tested immediately after termination o f treatment 
for cell death with a Cell Death ELISA kit (Promega, UK). Results from the ELISA kit 
showed no significant difference in the extent o f cell death between NGF and CYT-C 
pre-treated neurons after one week o f in vivo treatment (p = 0.5), or after four weeks o f 
in vivo treatment (p =  0.9). Figure 3.2 shows no difference between treatment and some 
difference between ages.
56
0.12
2  0.08
<  0.06
0.04
0.02
1wk 4wk
TREATMENT PERIOD
Figure 3.2: Cell death ELISA showing neuronal death following in vivo pre-treatment with either NGF (dotted  
columns) or CYT-C (control, striped columns) at three weeks of age and following a period of either one week  
(1 wk) or four weeks (4 wk) of treatment.
3.2.2 Counts o f total number o f neurons following retrograde tracing w ith Fluorogold; 
on ex vivo samples
Counts have been carried out after using conventional retrograde tracing techniques (in 
vivo), combined with stereological counting methods (ex vivo). The retrograde tracing 
dye, Fluorogold, was used followed by estimation o f  total neuron numbers using a 
physical disector (Tandrup, 1993) (see Chap II for details). M CA and iris projecting 
neurons were found mainly in the rostral pole o f  the superior cervical ganglion, often 
exhibiting labelled neurites. Iris neurons w ere generally larger than those projecting to 
the MCA, confirming previous observations using sim ilar techniques (Andrews et al, 
1996).
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The age-groups used are: young adult (6wk), middle aged (15m) and old aged (20- 
24m).
Although the retrograde tracing technique used is a conventional method, well known 
and regularly used in our lab, we experienced some difficulties w ith the oldest group, 
w hich included in some samples leaking o f  Fluorogold into adjacent cells (mainly glia) 
and tissues made counting o f labelled cell bodies difficult and hence second observer 
repetition was necessary. The second possible difficulty w ith the old group was the risk 
that neurons might be affected by age-related alterations in retrograde transport (Cooper 
et al. 1994). For this reason, counts were made about 3 days (short term , ST) or 10 
months (long term, LT) after tracing in vivo. The data showed very similar results for 
the ST com pared to the LT groups. See figure 3.3.
Figure 3.3: Number o f neurons retrogradely traced with Fuorogold in MCA versus iris SCG ganglia. Ganglia 
o f middle aged neurons (M ) and old neurons (O) have been harvested 48 hours after tracer have been applied 
(ST) or several weeks after application of tracer (LT)
HMCA 
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M (ST) M (LT) O (ST) O (LT)
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58
Besides when com paring M CA-projecting neurons, both showed a reduction in neuron 
number with age, and therefore no age-related reduction in retrograde transport o f  the 
Fluorogold tracer; as a result ST and LT groups were am algam ated for subsequent 
analysis. On the contrary only ST iris projecting neurons showed a small but significant 
(27%; p<0.01) reduction both between age-groups as well as between ST and LT 
groups, indicating a reduction o f  retrograde transport, therefore only LT iris data 
(labelling carried out before any age-related deficits in retrograde transport) were used 
for subsequent analysis. Considering neuronal num ber across ages, the results show a 
clear decrease w ith age in number o f  M CA-projecting neurons but no comparable 
decrease in iris-projecting neurons, confirming the selective vulnerability o f  M CA- 
compared to iris-projecting neurons. Our results also dem onstrate an age-related 
decrease in retrograde transport for the iris projecting neurons. See figure 3.4.
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Figure 3.4: Number o f neurons retrogradely traced with Fuorogold in MCA versus iris SCG ganglia. Ganglia 
of young neurons (Y), middle aged neurons (M ) and old neurons (O) harvested 48 hours after application of 
tracer or several weeks after application (LT).
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3.2.3 Effect o f ‘early’ (age 3-7wks) pre-treatment with NGF, A-NGF, CYT-C or serum 
on total numbers o f neurons and o f subpopulations o f MCA- and iris-projecting neurons 
counted either immediately after treatment (acute group) or 6 months later (8m group); 
on ex vivo samples
These experiments present results regarding the number o f neurons in the acute (7 
weeks old animals) and the 8 month old groups, following in vivo retrograde tracing 
with Fluorogold (see figure 3.5).
Figure 3.5: 20iim SCG section retrograde traced with Fluorogold. Figure A shows the entire section; while 
figure B shows a magnified section with traced SCG neurons.
Four acute groups were pre-treated in vivo with either NGF or CYT-C (control for 
NGF), or anti-NGF or serum (control for a-NGF); two 8 months old groups have been 
treated with either NGF or CYT-C. The acute group present a significant higher number
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o f neurons when pre-treated with NGF in vivo (p < 0.05), w hile at 8 months the overall 
number o f neurons is not significantly higher. See figure 3.6.
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Figure 3.6: Total number of acute and 8 months SCG neurons pre-treated in vivo with either CYT-C (control 
for NGF), NGF, a-NGF, or serum (control for a-NGF. The bars represent the means mean +/- sem o f the total 
number of neurons per ganglion, and the neurons have been retrogradely traced in vivo with Fluorogold.
The acute group presents a larger number o f M CA-projecting neurons com pared to iris- 
projecting one, w ith a significant difference between the two groups (p < 0.0.5) once the 
neurons have been pre-treated in vivo with NGF. The effect o f  NGF pre-treatm ent on 
the acute M CA-projecting neurons reveals a non-significant increase in the num ber o f  
neurons compared to controls (see figure 3.7); a-NGF in vivo pre-treatm ent, on the 
contrary, significantly reduces the num ber o f neurons (p = 0.05). The iris-projecting 
acute group o f  neurons shows no significance at all for any o f  the treatment; showing 
that previous results on vulnerability o f  M CA neurons is correlated with plasticity (in 
this case, the capacity to respond to NGF pre-treatment).
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Figure 3.7: Number o f acute MCA- and iris-projecting SCG neurons pre-treated in vivo with either CYT-C  
(control for NGF), NGF, a-NGF, or serum (control for a-NGF). MCA projecting neurons are identified with 
the dotted bars, while iris-projecting neurons are represented with short diagonal bars. The bars represent the 
means mean +/- sem of the total number o f neurons per ganglion, and the neurons have been retrogradely  
traced in vivo with Fluorogold.
The 8 months old group (see figure 3.8) results shows the num bers o f  M CA-projecting 
neurons as significantly greater (p < 0.05) once treated w ith N GF com pared to the 
control, as well as iris-projecting neurons are significantly m ore (p < 0.05) w hen treated 
with NGF compared to the control.
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Figure 3.8: Number o f 8 months MCA- and iris-projecting SCG neurons pre-treated in vivo with either CYT- 
C (control for NGF), or NGF. MCA projecting neurons are identified with the dotted bars, while iris- 
projecting neurons are represented with short bars. The bars represent the mean +/- sem o f the total number 
of neurons per ganglion, and the neurons have been retrogradely traced in vivo with Fluorogold.
Comparing the number o f  neurons across ages, results show a difference betw een the 
controls and the NGF pre-treated neurons (see figure 3.9). CYT-C (control) pre-treated 
neurons tend to decrease with age (for both M CA- and iris-projecting neurons); while 
once they have been treated with N GF, M CA and Iris react differently to the pre- 
treatment in vivo. W hile M CA-projecting neurons tend to  decrease w ith age, passing 
from being significantly more than iris to less, iris-projecting neurons increase, not only 
compared to M CA but as overall number. It seems that both an availability o f  N G F 
early in life and an anatomical difference betw een the tw o sets o f  neurons (single- 
versus multi-unit system) are determ ining the survival o f  neurons.
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Figure 3.9: Number of acute and 8 months M CA- and iris-projecting SCG neurons pre-treated in vivo with  
either CYT-C (control for NGF), or NGF. MCA projecting neurons are identified with the dotted bars, while 
iris-projecting neurons are represented with short bars. The bars represent the total number of neurons per 
ganglion, and the neurons have been retrogradely traced in vivo with Fluorogold.
These results showed in table 3.1 shows a summary o f the significant results. There is a 
significant result on the acute M CA-projecting neurons showing plasticity w ith a 
decreased num ber o f  neurons following pre-treatm ent in vivo w ith a-NGF. The 8 
months group is positively affected by N GF pre-treatm ent in vivo, causing a significant 
increase in the number o f  both M CA- and iris- projecting neurons. There is still 
significant difference, between acute M CA- and iris-projecting neurons, after N GF pre­
treatment in vivo.
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M CA IR IS M C A  VS. IR IS
A CU TE CYT-C vs. A-NGF 
p < 0.05
8M CYT-C vs. N GF 
p  < 0.05
CYT-C vs. NGF 
P < 0.05
N G F Acute vs. 8m 
P < 0.05
Acute vs. 8m 
P < 0.05
P < 0.05
Table 3.1: Summary o f significant p-value for the numbers o f  M CA- and iris-projecting neurons at different 
ages (acute and 8 months) with different in vivo pre-treatment (CYT-C, NGF or A-NGF).
3.2.4 Effect o f  ‘early’ (age 3-7wks) pre-treatm ent w ith N G F or CYT-C treatm ent on 
growth o f  SCG neurons in vitro: 8 M ONTH GROUP
The 8 m onths old group were treated between 3 and 7 w eeks old o f  age and analysed 6 
months after term ination o f  treatment. N eurons w ere grown in the absence o f serum and 
in the presence o f  NGF (see chapter II for details).The cell body size seems to be 
affected by pre-treatment in vivo (see figure 3.10), N GF pre-treatm ent increased the size 
o f  the cell body, but the increase is not significant.
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Figure 3.10: Cell body size of 8 months old SCG neurons pre-treated in vivo with NGF or CYT-C. Neurons 
have been cultured in serum-free medium for 24 hours.
The area covered by neurites in the 8 m onths old group (see figure 3.11) is significantly 
increased (p <  0.05) by N GF pre-treatment com pared to controls (CYT-C).
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Figure 3.11: Area covered by neurites of 8 months old SCG neurons pre-treated in vivo with NGF or CYT-C. 
Neurons have been cultured in serum-free medium for 24 hours.
The total neurite length o f 8 months old group is also affected by in vivo pre-treatm ent 
(see figure 3.12). N GF significantly increases the total neurite length (p <0.05).
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Figure 3.12: Total neurite length of 8 months old SCG neurons pre-treated in vivo with NGF or CYT-C. 
Neurons have been cultured in serum-free medium for 24 hours.
The number o f  intercepts o f  the 8 months old group is affected by pre-treatm ent in vivo 
(see figure 3.13). Even though NGF pre-treatm ent in vivo increased the num ber o f  
intercepts, the difference is not statistically different.
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Figure 3.13: Number of intercepts o f 8 months old SCG neurons pre-treated in vivo with NGF or CYT-C. 
Neurons have been cultured in serum-free medium for 24 hours.
3.2.5 Effect o f  ‘early’ (age 3-7wks) pre-treatm ent w ith NGF. A -NG F or CYT-C 
treatment on growth o f  neurons in vitro: 24 M ONTH GROUP
The cell body size o f  neurons pre-treated w ith N G F in vivo is not affected in 24 months 
old neurons (see figure 3.14). In contrast, a-NGF seems to be increasing cell body size 
compared to N GF pre-treated in vivo neurons (p < 0.05).
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Figure 3.14: Cell body size o f 24 months old SCG neurons pre-treated in vivo with NGF, CYT-C or a-NGF 
(ANGF). Neurons have been cultured in serum-free medium for 24 hours.
A-NGF pre-treatment in vivo caused a reduction o f  the area covered by neurites (p < 
0.05) in 24 m onths old SCG neurons w hen com pared w ith CYT-C (see figure 3.15).
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Figure 3.15: Area covered by neurites o f 24 months old SCG neurons pre-treated in vivo with NGF, CYT-C or 
a-NGF (ANGF). Neurons have been cultured in serum -free medium for 24 hours.
The total neurite length results are very similar to those o f  the area covered by neurites 
(see figure 3.16); w ith A-NGF pre-treatm ent in vivo significantly affecting the length o f 
the neurites compared to the control (p < 0.05).
71
120000
100000
8 0 0 0 0
6 0 0 0 0
4 0 0 0 0
20000
S3 total n eu rite  length
NGF CYT-C
Figure 3.16: Total neurite length o f 24 months old SCG neurons pre-treated in vivo with NGF, CYT-C or a- 
NGF (ANGF). Neurons have been cultured in serum -free medium for 24 hours.
Results obtained calculating the num ber o f  intercepts (see figure 3.17) shows that there 
is a non-significant increase in the num ber o f  intercepts w hen neurons have been treated 
in vivo w ith NGF compared to CYT-C , and a significantly (p < 0.05) decreased num ber 
o f  intercepts w hen neurons were pre-treated w ith a-NGF com pared to CYT-C.
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Figure 3.17: Number of intercepts of 24 months old SCG neurons pre-treated in vivo with NGF, CYT-C or a- 
NGF (ANGF). Neurons have been cultured in serum -free medium for 24 hours.
Results from in vitro cultured and im munostained senescent SCG neurons show that the 
m ost sensitive analysis for this group m ight be the num ber o f  intercepts. Results from 
24 months group show no significant difference due to N G F pre-treatment.
3.2.6 Effect o f  ‘late’ (age 3 months) pre-treatm ent w ith  N GF or CYT-C treatm ent on 
neurons in vitro
Neurons that have been pre-treated in vivo after term ination o f developm ent (i.e. at 3 
months o f age) seems to have unaltered cell body size (see figure 3.18). The late 
treatment group, in contrast to  the 24 m onths group, are neurons that have been 
examined im mediately after term ination o f  the in vivo pre-treatm ent, while 24 months 
group have been treated between 3 and 7 w eeks o f  age and exam ined 22 months after 
term ination o f  pre-treatm ent in vivo.
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In figure 3.18 are the results o f  the cell body size o f  neurons pre-treated in vivo with 
NGF compared to neurons pre-treated in vivo w ith CYT-C (control). There is no 
significant difference betw een the tw o groups o f  pre-treatm ent in vivo.
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Figure 3.18: Cell body size o f late treatment SCG neurons pre-treated in vivo with NGF, or CYT-C. Neurons 
have been cultured in serum-free medium for 24 hours.
Results from analysis o f  the area covered by neurites (see figure 3.19) shows a 
significant difference in neurons pre-treated in vivo w ith N GF com pared to control (p < 
0.05). NGF pre-treatment in vivo increases significantly the area covered by neurites.
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Figure 3.19: Area covered by neurites in late treatment SCG neurons pre-treated in vivo with NGF, or CYT- 
C. Neurons have been cultured in serum-free medium for 24 hours.
Similarly the total neurite length (see figure 3.20) is significantly different following 
late pre-treatment in vivo (p < 0.05). NGF pre-treatment in vivo significantly increases 
the length the neurites compared to control.
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Figure 3.20: Total neurite length in late treatment SCG neurons pre-treated in vivo with NGF, or CYT-C. 
Neurons have been cultured in serum-free medium for 24 hours.
Number of intercepts has been significantly increased (p < 0.05) following pre­
treatment in vivo with NGF compared to control (see figure 3.21).
Therefore neurite outgrowth in the late treatment group has been significantly affected 
by pre-treatment in vivo with NGF compared to control, but not the size of the cell 
body.
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Figure 3.21: Number of intercepts in late treatm ent SCG neurons pre-treated in vivo with NGF, or CYT-C. 
Neurons have been cultured in serum-free medium for 24 hours.
Table 3.2 shows the summary of all the measurements from figure 3. to figure 3.21 with
a summing up of overall growth.
NEURITES
GROWTH
8M 24M LATE
TREATMENT
CELL BODY SIZE —
(or I  a-NGF)
—
NEURITES
NUMBER
t
(or I a-NGF)
t
NEURITES
LENGTH
T
(or I a-NGF)
T
NEURITES
INTERCEPTS
—
(or I a-NGF)
T
OVERALL
GROWTH
t
(or |  a-NGF)
t
Table 3.2: This table shows a summary o f the neurites growth in vitro. A rrow  pointing up shows increase, 
pointing down shows decrease and horizontal line shows no increase or decrease.
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3.2.7 Effect of ‘early’ (age 3-7wks) pre-treatment with NGF. A-NGF or CYT-C 
treatment on innervation of target tissues by MCA and iris projecting neurons: Acute. 8 
months. 18 months and late treatment groups; on ex vivo samples 
Target tissues are innervated by specific subpopulations of neurons, for simplicity MCA 
refers to innervation of the MCA target tissue and iris refers to innervation of the iris 
target tissue. Figure 3.22 shows a significant increase in innervations o f acute group 
MCA following pre-treated in vivo with NGF (p < 0.05).
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Figure 3.22: Acute group percentage of innervation o f the MCA target tissue, following in vivo pre-treatment 
with either NGF, a-NGF or CYT-C.
Figure 3.23 shows no significant increase in innervations of acute group iris tissue 
following pre-treated in vivo with NGF.
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Figure 3.23: Acute group percentage of innervation o f the iris target tissue, following in vivo pre-treatment 
with either NGF, a-NGF or CYT-C.
Figure 3.24 shows the effect of NGF pre-treatment in vivo on the percentage of 
innervation of the 8 months MCA tissue and figure 3.25 shows the effect on iris, both 
tissues are not significantly affected by NGF pre-treatment in vivo.
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Figure 3.24: 8 months group percentage o f innervation o f the MCA target tissue, following in vivo pre­
treatment with either NGF, or CYT-C.
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Figure 3.25: 8 months group percentage of innervation of the iris target tissue, following in vivo pre-treatment 
with either NGF or CYT-C.
Figures 3.26 and 3.27 show the effect on percentage of innervation of NGF pre­
treatment in vivo tissue, respectively MCA and iris tissues, both tissues are not 
significantly affected by treatment when compared to control.
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Figure 3.26: 18 months group percentage o f innervation o f the MCA target tissue, following in vivo pre­
treatment with either NGF or CYT-C.
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Figure 3.27: 18 months group percentage of innervation o f the iris target tissue, following in vivo pre­
treatment with either NGF or CYT-C.
Figures 3.28 and 3.29 show the late treatment percentage of innervation of respectively 
MCA and iris target tissues, following in vivo NGF pre-treatment. MCA tissue shows a 
significant decrease of innervation following NGF pre-treatment in vivo (p < 0.05). No 
significant effect is present on the iris target tissue.
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Figure 3.28: Late treatment group percentage of innervation o f the MCA target tissue, following in vivo 
treatment with either NGF or CYT-C.
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Figure 3.29: Late treatment group percentage o f innervation o f the iris target tissue, following in vivo pre­
treatment with either NGF or CYT-C.
3.3 Discussion
NGF is mandatory for the survival of sympathetic neurons during maturation (Davies, 
1996; Levi-Montalcini and Angelletti, 1968; Lewin, 1996); as they mature they lose 
their absolute dependence on NGF for survival, and NGF becomes involved in 
selection, specification, and maintenance of differentiated neuronal phenotypes (Lewin, 
1996; Lewin et al., 1992; Lindsay, 1996). NGF is also known to cause inflammation 
(Le Bars and Adam, 2002; Safieh-Garabedian et al., 2002; Boucher and McMahon, 
2001; Woolf and Salter, 2000; Mannion et a l, 1999; McMahon, 1996; Lewin, 1995; 
Andreev et a l,  1995), and pre-treatment in vivo might be causing neuronal toxicity and 
therefore neuronal death during treatment; resulting in a study carried out on a subset of
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neurons (i.e. neurons survived to treatment), rather than the entire population. The 
results of a simple test carried out with a Promega Elisa kit showed no neuronal death 
due to NGF pre-treatment in vivo either during the treatment (after 1 week) or 
immediately after the termination of the treatment regime (after 4 weeks). Even though 
there is some difference in the amount of cell death between 1 and 4 weeks of pre- 
treatment in vivo, such difference may be due to normal early development cell death; 
in fact according to the neurotrophic hypothesis (Purves, 1988) structure and 
connections of developing and mature neurons are governed by their ongoing 
interactions with target tissues and therefore target fields requirement and size 
determines the number of neurons surviving (Davies, 1996). Studies on timing of 
neuronal death have shown that sympathetic neurons become dependent on the supply 
of two neurotrophins, NGF and NT3, shortly after they begin to innervate their targets 
(Crowley et a l,  1994; Wyatt et al., 1997; Francis et a l,  1999, Orike et a l, 2000).
Once the early age developmental mechanisms have been settled according to the 
neurotrophic hypothesis system, where NGF played a central role in determining the 
phenotypes of different subpopulations of neurons, the interesting issue is to understand 
the characteristics of neuronal degeneration in old age. Neuronal degeneration can be 
assessed by studying the fluctuation in neuronal number with increasing age and the 
variation between subpopulations of neurons (MCA- and iris-projecting neurons) 
characterised by differential vulnerability due to the phenotype determined in early age 
by NGF availability.
Donaldson (1895) already contemplated the importance of neuron number and brain 
function, and was followed by numerous other scientists, Bok and Van Erp Taalman 
Kip (1939), Frankhauser et al. (1955), Vernon and Butsch (1957), Jerison (1963),
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Williams and Herrup (1988). Williams and Rakic (1988) suggested the ‘three- 
dimensional counting’ method to estimate number of cells in sectioned material; and in 
this study we utilised a revised format of the ‘three-dimensional counting’ method 
(Williams and Rakic, 1988) to carry out the analysis. Results showed that while a 
vulnerable subpopulation of neurons (MCA-projecting neurons) decrease in number 
significantly with age, iris-projecting neurons (resistant neurons) shows only a slight 
decrease in number with age. These results confirm the hypothesis that neurons 
receiving a limited amount of NGF in early life are characterised by a phenotype 
conferring vulnerability in later life.
Rita Levi-Montalcini and Victor Hamburger (1953) described in a seminal paper that 
the survival of developing neurons is directly related to the availability of their 
innervating targets, and therefore by pre-treating in vivo neurons early in life we created 
and environment of overabundance of NGF for all neurons. What is still unknown is if 
with abundant NGF availability, in early life development, the number of neurons is 
going to be different.
Research results on the differential numbers of neurons, when cells have been pre­
treated in vivo with NGF compared to when they have been pre-treated in vivo with 
CYT-C (control), showed an overall increased cell number followed treatment. MCA- 
projecting neurons are more plastic and the availability of NGF caused an increased cell 
number, which is significant at 8 months (p < 0.05); the MCA plasticity is also shown 
by the results with the A-NGF pre-treatment in vivo where the number of neurons 
survived are significantly lower compared to control (p < 0.05). According to Crowley 
et a l  (1994) and Zhou and Rush (1995), lack o f NGF caused neuronal death, and 
similar results are obtained when A-NGF is applied to neurons (De Vries et al., 2002;
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Shadiack et a l,  2001; Tafreshi et al., 1998; Luo et al., 1997; Qian and Naftel, 1996; 
Zigmond et al., 1995; Gorin and Johnson, 1979; Bjerre et a l,  1975). Furthermore 
MCA-projecting neurons tend to decrease in number with age and this is in accordance 
with results from Gatzinsky et a l  (2004). Iris-projecting neurons don’t decrease with 
age (in accordance with Gatzinsky et a l ,  2004 results) and increase significantly 
compared to control at 8 months following NGF pre-treatment in vivo. The above 
results show that vulnerable neurons (MCA-projecting) can be protected by in vivo 
NGF pre-treatment and that resistant neurons (iris) dying in old age can be protected as 
well by in vivo NGF pre-treatment.
The next logical question would be to examine if  the NGF pre-treatment in vivo is 
affecting growth. Crutcher (1989) introduced some important information in 
understanding the potential of axonal growth within the mature mammalian brain and 
spinal cord by looking at axonal regeneration stating that differential axonal growth 
may be attributed to absence of growth-promoting substances, or the presence of 
growth-inhibiting substances.
During ageing basal forebrain cholinergic neurons are prone to degeneration for 
unknown reasons. De Lacalle et a l (1996) studied the reduced retrograde labelling with 
fluorescent tracer and found neuronal atrophy of basal forebrain cholinergic neurons in 
aged rats.
Results from the 8 months group shows that while there is no difference in the cell body 
size of neurons, neurites number and length are significantly increased by NGF pre­
treatment in vivo (p < 0.05). The 24 months group shows no increase in either cell body 
size or neurites following NGF pre-treatment in vivo but a significant decrease 
following A-NGF pre-treatment in vivo (p < 0.05). The above results clearly show that 
NGF availability increases neuronal growth at 8 months but not at 24, while lack of
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NGF (A-NGF in vivo pre-treatment) causes the neurons to retract neurites and 
eventually die in old age; death of neurons following neurite retraction was also found 
by studies carried out by Mearow and Kril (1995).
The late treatment group (neurons pre-treated in vivo after termination of development) 
results are very similar to the 8 months results; where the cell body size is maintained 
while the neurites are increased following NGF pre-treatment in vivo compared to 
control. The above results show that NGF pre-treatment has also an effect on growth 
after the termination of development. According to Gorin and Johnson (1980), and 
Orike et a l (2001), neurons are dependent on NGF for survival in early development 
but only for growth after termination of development.
Is NGF pre-treatment in vivo affecting innervation of target tissues? This research 
results shows that, in accordance with the subpopulations ’ neurons number results, the 
MCA target tissue tend to be mainly affected. MCA subpopulations of neurons are more 
plastic compare to iris and therefore respond more readily to and increase or decrease of 
NGF availability. If MCA neurons were not plastic the a-NGF treatment on acute iris 
neurons would have caused a decrease in neuron number, as for resulted for the MCA- 
projecting neurons. Furthermore increase in iris acute neuron number, following NGF 
pre-treatment, does not occur maybe because the level of iris neurons surviving at this 
age is already at its upper limit.
These results are in accordance with review of Bleys and Cowen (2001) where they 
extensively describe the characteristics of innervation and plasticity MCA tissue with 
particular reference to target associated factors, for example NGF.
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CHAPTER IV
IN VITRO NEURONAL SURVIVAL OR MORTALITY AND SELECTIVE 
VULNERABILITY FOLLOWING PRE-TREATMENT IN VIVO WITH NGF OR
NGF ANTIBODIES
4.1 Introduction
Neurons are initially dependent on NGF for survival but, during postnatal development, 
sympathetic neurons lose their dependence on NGF for survival but continue to require 
it for growth and for development of mature neurotransmitter phenotype (Gorin and 
Johnson, 1980, Orike et al., 2001), similarly happens in sensory neurons (Diamond et 
a l , 1992).
The purpose is to investigate the possibility that the level of exposure of developing 
neurons to NGF early in life determines the capacity to survive the stresses and strain of 
ageing. Such investigation is carried out in two ways: one ex-vivo (as explained in 
chapter III) and one in vitro with primary culture of SCG neurons pre-treated in vivo 
with NGF, NGF antibodies or CYT-C (control).
Furthermore this study investigates selective vulnerability of subpopulations of SCG 
neurons. According to Purves (1980), neurons compete for a limited supply of 
neurotrophic factors, and therefore targets and neurotrophic availability regulate the 
population of innervating neurons (Korsching, 1993). Suggesting that the differential 
behaviour and the selective vulnerability of the MCA and the iris projecting neurons 
could be associated not only with the type of innervation but also with the neurotrophic 
availability from target tissues.
PI3-K mediates neurotrophin-induced survival as well as regulating vesicular trafficking 
of various kinds (Brunet et al., 2001; Cantley, 2002). According to Furman et al.
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(1998) there are multiple enzymes phosphorylating the D3 position of inositol lipids; 
neurotrophins activates the heterodimeric class la enzyme consisting of a regulatory 
subunit (p85) and a catalytic subunit (pi 10); with 3 catalytic isoforms (a, (3, and y) and 
4 regulatory isoforms (p85a and (3, p55a and y). Few differences among isoforms are 
just beginning to be defined (Bartlett et al., 1999; Shin et al., 1998; Tolias and Cantley, 
1999). Andjelkovic et al. (1998) and Bartlett et al. (1997) have defined the isoforms 
important in neurotrophin signalling. Trk activation by NGF pre-treatment leads to 
stimulation of PI3-K and binding of the regulatory subunit to the linker proteins Grb-2 
and Gabl/2; according to Downward (1998) the catalytic subunit is also stimulated by 
binding directly to the activated Ras proteins. Maclnnis and Campenot (2002) suggest 
that following NGF stimulation there is an abnormal increase in PI3-K activity. Class I 
PI3-K generates lipids products, such as phosphatidylinositol3,4-P2 (Ptdlns3,4-P2), 
phosphatidylinositol3,4,5-P3 (Ptdlns3,4,5-P3), and phosphatidylinositol-3-P (Ptdlns3- 
P), that binds to PH domains on target proteins. Akt/PKB binds to Ptdlns3,4,5-P3, 
becomes phosphorylated and mediates neuronal survival. Alessi et al. (1997) found that 
Ptdlns3,4,5-P3 also binds to the PH-domain containing kinase PDK1, which is an 
enzymes that phosphorylates and associates with Akt. Brunet et al. (2001) and Dudek 
et al. (1997) studied the complex array of survival-promoting pathways activated by 
Akt kinase. The three main survival pathways activated by Akt are explained as 
follows:
1) the proapoptotic protein Bad is inactivated by Akt-dependent phosphorylation, 
allowing bcl-2-dependent survival (Datta et al., 1997; and del Peso et al., 1997);
2) Akt phosphorylates transcription factors of the Forkhead family and reduces 
expression of several antiapoptotic genes (Biggs et al., 1999; Brunet et al., 1999; 
and Kops et al., 1999);
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3) Akt phosphorylates and inactivates glycogen synthase kinase3 (GSK3).
Growth factor such as: Brain-derived neurotrophic factor (BDNF), insulin, glial derived 
neurotrophic factor (GDNF), and insulin-like growth factor-1 (IGF-1) seems to have a 
remarkable effect on neuronal survival. BDNF belongs to the same group of factor as 
NGF, and they are identified by their capacity to suppress neuronal apoptosis in many 
populations of neurons. BDNF provided survival through PI3-K in spinal cord motor 
neurons (Dolcet et al., 1999), in retinal ganglial cells (Meyer-Franke et al., 1998), 
cerebellar granule cells (Skaper et al., 1998), cortical neurons (Takei et al., 1999), as 
well as many other groups of neurons. Both Skaper et al. (1998) and Takei et al. (1999) 
found that the protection by BDNF/PI3-K was also partially dependent on ERK1/2, 
suggesting the possibility that both pathways are involved in neuronal survival.
Members of the GDNF family do play essential early roles in development of SCG. The 
requirement for GDNF family members precedes the dependence of SCG neurons on 
NT-3, NGF, and TrkA (Huang and Reichardt, 2001). According to Durbec et al., (1996) 
mice lacking c-ret (i.e. the tyrosine kinase activated by GDNF) lack all neurons in the 
SCG without any obvious phenotype in the sympathetic chain at the trunk level, with a 
loss of neural crest-derived precursors. Nishino et al. (1999) reported that mutation of 
the GFRa3 binding subunit has a similar effect. GFRa3 mediates activation of c-ret by 
artemin, a protein closely related to GDNF.
In mammals, insulin and IGFs are key hormones for the regulation of metabolism, 
growth, and differentiation. In Caenorhabditis elegans (C. elegans) the gene that 
encodes the protein named DAF-2 is orthologous to the mammalian insulin receptor, 
and is involved in longevity as well as entry into the growth-arrested dauer larva, a kind 
of diapause, of the nematode (Hsin and Kenyon, 1999). Kirkwood (2001) suggested the
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hypothesis that survival mechanisms in postmitotic neurons and organisms are linked. 
This suggests that growth arrest, ageing and metabolism should be closely related to one 
another in the animal kingdom, and therefore C. elegans has been widely used as model 
for studying and insulin/IGF-signaling pathway in several aspects (Kawano et al., 
2000).
Insulin has a dual effect, while attenuating neuronal apoptosis in mouse cortical culture 
it induces neuronal necrosis with 48 hours of exposure (Noh et al. 1999). Exposure to 
insulin led to tyrosine phosphorylation o f the insulin receptor and activation of protein 
kinase C (PKC) and PI3-K; inhibitors of tyrosine kinase and PKC, but not PI3-K, 
attenuated the insulin neurotoxicity. Conversely, inhibition of PI3-K, but not PKC, 
caused an apoptotic effect of insulin. Cao et al. (2000) suggests that gene activity- 
dependent emergence of excitotoxicity contributed to insulin neurotoxicity, 
macromolecule synthesis inhibitors and N-methyl-D-aspartate (NMDA) antagonists 
blocked it. NMDAs are critically involved in synaptic plasticity in the visual cortex of 
the rat. Exposure to insulin increased the level of the NR2A subunit of the NMDA 
receptor without altering NR1 or NR2B levels. NR1, NR2A, and NR2B changes in 
expression may underlie developmental changes. Therefore insulin can be both 
neuroprotective and neurotoxic in the same cell system but by way of different signaling 
cascades.
4.1.1 Aims
This chapter aims at studying the effect of pre-treatment in vivo with NGF, anti-NGF or 
CYT-C (control) across ages (acute, 8 months, 18 months, 24 months) by looking at 
neuronal behaviour in vitro.
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A further group, eight months old, ‘the subpopulations group’ have been examined in 
order to understand if  there is any distinction in survival/mortality pattern of vulnerable 
(characterised by multi-unit innervation, i.e. MCA) versus resistant (single unit 
innervation i.e. iris) populations of neurons.
The ia te  treatment’ is a group of animals that have been treated with the same regime 
as all the other groups with the exception that it started at three months of age, instead 
of seven weeks, and animals have been sacrificed 6 months after termination of 
treatment. Three months has been determined as the age at which development has been 
terminated and therefore adulthood starts. These experiments aim to test if  the NGF pre­
treatment has the same effect whether it has been started late (i.e. adulthood) or early 
(i.e. during the developmental stage).
4.1.2 Hypothesis
Cowen et al. (2003) described extensively how sympathetic neurons undergo age- 
related neurodegeneration with reduced plasticity of neurotrophin receptor expression 
and innervate tissues with low levels of neurotrophin.
Therefore we hypothesize that cells pre-treated in vivo with NGF will be permanently 
affected and their survival pattern will be significantly changed.
The appropriate technique to test such hypothesis is cell culture which allows to study 
the effect as well as the specific time and mode of in vivo pre-treatment. While chapter 
III reported the effect of pre-treatment on ex vivo tissue, the in vitro results from this 
chapter gives us an opportunity to investigate the capacity of adult and ageing neurons 
to survive under in vitro conditions which includes absence of neurotrophic support. 
Orike et a l (2001a) were the first to establish a method for dissociation of SCGs
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eliminating the confounding influences of serum and non-neuronal cells. Furthermore 
Orike et al. (2001) discovered that neuron survival is unaffected by treatment with ant- 
NGF antibodies in vitro and duration of neuronal survival in culture increases 
significantly with age.
4.2 Results
4.2.1 Effect of ‘early’ (age 3-7wks) pre-treatment with NGF. anti-NGF or CYT-C 
treatment on in vitro neuron survival and mortality: ACUTE GROUP 
Results show interesting variation between different regimes of in vivo pre-treatment, as 
well as discrepancy at different ages. These results are analysed by looking at the 
different temporal phases as separate life stages and consequently the differences 
between the percentage of neuronal survival and the mortality rate become very relevant 
(Tatar M., personal communication). The effect of pre-treatment changes between age 
groups, and therefore it is important to analyse these effects both as single results as 
well as comparing them across ages. Intra-age-groups statistical analysis is carried out 
using analysis of variance (ANOVA) followed by the Tukey HSD post hoc test.
In vivo pre-treatment of SCG neurons cultured in the absence of NGF or anti-NGF are 
shown in figure 4.1
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Figure 4.1: In vitro survival of acute group SCG neurons from animals pre-treated in vivo at 3-7 weeks old
with NGF (diamond, black solid line), NGF antibodies (i.e. A-NGF; triangle, black segmented line), or CYT-C 
as a control (i.e. CYT-C; square, grey solid line).
Generally, in neurons taken from animals soon after the cessation o f treatment (acute 
group), a higher number o f  neurons from animals pre-treated in vivo with NGF tend to 
survive when compared to the number o f  neurons that have been pre-treated w ith either 
cytochrome-c or anti-NGF antibodies. The survival curve shown in figure 4.1 may be 
considered as divided into 3 phases: phase 1, days 1 to 3-5; phase 2, days 3-5 to day 15; 
phase 3, days 15 to 25 (or more) (see Methods in chapter II). In phase 1, the three 
groups behave similarly, indicating a common recovery response to the in vitro 
manipulations. However, already from day 3, the NGF pre-treated group begin to 
survive significantly better than the other two groups. Throughout phase 2, the NGF 
group survive significantly better than the control or anti-NGF pre-treated groups. Thus 
there are significant differences between NGF and CYT-C and between A-NGF and 
NGF (both p<0.01); while the difference between CYT-C and A-NGF is not significant. 
Survival analysis provides formal terms with which to describe cell survival in culture
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(see Appendix — Glossary). A-NGF shows lower lt (i.e. cumulative proportion o f 
surviving cells) as well as a lower t to t + 1 (i.e. survival over whole period in culture) 
compared to both CYT-C and NGF. In contrast NGF presents the highest t to t + 1 as 
well as the highest lt. Phase 3 seems to start at day 11 in this group. All A-NGF cells are 
dead by phase 3, while the CYT-C and NGF curves adopt a similar behaviour, with the 
only difference that NGF cells have a higher t to t+1 compared to CYT-C.
Mortality analysis provides further proof o f  the priming effect o f NGF pre-treatment in 
the acute group by showing that NGF pre-treated cells exhibit a higher percentage 
survival (lt) despite the high mortality rate in phase three compared to the control (figure 
4.2).
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Figure 4.2: log plot of the acute group mortality rate in vitro of SCG neurons treated in vivo at 7 weeks old 
with NGF (black diamond), NGF antibodies (i.e. A-NGF; black triangle) or cytochrome-C (i.e. CYT-C; grey 
square). The lower values in the y axis (i.e. -3) indicate the lower mortality while higher values (i.e. -1) 
represent higher mortality.
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NGF pre-treatment therefore delays the onset of cell death in vitro compared to anti- 
NGF and control pre-treatments, causing not only an increase but also a change in the 
survival pattern.
4.2.2 Effect of "early’ (age 3-7wks) pre-treatment with NGF, or CYT-C on in vitro 
neuron survival and mortality: 8 MONTH GROUP
SCG neurons were taken 6 months after pre-treatment at 3-7wk, i.e. at 8 months of age, 
with NGF or CYT-C (see chapter II). Survival of these neurons was examined as before 
(see 4.1). No animals were treated with anti-NGF for this group. Eight months of age in 
the Sprague Dawley rat represents adulthood, including achievement of maximum 
crown-rump length (T Cowen, personal observations). NGF and CYT-C pre-treated 
neurons show a similar steep decline in survived over Phase 1 (Days 1-5; Fig. 4.3). In 
Phase 2, however, NGF cells exhibit significantly (p < 0.01) enhanced survival 
(maintained lt) compared with CYT-C neurons (steep decrease in lt) (Fig. 4.3) indicating 
that increased availability o f NGF in early postnatal life has significant and prolonged 
effects on the capacity of neurons to survive in vitro in the absence of NGF or serum. In 
contrast to the acute group, few neurons from 8 month old animals in either treatment 
group survive beyond Phase 2. Therefore phase 1 is characterised by evidence of early 
cell loss in both groups, while phase 2 shows the main differences between the 
treatments at 8 months. Phase 1 is characterised by a higher but not significant lt for 
CYT-C; when phase 2 starts NGF shows the characteristic plateau, and the CYT-C 
shows a steep decrease in lt (see figure 4.3). Phase 3 shows a rapid decline in lt for both 
treatments, with a faster decline in CYT-C compared to NGF, even though t to t+1 is 
longer in CYT-C compared to NGF.
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Figure 4.3: In vitro survival of 8 months group of SCG neurons from animals pre-treated in vivo at 3-7 weeks 
old with NGF (diamond, black solid line), or CYT-C as a control (square, grey solid line).
The mortality rate results (see figure 4.4) show a phase one with slightly but not 
significant higher mortality of NGF pre-treated neurons compared to CYT-C, followed 
by phase two where NGF pre-treated neurons have a substantially higher lt ( therefore a 
low mortality) compared to CYT-C.
Phase three is distinguished by a low mortality of NGF pre-treated neurons. These 
behaviours may be due to the fact that NGF pre-treated neurons once plated in vitro 
tend to have a worst reaction than CYT-C at the beginning (i.e. phase one), but a lower 
mortality rate in phase three, which may be attributed to the in vivo NGF pre-treatment 
positive effect.
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Figure 4.4: log plot of the 8 months group mortality rate in vitro of SCG neurons treated in vivo at 7 weeks old 
with NGF (black diamond) or CYT-C (grey square). The lower values in the y axis (i.e. -3) indicate the lower 
mortality while higher values (i.e. -1) represent higher mortality
4.2.3 Effect o f 'early ’ (age 3-7wks) pre-treatment with NGF, anti-NGF or CYT-C on in 
vitro neuron survival and mortality: 18 MONTH GROUP
In this group, SCG neurons were taken 16m after pre-treatment with NGF, anti-NGF or 
CYT-C, i.e. at 18 months o f age. Eighteen months represents an age intermediate 
between senescence (24m), when approximately 50% o f the cohort has died, and 8 
months, representing the achievement o f full adulthood. Eighteen months is also the 
age around which vulnerable neurons appear to be lost due to ageing SCG (Gatzinsky et 
al., in press). Over the large majority o f the survival period in vitro, the NGF pre-treated 
neurons exhibit significantly enhanced survival compared with CYT-C pre-treated cells 
(p < 0.01). A-NGF neurons, in contrast, exhibit significantly lower levels o f survival 
than either o f  the other pre-treatment groups (both p < 0.01; see figure 4.5). In the early 
part o f phase 1, NGF and CYT-C cells show a similar decline in survival, while A-NGF
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neurons already in phase 1 survive less well than either o f the other two groups. 
However, from day 3, NGF neurons show a significant higher lt compared to the control 
and A-NGF. A-NGF has the shortest t to t+1, and all neurons were lost by day 7 NGF 
neurons had the longest t to t+1. Phase three is characterised by a significantly higher 
NGF lt compared to control. The results at eighteen months are similar to results from 
earlier groups, in that NGF pre-treatment significantly increases both lt and t to t+1 
compared with CYT-C. However, in this group, A-NGF has a more rapid effect than 
NGF and a far more deleterious effect on survival overall compared to the acute group. 
In addition, the maximum survival time for all treatments was shorter than in previous 
groups.
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Figure 4.5: In vitro survival of 18 months group of SCG neurons from animals pre-treated in vivo at 3-7 weeks 
old with NGF (diamond, black solid line), NGF antibodies (i.e. A-NGF; triangle, black segmented line), or 
CYT-C as a control (i.e. CYT-C; square, grey solid line).
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In phase 1, the mortality rate for 18m A-NGF neurons is very high, while that for NGF 
neurons is low (figure 4.6). The mortality o f  the latter tends to increase slightly in phase 
two, but it is still characterised by a longer t to t+1, showing once more the positive 
effect o f  ‘primed cells’ due to the in vivo pre-treatment with NGF and the resulting 
delayed cell death in vitro. CYT-C neurons show mortality values intermediate between 
those o f NGF and A-NGF.
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Figure 4.6: log plot of the 18 months group mortality rate in vitro of SCG neurons treated in vivo at 7 weeks 
old with NGF (black diamond), NGF antibodies (i.e. A-NGF; black triangle) or cytochrome-C (i.e. CYT-C; 
grey square). The lower values in the y axis (i.e. -3) indicate the lower mortality while higher values (i.e. -1) 
represent higher mortality
4.2.4 Effect o f  ‘early’ (age 3-7wks) pre-treatment with NGF. anti-NGF or CYT-C 
treatment on in vitro neuron survival and mortality: 24 MONTH GROUP 
24 months o f  age in Sprague Dawley rats from the RFUCMS colony represents 
senescence, i.e. the age by which approximately half o f the cohort has died.
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Results from the twenty-four months groups are very different from previous results 
(see figure 4.7). Even though there are some significant differences when comparing the 
three different groups (p = 0.02) and between the A-NGF and the CYT-C (p = 0.003), 
there is no significant difference between the NGF and the CYT-C, or between the NGF 
and A-NGF groups. The lt is very similar between treatments although A-NGF has the 
longest t to t+1 value. Compared to the 18m neurons, those at 24m on average survive 
longer, reinforcing the suggestion that vulnerable neurons have already died.
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Figure 4.7: In vitro survival of 24 months group of SCG neurons from animals pre-treated in vivo at 3-7 weeks 
old with NGF (diamond, black solid line), NGF antibodies (i.e. A-NGF; triangle, black segmented line), or 
CYT-C as a control (i.e. CYT-C; square, grey solid line).
Results form the mortality rate gives us more information on the behaviour of this 
particular group (see figure 4.8). In actual fact there is a longest t to t+1 for the A-NGF 
compared to the other two pre-treatment in vivo; but if  we observe the mortality rate 
across the three different phase we may notice that during phase one the highest
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mortality is recorded for NGF and the lowest for CYT-C. The end o f phase two shows a 
very low mortality for NGF, again this may indicate the real survival behaviour after a 
phase one o f settlement. Phase three shows the lowest mortality for CYT-C.
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Figure 4.8: log plot of the 24 months group mortality rate in vitro of SCG neurons treated in vivo at 7 weeks 
old with NGF (black diamond), NGF antibodies (i.e. A-NGF; black triangle) or cytochrome-C (i.e. CYT-C; 
grey square). The lower values in the y axis (i.e. -3) indicate the lower mortality while higher values (i.e. -1) 
represent higher mortality
4.2.5 Effect o f  ‘early’ (age 3-7wks) pre-treatment w ith NGF. anti-NGF or CYT-C 
treatment on in vitro neuron survival and mortality: ACROSS AGE COMPARISONS 
During phase one o f  the CYT-C pre-treated groups across ages, there are no particular 
differences between the age groups. However we can notice a difference in lt, starting in 
phase two and continuing in phase three. The 24 month group has t to t+1 and It which 
are significantly higher compared to the acute (p < 0.01), to the 8 months (p < 0.01), and 
the 18 months (p < 0.01). The shortest t to t+1 is in the 18 months group. It seems that
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survival o f  control (CYT-C pre-treated) neurons is unexpectedly better in the most aged 
group compared to the younger stages, at least over the longer periods in culture.
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Figure 4.9: Comparison of in vitro survival of SCG neurons pre-treated in vivo with CYT-C across ages. 
Acute group (diamond, black solid line); 8 months group (grey square, solid line); 18 months group (grey 
empty diamond, solid line); 24 months group (black cross, dotted line).
Comparisons across ages o f  neurons pre-treated in vivo with NGF are shown in figure 
4.10. The acute group seems to have an lt significantly higher than the 8 months (p =
0.01), the 18 months (p = 0.0007), and the 24 months (p = 0.002) groups, i.e. NGF pre­
treatment enhances survival most at the earliest stage. The eighteen month group has the 
lowest response to NGF and exhibits the shortest overall duration o f survival in vitro, 
differing substantially from the other groups; again suggesting that the 18m is the age at 
which the most vulnerable neurons die.
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Figure 4.10: Comparison of in vitro survival of SCG neurons pre-treated in vivo with NGF across ages. Acute 
group (diamond, black solid line); 8 months group (grey square, solid line); 18 months group (grey empty 
diamond, solid line); 24 months group (black cross, dotted line).
Comparisons across ages o f  neurons pre-treated in vivo with A-NGF are shown in 
figure 4.11. The 24 month group is relatively unaffected by A-NGF pre-treatment in 
vivo as the lt is the highest o f  all (see figure 4.11). The lt o f the acute, the 18 months and 
the 24 months are significantly different (p < 0.01); with the eighteen months being the 
lowest o f  the three, showing again that this is the age at which the most vulnerable 
neurons die. The t to t+1 o f  the 18 months is the lowest, while the 24 months is the 
highest. This com parison underlines once again the lack o f an apparent pre-treatment 
effect on the 24 month group, suggesting that only ‘super’ neurons are left at this age.
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Figure 4.11: Comparison of in vitro survival of SCG neurons pre-treated in vivo with A-NGF across ages. 
Acute group (diamond, black solid line); 8 months group (grey square, solid line); 18 months group (grey 
empty diamond, solid line); 24 months group (black cross, dotted line).
4.2.6 Effect o f  Tate’ (age 3 months) pre-treatment with NGF or CYT-C treatment on in 
vitro neuron survival and mortality
The effect o f  the pre-treatment administered at later period o f postnatal development,
i.e. at 3 months as opposed to 3-7 weeks as in the previous experiments, demonstrates a 
completely different effect. NGF pre-treatment at this later stage fails to provide any 
protection o f  neuron survival in vitro at any stage o f  the culture period. While there is 
no difference in survival during phase 1, there appears to be reduced survival o f the 
NGF pre-treated group compared to CYT-C in phase 2. In addition, CYT-C pre-treated 
cells appear to survive farther into phase 3 than their NGF-pre-treated counterparts. 
Thus postnatal age has a major effect on the capacity o f  neurons to alter their in vitro 
survival response to NGF pre-treatment., in fact, as shown in figure 4.12, SCG neurons
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pre-treated in vivo with NGF don’t manifest a higher lt, with the exception o f phase one. 
Phase two shows a significantly lower lt for NGF pre-treated neurons compared to the 
control (p < 0.01); t to t+1 is also lower for NGF compared to CYT-C. NGF pre­
treatment in vivo seems to have a negative effect in vitro SCG.s neuronal survival.
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Figure 4.12: In vitro survival o f late treatment group of SCG neurons from animals pre-treated in vivo at 3 
months old with NGF (diamond, black solid line), or CYT-C (square, grey solid line).
The mortality rate (figure 4.13) shows some more details on the behaviour o f the cells 
with different pre-treatment. CYT-C pre-treated cells shows a high mortality in phase 
one contrasted by a very low one in phase two. NGF pre treated neurons present the 
highest mortality in phase three.
108
DAYS IN CULTURE
Figure 4.13: log plot of the late treatment group mortality rate in vitro of SCG neurons treated in vivo at 3 
months old with NGF (black diamond) or cytochrome-C (i.e. CYT-C; grey square). The lower values in the y 
axis (i.e. -3) indicate the lower mortality while higher values (i.e. -I) represent higher mortality.
The lt o f the 8 m onths group is significantly higher than the late treatment group (p < 
0.01). Therefore, from comparison o f  the early and late treatment groups at 8m it seems 
that the ‘early’ in vivo pre-treatment has a significant effect in increasing neuronal 
survival across ages, while late treatment doesn’t have the same effect.
4.2.7 Effect o f  ‘early’ (age 3-7wks) pre-treatment with NGF, or CYT-C treatment on in 
vitro neuron survival and mortality: SUB-POPULATIONS OF NEURONS
PROJECTING TO THE IRIS AND MCA
In these experiments, the subpopulations o f neurons projecting to iris and MCA were 
retrogradely traced some days before the ganglia were removed for tissue culture. Pre­
treatment with NGF or CYT-C was carried out as before and the animals were killed 
(6m after term ination o f  treatment), i.e. at 8 months o f age. The results in figure 4.14
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show how the two different subpopulations of SCG neurons respond in vitro after the 
different in vivo pre-treatments. Phase 1 exhibited similar survival responses for all 
groups. Phase 2, however, saw the lowest survival in the CYT-C pre-treated, MCA- 
projecting neurons, while CYT-C-treated iris-projecting neurons survived somewhat 
better (although there is no significant difference, p = 0.08), i.e. control MCA neurons 
seems to be more vulnerable than iris neurons under in vitro conditions, just as they are 
during ageing. Also during phase 2, NGF pre-treatment significantly enhanced survival 
of MCA neurons (p < 0.01), indicating plasticity of phenotype of this subpopulation 
during early postnatal life. However, NGF pre-treatment had some significant effect on 
survival of iris-projecting neurons (p < 0.01) compared to control, as well as between 
MCA and iris (p < 0.01), both showing a very small standard error. Only iris neurons 
(NGF or CYT-C pre-treated) and NGF pre-treated MCA neurons survived significantly 
into phase 3. Phase two and phase three describe an interesting behaviour; in phase two 
lt of the MCA subpopulation pre-treated with NGF, is the highest, showing a large 
effect of the pre-treatment on a subpopulation characterised by a single unit innervation. 
Phase three shows a significant lower lt of the MCA subpopulation pre-treated with 
CYT-C, while the NGF pre-treatment seems to have pushed the survival curve up to the 
iris level.
110
100
3
UJz
; F tt i i i  r i i '* 1*4  i * i
7 9 11 13 15 17531
— *—-N G F  MCA
• NGF RIS
, .  .A. . ■ CYT-C MCA
—  0* - CYT-C RIS
DAYS IN CULTURE
Figure 4.14: Comparison of in vitro survival of subpopulations projecting either to the iris or to the MCA 
target tissues o f SCG.s neurons pre-treated in vivo with NGF or CYT-C. MCA pre-treated with NGF (black 
triangle, solid line); iris pre-treated with NGF (grey square, solid line); MCA pre-treated with CYT-C (black 
triangle, dotted line); iris pre-treated with CYT-C (grey square, dotted line).
In figure 4.15 the results have been separated, and it shows MCA pre-treated either with 
NGF or CYT-C. Lt o f  M CA pre-treated in vivo with NGF is significantly higher (p < 
0.01); therefore the survival behaviour o f vulnerable subpopulation o f neurons, such as 
MCA, can be enhanced w ith pre-treatment in vivo with NGF during maturation.
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Figure 4.15: Comparison of in vitro survival of subpopulations of SCG neurons projecting to MCA in animals 
pre-treated in vivo with NGF or CYT-C. MCA pre-treated with NGF (black triangle, solid line); MCA pre­
treated with CYT-C (black triangle, dotted line).
Results o f  the iris projecting neurons pre-treated in vivo with either NGF or CYT-C are 
shown in figure 4.16. Even though there is significance difference between the two 
curves (p < 0.01), in every phase there seems to be a similar behaviour. Despite the fact 
that NGF pre-treatment in vivo seems to have elevated significantly the lt o f these 
neurons, if  we compare these results with those from the MCA, we can observe that the 
increase in survival due to pre-treatment is much lower for the iris compared to the 
MCA.
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Figure 4.16: Comparison o f in vitro survival of subpopulations of SCG neurons projecting to the iris in 
animals pre-treated in vivo with NGF or CYT-C. Iris pre-treated with NGF (grey square, solid line); iris pre­
treated with CYT-C (grey square, dotted line).
The mortality rate graph gives us interesting information as well (see figure 4.17). There 
is very low mortality for all groups during phase one, which starts to increase only 
during the first part o f  phase three. The subpopulations group is therefore characterised 
more by phase three rather than phase two or one like previous groups. Phase three is 
showing a higher mortality rate for both iris and MCA pre-treated in vivo with CYT-C; 
meaning that the effect o f  NGF pre-treatment has elevated lt, in MCA subpopulation 
more than in the iris one.
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Figure 4.17: log plot o f the subpopulation groups of SCG neurons projecting either to the iris or to the MCA 
target tissues eight pre-treated in vivo at 3-7 weeks old. MCA pre-treated with NGF (black triangle, solid 
line); iris pre-treated with NGF (grey square, solid line); MCA pre-treated with CYT-C (black triangle, dotted 
line); iris pre-treated with CYT-C (grey square, dotted line). The lower values in the y axis (i.e. -3) indicate the 
lower mortality while higher values (i.e. -1) represent higher mortality; trendlines are purely illustrative, the 
results are based on p-values.
4.2.8 Effect o f  in vitro treatm ent w ith growth factors (insulin. IGF. BDNF and GDNF) 
on survival and mortality o f  SCG neurons, pre-treated at 3-7wk o f age, with NGF or 
CYT-C: ACUTE GROUP
It is interesting to know whether the in vitro responsiveness o f  acute SCG neurons to 
neurotrophic and growth factors was altered by in vivo pre-treatment during early 
postnatal life w ith NGF (figure 4.18) or CYT-C (figure 4.19). The effects obtained by 
adding growth factors in culture to pre-treated neurons were remarkable. NGF, insulin, 
IGF-1, BDNF and GDNF all had similar effects in vitro. However, their effects were
114
opposite in NGF pre-treated cells compared to CYT-C pre-treated cells: thus where the 
cells had been pre-treated with NGF the effect o f all the factors was to lower the lt 
value; while where the cells have been pre-treated with CYT-C the effect o f the factors 
in culture was the opposite and therefore served to increase the lt level. The lt for 
neurons pre-treated with NGF was significantly lowered by insulin (p < 0.01), IGF-1 (p 
< 0.01), GDNF (p =  0.01), and BDNF (p < 0.01). Comparisons o f  the effect o f the same 
factor on neurons subject to different pre-treatments in vivo, insulin and IGF-1 showed 
significant differences (p < 0.05, p = 0.01, respectively), but neither GDNF (p = 0.06) or 
BDNF (p = 0.5) showed significant differences, suggesting that these factors supported 
comparable level o f  neuron survival, irrespective o f  the pre-treatment.
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Figure 4.18: Effects of in vitro growth factor treatment on survival acute SCG neurons pre-treated in vivo at 
3-7 weeks with NGF. The legend reads: NGF (NGF applied in vivo; black diamond); INSULIN (i.e. insulin 
applied in vitro, NGF applied in vivo; black triangle); IGF-1 (i.e. IGF-1 in vitro, NGF in vivo; black square); 
GDNF (i.e. GDNF in vitro, NGF in vivo; grey triangle); BDNF (i.e. BDNF in vitro, NGF in vivo; grey square).
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Figure 4.19: Effects of in vitro growth factor treatment on survival acute SCG neurons pre-treated in vivo at 
3-7 weeks with CYT-C. The legend reads: CYT-C (CYT-C applied in vivo; grey diamond); INSULIN (i.e. 
insulin applied in vitro, CYT-C applied in vivo; black triangle); IGF-1 (i.e. IGF-1 in vitro, CYT-C in vivo; 
black square); GDNF (i.e. GDNF in vitro, CYT-C in vivo; grey triangle); BDNF (i.e. BDNF in vitro, CYT-C in 
vivo; grey square).
4.3 Discussion
In Chapter I, as well as in the introduction o f  this chapter three main assumptions have 
been stated: firstly adult neurons become partly independent o f neurotrophic factors for 
their survival in vitro (Diamond et al., 1992; Orike et al., 2001); secondly there is no 
evidence for age-changes in level o f  expression o f neurotrophic factors which might 
explain altered patterns o f  survival (Kuchel et al., 1999; Cowen, 2002; Gatzinsky et al., 
2004); and thirdly evidence that vulnerability is associated with early-life (and perhaps 
life-long) exposure to different levels o f neurotrophic factors (Cowen et al., 2003).
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My hypothesis is therefore that pre-treatment during early postnatal life (maturation) 
with NGF and NGF antibodies would permanently affect SCG neuron survival in later 
life. If this hypothesis is proved, can altered availability of NGF in later (adult) life have 
similar effects? Are we looking at a maturational phenomenon, or at a lifetime 
neuroprotective programme?
Results indicate that altering NGF availability during postnatal life has a significant 
effect on the capacity of sympathetic neurons to survive in vitro in the absence of serum 
and neurotrophic factors and without supporting glial cells.
The first question regarding my results is whether early life 're-setting* of neuron 
survival is equally effective with different pre-treatments and whether this effect 
changes with age?
My studies of neuron survival in vitro have shown three major phases. In all groups 
studied, phase one is characterised by an initial high mortality, probably due to a 
settling time in the new in vitro environment. Once the mortality rate reaches a plateau, 
normally between day 3 and 5, the second phase starts with a lower mortality, followed 
by the third phase of high mortality, which may be attributed to a mutation 
accumulation effect. The end of the third phase is characterised by low mortality and the 
prolonged survival of a very few ‘super neurons’ which may be comparable to human 
centenarians.
Acute group: Comparison of the acute effects of in vivo NGF pre-treatment in the 
present study with in vitro NGF treatment (Orike et al., 2001) reveals different effects 
on survival: NGF pre-treatment in vivo enhances neuronal survival in vitro (see above), 
while NGF treatment in vitro does not. Results, from the acute group, show that the 
NGF effect, from day 3 in vitro, enhances and extends survival, right through phase
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three. According to Tsui-Pierchala and Ginty (1999), the half life of the signaling NGF- 
phospho-TrkA complex in adult sympathetic neurons is about 2 days, indicating that 
even at this early stage, active NGF signaling is unlikely to be retained long enough to 
cause an altered survival response and for that reason we can assume that the effect in 
vitro is a 'conditioning' response to NGF and not just an ongoing direct effect of the 
treatment.
In contrast, anti-NGF shows no effect at this stage; this might be due to a temporary 
inflammatory effect caused by the anti-NGF pre-treatment in vivo which in turn 
initiated endogenous NGF production (Mcmahon, 1996; Safieh-Garabedi et al., 2002). 
This endogenous upregulation of NGF might have rescued neurons and hence masked 
the effect o f the anti-NGF pre-treatment.
Another possible explanation is that anti-NGF pre-treatment has killed neurons in vivo 
and therefore we are looking at a normal survival pattern of the remaining cells in vitro. 
However, the neuron counts that were made on ganglia pre-treated in the same way in 
vivo (see Chap. Ill) do not demonstrate any significant cell loss as a result of pre- 
treatment with anti-NGF, therefore the latter possibility is effectively ruled out.
Thirdly, I suggest a combination of neuronal depletion (due to NGF deprivation) in 
some areas and rescue (by upregulation of endogenous NGF as a result of inflammatory 
responses) in other areas such as skin, ears and other target tissues.
Accordingly from the NGF pre-treatment results we may deduce that SCG neuronal 
cells become primed by the NGF pre-treatment in vivo. However the following question 
arises: do neurons retain such characteristics throughout life?
8 months group: This question is answered by the NGF effect 6 months after 
termination of treatment, where neurons survival pattern is still high compared to
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control, particularly in phase two, and therefore neurons have been primed by the in 
vivo pre-treatment and what we were looking at in the acute group is not only a 
temporary effect.
NGF has a number of roles in the development of neurons, as is widely known; during 
development NGF promotes survival and later supports maturation of sympathetic 
neurons through growth, enhancement of tyrosine hydroxylase synthesis and other 
aspects of mature neuronal phenotype (Conover and Yancopoulos, 1997; Johnson et al., 
1986; Snider, 1994). Once mature, SCG neurons lose their absolute dependence on 
NGF for survival; NGF signaling shifts to regulation of neuronal phenotype and 
function (Johnson and Deckwerth, 1993; Sofroniew et al., 1990, 1993; Svendsen et al., 
1994).
The 8 month’s NGF effect, from day 5, enhances the proportion of neurons surviving, 
principally in phase 2, but no extension of survival is detected. Results were most 
exciting, because they almost mirrored the acute group results with the exception of 
phase one, in fact NGF pre-treatment had no significant effect on neuronal survival 
pattern until day 5 in culture. Phase two, changes in which are characteristic of every 
group, revealed a clear significant increase in survival showing that NGF pre-treated 
cells are primed compared to CYT-C (control).
The natural next question is: how would the primed cells react to pre-treatment during 
ageing? Understanding of changes with increased age has been attempted by several 
scientists. According to Cowen et al. (2003), ageing shows a decrease in neurotrophin 
uptake.
18 months group: Therefore 16 months after termination of pre-treatment in vivo we 
looked at the results in 18 months old SCG neurons. The 18 month NGF pre-treated
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group shows enhanced survival from day 2, but the shortest t to t+1 of all groups. NGF 
pre-treatment shows a small extension o f survival, but this doesn't reach phase 3. The 
A-NGF effect is stronger, compared with acute, affecting neurons from day 1 and 
reducing maximum survival time to 7 days (shortest of whole study). Ageing neurons in 
vitro had a very similar result to the acute group in terms of phase pattern, with two 
exceptions; primarily t to t+1 is half as long, and therefore as neurons age lifespan in 
vitro is reduced, and secondly the NGF antibody pre-treatment has a marked effect by 
reducing neuronal survival. The anti-NGF effect may also support the idea that neuronal 
vulnerability is increasing at 18 months (Gatzinsky et al., 2004) i.e. neurons may be 
close to a threshold affecting their capacity to survive in vitro and therefore both NGF 
and anti-NGF pre-treatment in vivo have a marked effect on survival of neurons in 
vitro.
24 months group: There is an unexpected absence of difference between the three pre- 
treatments in vivo; these results may be explained by the fact that the majority of the 
neurons (vulnerable neurons) have already died (around 18 months of age) and the 
remaining cells are the ‘super’ neurons, a subpopulation which for reason we do not 
presently understand are capable o f surviving perhaps beyond the mean lifespan of the 
organism. This subpopulation may include the protected iris-projecting neurons which 
survive successfully to 24 months (Gatzinsky et ah 2004)
Across age comparisons show another interesting result, when pre-treated with anti- 
NGF or NGF, the 24 months group have in general a better survival curve in vitro 
compared to the 18 month group; except for phase one with NGF pre-treatment when 
the 24 months group has lower survival. The anti-NGF and phase three of the NGF pre­
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treated cells (corresponding to senescence in culture) have a positive effect on the 24 
months group.
Across-ages comparison is very important: the results show that NGF pre-treatment in 
vivo rescues successfully in acute, 8m and 18m groups, but not in 24m, while anti-NGF 
gives adverse effects only at 18m, and not in acute (possibly because of inflammatory 
response) or at 24m (because all vulnerable neurons have died earlier). No anti-NGF 
pre-treatment have been done at 8 months.
In vivo pre-treatment has therefore been shown to prime cells such that their in vitro 
survival is altered when administered before the end of development (3 to 7 weeks old), 
but are cells primed as well if  treatment is begun after the end o f maturation in early 
adulthood, starting at 3 months old?
The late treatment group show that this is apparently not the case. In contrast to 
treatment at 3-7wk, NGF pre-treatment at 3 months doesn’t enhance the survival curve 
but on the contrary it reduces survival. Therefore, we are looking at a developmental or 
maturational phenomenon, rather than a lifetime regulatory mechanism of neuronal 
survivability. We predict therefore that the association between target levels of NTFs 
and neuronal vulnerability established in Gatzinsky et al. (2004) is based on the 
exposure of neurons to differing levels of NTFs during development and maturation 
only and that later life alterations will not affect this aspect of phenotype which we can 
therefore designate as a ’survivability programme' which operates during late 
development (maturation).
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Subpopulations group: How vulnerable subpopulations react to the pre-treatment is the 
next issue; results confirmed observations from Gatzinsky et al. (2004), where it was 
shown that age-related neurodegeneration and neuronal cell death, in subpopulations of 
SCG neurons, are associated with die level o f NGF availability from the target, which 
was high for the iris and low for cerebral vessels (CV); NGF uptake was 
correspondingly low for the vulnerable CV projecting neurons and higher for the 
protected iris-projecting neurons. I have shown that the survival pattern o f vulnerable 
neurons (CV-projecting) pre-treated in vivo with NGF is changed and enhanced to reach 
the level of protected subpopulations of neurons (iris). However the survival curve of 
protected iris projecting neurons is not enhanced by pre-treatment with NGF. An 
hypothesis could be that iris neurons are already programmed (by high target levels of 
NGF) to survive maximally, while the MCA neurons are not, and only in the latter 
group can their later life survivability be re-set by altering levels of NGF availability 
during maturation.
The difference may lie in the phenotype and functional adaptations that differentiate the 
two populations: single-unit innervation by large complex neurons characterises the iris- 
projecting population, while multi-unit innervation by smaller, simpler neurons 
characterises the CV-projecting group (Andrews et al., 1996; Bumstock, 1993). When 
both subpopulations receive high levels o f NGF during maturation, the survival levels 
of both populations at later stages in vitro become very similar. Thus, NGF pre­
treatment enhances survival o f  MCA neurons (both It and t to t+1, extending into phase 
3) but not in iris neurons (either proportion or duration of survival). Therefore the level 
of NGF supplied by the target tissues seems to determine the phenotype of the cells as 
well as their vulnerability (Cowen et al., 2003; Andrews et al., 1996; Cowen, 1984). 
Furthermore there is a maximum potential level of survival for SCG neurons which
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corresponds to the level reached by the iris-projecting neurons. This helps to understand 
the 24 months group results. These ‘super’ neurons resemble, and include, iris- 
projecting neurons which do not exhibit age-related cell death (Gatzynsky et al. 2004). 
They appear to be resistant to pre-treatment with both anti-NGF and NGF, hence either 
their survival is regulated by different mechanisms, or their ‘survival threshold’ is set at 
such a level that they are unaffected by pre-treatment.
The regulation o f apoptosis by survival factors is critical for normal development and 
proper functioning o f the nervous system. Nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) belong to the first identified group o f factors suppressing 
neuronal apoptosis (Levi-Montalcini and Booker, 1960; Barde, 1989).
Cowen et al. (1996) failed to find an association between age-related neuronal 
vulnerability and reduced NGF availability. Katoh-Semba, Semba et al. (1998) studied 
the brain o f senescence-accelerated (SAM) mice, and also, despite evidence of 
neurodegeneration, found no reduced levels o f neurotrophin expression compared with 
wild-type animals. My results, however, show that when NGF levels are varied before 
the end of development in vivo neurons become primed (results for the acute group) and 
retain such characteristic later on in life (8 and 18 months group). This emphasises the 
above conclusion that early life conditions, including the level of availability of target- 
derived factors, in some way set the subsequent capacity of neurons to survive into old 
age.
In vitro treatment with growth factors suggests that altered exposure to NGF changes 
the pattern o f acute responsiveness o f SCG neurons to other NTFs and growth factors.
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The addition in culture o f exogenous growth factors such as, insulin, IGF-1, GDNF, and 
BDNF caused a very interesting effect; all factors caused decreased survival of neurons 
pre-treated in vivo with NGF, but enhanced survival when cells had been pre-treated 
withCYT-C.
Are external factors triggering a receptor mediated response? According to Segal (2003) 
various tissue culture and animal experiments indicate that the nature of the receptor 
ligand specifies the signaling pathways activated. Furthermore in vivo studies (Fan et 
a l , 2000) demonstrate clearly that biological responses elicited by for example TrkB 
(BDNF receptor) signaling are modulated by the identity of the activating ligand.
Or are external factors converging on common pathways which result in stimulating 
phosphorylation o f CREB? Ginty et a l  (1994) suggested that CREB might be involved 
in growth factor-stimulated gene expression. Bonni et a l (1995) revealed that CREB 
plays a critical role in mediating growth factor induction of c-fos gene transcription, and 
showed that induction occurs in a Ser 133-dependent manner, and activation of CREB- 
dependent transcription. Finkbeiner et a l  (1997) found that BDNF stimulates both 
Ca2+/calmodulin-dependent kinase IV and the Ras-MAPK cascade, leading to CREB 
phosphorylation at Ser 133. Nakajima et a l (1996) suggested that certain signals 
initiated by growth factor stimulation interfere with the association of CREB with 
CREB-binding protein (CBP), for example NGF stimulation of Ras-MAPK pathway in 
PC 12 cells induces a CBP-RSK (RSK is the ribosomal protein SG Kinase, a substrate of 
ERKs) interaction, thereby sequestering CBP and inhibiting c-AMP responsive 
element- (CRE) and CREB- mediated transcription. Insulin also represses cAMP- 
induced activation o f CREB, and both NGF and insulin represses c-AMP-induced 
activation of CREB (Yeagley et a l , 1998).
In conclusion, my results show:
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1. That NGF by itself increased survival during later life, and that anti-NGF decreased 
it. Both effects were most marked at 8-18 months.
2. The lack o f effect of late treatment effect suggests that only those neurons pre-treated 
before the end o f development are affected.
3. Subpopulations o f neurons are affected differently according to the level o f NGF they 
receive, but pre-treatment affects CV-projecting neurons more than iris-projecting 
neurons possibly due to the fact that iris-projecting neurons are already programmed to 
reach a maximum threshold, while CV-projecting neurons survivability can be re-set by 
altering levels of NGF availability before the end of development; possibly due to the 
difference in phenotypes between the two subpopulations of neurons.
4. A range o f growth and neurotrophic factors by themselves also increased survival; 
however, pre-treatment in vivo with NGF together with the treatment in vitro with other 
factors appears to repress survival.
We have shown a programme that can be manipulated during maturation but not in 
adulthood, which has effect in late life neuron survival in vitro. How should we 
understand this apparent contradiction? We suggest that early life conditions which 
determine trophic availability, phenotype and function, have a ‘knock on’ or pleiotropic 
effect on late life survival. Furthermore, we hypothesize that there are adaptations i.e. 
increasing survival o f vulnerable neurons does not enhance function during maturation 
or in adult life. Alternatively I hypothesize an adaptive outcome o f this programme, 
namely functional adaptation o f neuronal phenotype to the particular needs of different 
targets (as previously explained in the general introduction and the chapter 
introduction). If NGF pre-treatment in vivo confers additional protection by inducing 
vulnerable neurons to survive than we might suggest that target receive additional
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innervation but which may not contribute to function. Alternatively NGF pre-treatment 
in vivo protects neurons that survive postnatal competition but remain vulnerable to 
age-related degeneration.
The NGF pre-treatment in vivo caused an increased in survival of SCG.s neurons, with 
changes that are likely to involve the PI3-K/Akt pathway with possible activation of 
PTEN, p53, and GSK-3|3, and/or ERK pathway.
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CHAPTERV
SIGNALING PATHWAYS INVOLVED IN ALTERED SURVIVAL OF ADULT 
AND AGEING NEURONS INDUCED BY NGF PRE-TREATMENT IN VTVO
5,1 Introduction
The nature and mechanisms o f activation of anti-apoptotic signaling pathways triggered 
by neurotrophins have been extensively described by Segal and Greenberg (1996), 
Kaplan (1998), Friedman and Greene (1999), and Klesse and Parada (1999). The Trk 
neurotrophin receptors trigger activation of the signaling kinases PI3-K (Franke et al., 
1997; Hemmings, 1997), and ERK1/2 (Lewis et al., 1998; Cobb, 1999; Grewal et al., 
1999) which play a key role in the survival o f developing sympathetic and other 
neurons. Yao and Cooper (1995), and Xia et al. (1995) first studied the role of PI3-K 
and ERK1/2 in suppressing apoptosis in PC 12 cells. NGF mediated survival was shown 
to be transduced by PI3-K in SCG neurons as well as in DRG and PC12 cells (Crowder 
and Freeman, 1998; Klesse and Parada, 1998, Meyer-Franke et al., 1999).
Following TrkA phosphorylation, PI3-K catalyzes the production of 3- 
phosphoinositides, including PI-3,4,5-P3, which bind to and activate PDK1 which in 
turn associates with and phosphorylates the serine-threonine kinase Akt. Akt 
phosphorylates Bad inducing its association with the 14-3-3 protein, and sequestering it 
from heterodimerization with Bcl-XL. At this point B c1-X l is able to heterodimerize 
with Bax, preventing Bax homodimerization. Homodimerized Bax is a key element in 
apoptotic signaling, via altering mitochondrial membrane potential. The balance of Bax: 
Bax homodimers versus Bax: Bcl-XL heterodimers may determine whether the cell lives 
or dies (Allsopp et a l, 1993) . The anti-apoptotic targets for PI3-K/Akt pathway are
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negative regulation o f GSK-3P, caspase 9, FKHRL1 and Bad and positive regulation of 
L-Ca, IKKa, and eNOS.
Akt (also known as PKB) has two mechanisms o f regulation: binding o f the lipid to the 
PH domain, and activation by autophosphorylation (Burgering and Coffer, 1995). The 
exact mechanism o f this phospho-regulation became apparent when Alessi et al. (1996) 
demonstrated that Akt could be activated by treating cells with insulin or IGF-1, and 
this activation was accompanied by phosphorylation on residues Thr308 and Ser473. 
These phosphorylations were completely blocked by wortmannin (Arcaro and Wymann, 
1993) and LY294002 (Vlahos et al., 1994). Kohn (1995 and 1996) demonstrating the 
role o f Akt in glucose uptake and metabolism. Cross et a l (1995) first described GSK- 
3p as a substrate for Akt. Akt phosphorylates GSK-3P on S9 to inactivate it, and neurons 
in which this pathway is activated become resistant to apoptotic stimuli. The second 
regulatory site on GSK-3p is Y216, phosphorylation of which is necessary for functional 
activity and increased response to apoptotic signals. GSK-3p inhibits the microtubule- 
associated protein (MAP)IB and hyperphosphorylates the microtubule-associated 
protein x (i.e. tau, which form paired helical filaments in Alzheimer’s disease). As 
described by Muller et al. (1994), MAPI A and B are members of the same family of 
high molecular weight microtubule-binding phosphoproteins. MAP IB is found in 
neurons particularly during development, and several phosphorylated isoforms are 
present only in axons. Gordon-Weeks (1997) described the importance of MAP IB in 
regulation of axon outgrowth by influencing the organisation and dynamics of 
microtubules in growing and regenerating axons and growth cones (Gordon-Weeks and 
Fischer, 2000).
The second survival pathway downstream of TrkA is the Ras-MAP kinase cascade. 
Following phosphorylation of tyrosine 490 on TrkA, the adaptor protein She is recruited
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to the receptor; She activates Ras w hich in turn recruits and activates Raf. R af is a 
serine-threonine kinase that phosphorylates the MAP kinase kinase MEK on 2 serines 
initiating the activity o f  a  dual specificity kinase which activates the MAP kinase E rkl/2  
via phosphorylation o f  threonine 202 and tyrosine 204. A t this point phosphorylated 
E rk l/2  m ay either translocate into the nucleus, where they phosphorylate the 
transcription factor Elk-1, or they may phosphorylate the kinase Rsk. Phosphorylation 
o f Elk-1 allows interaction w ith the accessory transcription factor SRF which binds to 
the serum response elem ent (SRE) within the c-fos promoter region and contributes to 
initiation o f  transcription. On the other hand phosphorylation o f Rsk causes its nuclear 
translocation and phosphorylation o f  CREB on serine 133. CREB is bound to the 
coactivator protein CPB, w hich binds to SRF-Elk complex that leads to c-fos 
transcription. A  sim plified diagram is shown in figure 5.1.
NGF
PI3-K
P IP .
P IP
Ras
Akt
Cell survival
Figure 5.1: Schematic representation of the relevant signaling pathways in SCG neurons. Arrows indicate 
stimulation and line indicates inhibition.
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Orike et al. (2001) and others have shown that sympathetic and sensory neurons 
become at least partially independent of NGF and of NGF induced Trk signalling for 
their survival during maturation. Presumably because adult neurons are no longer 
acutely dependent on NGF availability, they are better able to resist injury and possible 
separation from their target tissues. Do these ‘NGF-independent’ neurons therefore 
continue to require a longer term supply NGF for their survival?
NGF-independent adult sympathetic neurons continue to require activation of the PI3-K 
pathway for their survival, despite their loss of responsiveness to Trk activation (Orike 
et al., 2001). The question is therefore raised: does NGF-independence depend on an 
intrinsic and ongoing upregulation of PI3-kinase signalling in adult sympathetic 
neurons? and do different levels of PI3-K activity distinguish those neurons which are, 
or are not, vulnerable to age-related cell death?
Furthermore according to Orike et al. (2001) there is a greater sensitivity of in vitro 
survival of adult sympathetic neurons to PI 3-K inhibition compared to inhibition of 
ERK/MAP-K. Does PI 3-K remain the predominant survival pathway for adult and 
ageing sympathetic neurons, or does the relative contribution of these two pathways 
change during adult life?
Gatzinsky et al. (2004) have recently shown that vulnerable (CV-projecting) SCG 
neurons exhibit cell loss of about 50% between 12 and 18m of age, while iris projecting 
neurons do not exhibit age-related cell loss on the same scale. Will manipulation of 
NGF availability in early life affect differently the capacities of these subpopulations of 
neurons to resist inhibition of the key survival pathways?
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5.1.1 Aims
This chapter aims at studying the effect of pre-treatment in vivo with NGF, A-NGF, or 
CYT-C (control) across ages (acute, 8 months, 18 months, 24 months) on survival 
pathways (PI3-K and ERK1/2) by looking at neuronal behaviour in vitro. In a further 
experiment, the ‘late treatment’ group of animals were treated with the same regime as 
all the other groups with the exception that treatment started at 3 months of age (instead 
of 7 weeks) and animals were sacrificed 6 months after termination o f treatment (i.e. at 
a time interval comparable to the 8 months group). By three months of age male 
Sprague Dawley rats are fully grown and sexually mature; this age has therefore been 
chosen as representing the start o f adulthood.
These experiments aim to test if  the NGF pre-treatment has an effect on survival 
pathways in adult and ageing neurons and whether the effect is the same when pre­
treatment has been started late (i.e. adulthood) or early (i.e. during early postnatal 
development).
5.1.2 Hypothesis
Orike et al. (2001) have described how PI3-K inhibition in vitro affects survival of 12 
wks old SCG neurons, and Crowder and Freeman (1998) showed that prenatal neurons 
are responsive to PI3-K in the presence o f NGF. Therefore my hypothesis is that in vivo 
manipulations o f NGF levels during postnatal maturation will affect permanently one or 
both of the PI3-K and ERK survival pathways and that NGF pre-treatment will protect 
neurons from inhibition o f those pathways. Furthermore, the differential effects of NGF 
pre-treatment on subpopulations of neurons may be the result of different degrees of 
alteration in the activity o f key survival pathways. We predict that different age groups 
will respond differently to either pre-treatment in vivo and/or to treatment in vitro, with
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the 8m and the 18m groups being most vulnerable to inhibition of survival pathways as 
well as to reduced availability o f NGF in early life.
This hypothesis is tested in ex vivo tissues (Chap. Ill) and in cell culture (Chap. IV and 
here) which allows us to study the effect of different in vivo pre-treatment regimes as 
well as in vitro treatment with pathway inhibitors.
5.2 Results
5.2.1 Pharmacological inhibition o f PI3-kinase and ERK signaling pathways, and 
regulation of survival induced bv NGF pre-treatment in vivo: Acute group 
The acute group (SCG neurons taken for dissociated cell culture immediately after the 
cessation of treatment) results of SCG neurons pre-treated in vivo with NGF are shown 
in figure 5.2.
NGF pre-treatment resulted in enhanced survival in vitro compared to neurons from 
animals receiving CytC (p < 0.05). The enhanced survival with NGF was effectively 
blocked by inhibition of PI3-kinase, which was however ineffective in the Cyt-C 
pretreated group. Inhibition o f ERK, in contrast, was effective in both groups. These 
results suggest that altered NGF availability in early postnatal life enhances neuron 
survival by upregulating PI3-kinase, but not ERK/MAP-kinase. The contrasting results 
of inhibiting PI3-kinase and ERK in the control group suggest that at this early postnatal 
stage, and in the absence o f altered NGF availability, ERK/MAP-kinase is the more 
important survival pathway.
There is a significant higher lt (i.e. larger overall number of neurons alive at the time of 
counting) as well as t to t+1 (i.e. individual neurons surviving for longer) for untreated 
neurons in vitro compared to LY (i.e. LY294002; PI3-K inhibitor) or UO (i.e. U0126; 
ERK inhibitor) (p = 0.01; p < 0.01 respectively), meaning that both PI3-K and ERK
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inhibitors have tw o causes: reductions in number o f neurons and reduction in survival 
time. The survival pathways are clearly inhibited and ERK inhibition has at this stage a 
stronger effect on survival compared to PI3-K inhibition (p = 0.05). It is important to 
note that both LY and UO exert a rapid inhibitory effect during phase 1 -  i.e. during the 
initial settling phase in culture (days lto  day 3/5). There is a clear separation between 
phase one, w ith a sharp decline with LY and UO; while phase 2 in all the in vitro 
treatment shows a similar rate o f  decline in neuron survival, resulting in shortened 
maximal survival for the inhibited cultures compared to the control (untreated) cultures. 
(NB no phase 3 for treated cultures).
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Figure 5.2: In vitro survival of acute group SCG neurons from animals pre-treated in vivo at 3-7 weeks old 
with NGF (diamond, black solid line); pre-treated in vivo with NGF and treated in vitro with LY294002 a PI3- 
K inhibitor (square, grey solid line); pre-treated in vivo with NGF and treated in vitro with U0126 an ERK 
inhibitor (white triangle, dotted line).
Figure 5.3 shows SCG neurons pre-treated in vivo with CYT-C and inhibited in vitro 
with either LY294002 or U 0126. LY doesn’t have a significant effect on survival
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compared to the untreated cultures, while UO has a significant effect compared to 
untreated (p < 0.01). This may show that at this stage of development ERK plays a 
predominant role in regulating cell survival in untreated neurons, although this 
contradicts the findings o f  a previous study (Orike et al., 2001) where 12 weeks old 
SCG neurons have been studied.
Thus, NGF pre-treated neurons tend to be more vulnerable to PI3-K inhibition 
compared to the CYT-C controls suggesting that NGF pre-treatment in vivo is acting 
mainly on PI3-K rather than on ERK-mediated survival pathways.
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Figure 5 3 :  In vitro survival of acute group SCG neurons from animals pre-treated in vivo at 3-7 weeks old 
with CYT-C (triangle, black solid line); pre-treated in vivo with CYT-C and treated in vitro with LY294002 a 
P13-K inhibitor (square, grey solid line); pre-treated in vivo with CYT-C and treated in vitro with U0126 an 
ERK inhibitor (white triangle, dotted line).
Table 5.1 summarises the ANOVA p-values results, with no significant difference in lt 
when com paring CYT-C with LY, and no significance between treatments when UO is 
added in vitro.
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p-VALUES 
ACUTE GROUP
NGF CYT-C j
UNTREATED vs. LY294002 0.00115 Not significant (0.2)
UNTREATED vs. U 0126 0.00972 0.000362
LY294002 vs. U 0126 0.00578 0.00112
LY294002 (NGF) vs. 
LY294002 (CYT-C)
0.000241
U0126 (NGF) vs. U0126 
(CYT-C)
Not significant (0.06)
Table 5.1: Sum m ary o f  the p-value results for the acute group
5.2.2 The 8 months group: pharmacological inhibition of PI3-kinase and ERK signaling 
pathway, and regulation of survival induced bv NGF pre-treatment in vivo 
In the 8 months group neurons have been pre-treated in vivo with NGF or CYT-C 
(control) as in the acute group but observation are carried out six months after 
termination o f the in vivo pre-treatment in order to detect whether the effect of 
treatment is still effective. Results show significant increase in survival following NGF 
in vivo pre-treatment compared to control (p < 0.05). Both PI3-K and ERK inhibitor 
have significant effect in causing decreased survival in vitro following NGF in vivo pre­
treatment (both p < 0.05). See figure 5.4. Both inhibitor have significant effect on CYT- 
C in vivo pre-treated neurons (both p < 0.05), but compared to the acute group, where 
ERK inhibition was stronger, the 8 months group seems to be principally affected by 
PI3-K inhibition (p < 0.05). These latest results are suggesting that there is a switch in 
survival pathway with age, specifically between 7 weeks and 8 months of age.
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NGF in vivo pre-treated neurons shows that LY and UO both depress survival 
significantly in vitro with a lower lt compared to control (both p < 0.01). See table 5.2. 
Comparing LY with UO effect on NGF in vivo pre-treated neurons, there is no 
significant difference at 8m which is different from the acute group where UO was 
significantly more potent than LY, suggesting that the effects of NGF pre-treatment on 
PI3-K-mediated survival have increased with time.
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Figure 5.4: In vitro survival of the 8 months old group SCG neurons from animals pre-treated in vivo at 3-7 
weeks old with NGF (diamond, black solid line); pre-treated in vivo with NGF and treated in vitro with 
LY294002 a P13-K inhibitor (square, grey solid line); pre-treated in vivo with NGF and treated in vitro with 
U0126 an Erk inhibitor (white triangle, dotted line).
Results from figure 5.5 provide strong confirmation that NGF pre-treatment affects 
neuronal survival by upregulating PI3-kinase. Thus, with NGF and CYT-C pre­
treatments, the effects of UO are similar (p = 0.03). However, following NGF pre- 
treatment, resistance to LY is significantly increased compared to UO (p<0.002), 
compared to the NGF pre-treatment results in figure 5.3. There is a significant
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difference between LY and UO (p <0.01) as well as between the two LY pre-treated in 
vivo with NGF or CYT-C and the two UO (respectively p < 0.01, and p = 0.01).
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Figure 5.5: In vitro survival o f the 8 months old group SCG neurons from animals pre-treated in vivo at 3-7 
weeks old with CYT-C (triangle, black solid line); pre-treated in vivo with CYT-C and treated in vitro with 
LY2940O2 a PI3-K inhibitor (square, grey solid line); pre-treated in vivo with CYT-C and treated in vitro with 
U0126 an Erk inhibitor (white triangle, dotted line).
Table 5.2 summarises the p-value results for the 8 months group.
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| p-VALUES
8 M ONTHS OLD GROUP
NGF CYT-C
UNTREATED vs. LY294002 0.00141 0.002
UNTREATED vs. U0126 0.00543 0.003
LY294002 vs. U 0126 Not significant (0.3) 0.002
LY294002 (NGF) vs. 
LY294002 (CYT-C)
0.001
U0126 (NGF) vs. U 0126 
(CYT-C)
.
0.01
Table 5.2: Sum m ary o f  the p-value results for the 8 months old group
5.2.3 The 18 months group: pharmacological inhibition of PI3-kinase and ERK 
signaling pathway, and regulation of survival induced bv NGF pre-treatment in vivo 
In the 18 months group the NGF in vivo pre-treatment significantly enhance survival 
compared to control (CYT-C), p < 0.05.
However, the effect is less than in the 8m group and there are no significant differences 
between the inhibitory effects o f LY and UO. A possible explanation for this result is 
that vulnerable neurons which were rescued by NGF in vivo pre-treatment (as 
demonstrated in Chap. Ill) have been lost between 15 and 18m, confirming results from 
a recent study (Gatzinsky et al., 2004).
Results from figure 5.6 shows that NGF pre-treatment in vivo effect is still effective 
where p < 0.01 for the untreated group compared to LY and to UO. The interesting 
effect is that in phase one and two lt seems to be higher for UO compared to LY, 
something that was not seen in previous age groups. It is possible that during ageing the 
survival pathways switch such that neurons that were pre-treated with NGF availability 
are more affected by inhibition of PI3-K compared to inhibition of Erk.
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Figure 5.6: In vitro survival of the 18 months old group SCG neurons from animals pre-treated in vivo at 3-7 
weeks old with NGF (diam ond, black solid line); pre-treated in vivo with NGF and treated in vitro with 
LY294002 a P 1 3 -K  inhibitor (square, grey solid line); pre-treated in vivo with NGF and treated in vitro with 
U0126 an Erk inhibitor (white triangle, dotted line).
The results seems to be slightly different when neurons have been pre-treated in vivo 
with CYT-C, both survival pathways inhibited in vitro seems to have the same effect on 
neuronal survival. See figure 5.7.
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F ig u re  5 .7 : In v itr o  su r v iv a l  o f  th e  18 m o n th s  o ld  g r o u p  SCG n eu ro n s  from  a n im a ls  p re -tre a ted  in v iv o  a t 3 -7  
w e e k s  o ld  w ith  CYT-C (d ia m o n d , b la c k  so lid  lin e );  p r e - tr e a te d  in  v iv o  w ith  CYT-C and  tr ea te d  in v itr o  w ith  
LY294002 a P I 3 -K  in h ib ito r  (s q u a r e , g r e y  so lid  lin e ); p r e - tr e a te d  in  v iv o  w ith  CYT-C an d  tr ea te d  in v itr o  w ith  
U0I26 an  E r k  in h ib ito r  (w h ite  tr ia n g le , d o tte d  l in e ).
The untreated neurons lt is significant both compared to LY (p < 0.05) and compared to 
UO (p < 0.01); but there is no significant difference between LY and UO inhibition in 
vitro or the comparison of these inhibition between in vivo pre-treatment (see table 5.3).
140
p-VALUES
18 M ONTHS OLD GROUP
NGF CYT-C
UNTREATED vs. LY294002 0.001 0.02
UNTREATED vs. U0126 0.001 0.004
LY294002 vs. U 0126 Not significant (0.7) Not significant (0.09)
LY294002 (NGF) vs. 
LY294002 (CYT-C)
Not significant (0.4)
U 0126 (NGF) vs. U 0126 
(CYT-C)
Not significant (0.2)
Table 5 3 :  Sum m ary o f  the p-value results for the 18 months old group
The 18 months group is particularly interesting as pathways may change significantly 
due to old age
5.2.4 The 24 month group: pharmacological inhibition of PI3-kinase and ERK signaling 
pathway, and regulation o f survival induced by NGF or A-NGF pre-treatment in vivo 
At 24 months post-treatment, NGF has a small, but non-significant, effect on neuron 
survival in vitro. Equally, inhibiting both pathways has similar effects in the NGF and 
CYT-C in vivo pre-treated groups. A-NGF in vivo pre-treatment significantly decrease 
neuronal survival compared to control (p < 0.05) and both, PI3-K and ERK., inhibitor 
significantly reduce neuronal survival in vitro when neurons have been pre-treated with 
A-NGF in vivo (p < 0.05). Furthermore there is significant decrease in neuronal survival 
between PI3-K and ERK inhibition in vitro of neurons pre-treated in vivo with A-NGF 
compared to CYT-C (p < 0.05)
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The NGF and the CYT-C pre-treatment in vivo results in general confirm the 
interpretation of the 18m data, namely that most of the vulnerable neurons in the SCG 
have been lost by 18m, leaving a residue of'super-survivors’.
The 24 month group results from SCG pre-treated in vivo with NGF show similar 
effects of inhibiting both pathways with similar lt (see figure 5.8), although t to t+1 is 
different, with LY longer than UO which may account for the significant difference 
between the 2 treatments (p < 0.05). Cultures treated with LY or UO are significantly 
different from the untreated group (both p < 0.01).
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Figure 5.8: In vitro survival of the 24 months old group SCG neurons from animals pre-treated in vivo at 3-7 
weeks old with NGF (diamond, black solid line); pre-treated in vivo with NGF and treated in vitro with 
LY294002 a PI3-K inhibitor (square, grey solid line); pre-treated in vivo with NGF and treated in vitro with 
U0126 an Erk inhibitor (white triangle, dotted line).
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In figure 5.9 results show that inhibition o f  the two pathways have similar effects on lt 
with some difference in the t to t+1 (p < 0.01). Inhibition with LY or UO is significantly 
different from the untreated group (both, p <  0.01).
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Figure 5.9: In vitro survival of the 24 months old group SCG neurons from animals pre-treated in vivo at 3-7 
weeks old with anti-NGF (diamond, black solid line); pre-treated in vivo with anti-NGF and treated in vitro 
with LY294002 a PI3-K inhibitor (square, grey solid line); pre-treated in vivo with anti-NGF and treated in 
vitro with (J0126 an Erk inhibitor (white triangle, dotted line).
In figure 5.10 SCG neurons have been pre-treated in vivo with CYT-C. The results 
show that the results o f  in vitro inhibition o f  both survival pathways are similar with no 
significant difference between them. The treated groups are significantly different from 
the untreated group (both p < 0.01).
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Figure 5.10: In vitro survival of the 24 months old group SCG neurons from animals pre-treated in vivo at 3-7 
weeks old with CYT-C (diamond, black solid line); pre-treated in vivo with CYT-C and treated in vitro with 
LY294002 a P L 3-K  inhibitor (square, grey solid line); pre-treated in vivo with CYT-C and treated in vitro with 
U0126 an Erk inhibitor (white triangle, dotted line).
Table 5.4 show the p-values for the 24 months group; from the exact values results there 
is no significant difference in the UO pathways o f  both pre-treatment in vivo compared 
to the control, while there is significance between the two pre-treatment in vivo (p < 
0.01). The LY pathways results show significance between all pre-treatment in vivo (p 
< 0.01).
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P-VALUES 
24 M ONTHS GROUP
NGF A-NGF CYT-C
UNTREATEDvs.LY294002 0.00004 0.0002 0.000006
UNTREATED vs.U0126 0.00003 0.0006 0.00002
LY294002 vs. U 0126 0.02 0.007 Not significant 
(0.07)
L Y294002(N GF) vs. 
LY294002(CYT-C)
0.001
LY294002 (NGF) vs. 
LY294002 (A-NGF)
0.004
LY294002 (A-NGF) vs. 
LY294002 (CYT-C)
0.0005
U0126 (NGF) vs. U 0126 
(CYT-C)
Not significant (0.7)
U0126 (NGF) vs. U0126 
(A-NGF)
0.007
U0126 (A-NGF) vs. U 0126 
(CYT-C)
Not signi icant (0.2)
Table 5.4: Sum m ary o f  the p-value results for the 24 months old group
5.2.5 The late treatment group pharmacological inhibition of PI3-Kinase and ERK 
sipnalinp pathway, and regulation of survival induced by NGF pre-treatment in vivo 
The late treatment group shows a significant decrease in survival following NGF pre­
treatment in vivo compared to CYT-C (p < 0.05). PI3-K and ERK inhibitors seems to
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affect significantly both NGF and CYT-C in vivo pre-treated neurons (p < 0.05); but 
while neurons pre-treated in vivo with NGF tend to be affected by both inhibitors 
equally in vitro, control neurons are principally affected by ERK inhibition (p < 0.05). 
The late treatment group pre-treated in vivo with NGF (see figure 5.11) when treated 
with survival pathways inhibitor seems to show a significant decrease in lt (for both PI3- 
K and ERK inhibition p < 0.01). There is no significant difference between the two 
inhibitory survival pathways.
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Figure 5.11: In vitro survival o f the late treatment group SCG neurons from animals pre-treated in vivo at 3 
months old with NGF (diamond, black solid line); pre-treated in vivo with NGF and treated in vitro with 
LY294002 a PI3-K inhibitor (square, grey solid line); pre-treated in vivo with NGF and treated in vitro with 
U0126 an Erk inhibitor (white triangle, dotted line).
Neurons pre-treated in vivo with CYT-C are significantly different from those where 
one of the two survival pathways had been inhibited in vitro (both p < 0.01). See figure
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5.12. The difference between NGF and CYT-C pre-treatment in vivo is that the ERK 
inhibition is significantly more effective than PI3-K inhibition (p < 0.05) when pre­
treated in vivo w ith CYT-C; while the NGF pre-treatment in vivo significantly affect 
both, ERK and PI3-K inhibition (p < 0.05 and p < 0.01 respectively).
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Figure 5.12: In vitro survival o f the late treatment group SCG neurons from animals pre-treated in vivo at 3 
months old with CYT-C (triangle, black solid line); pre-treated in vivo with CYT-C and treated in vitro with 
LY294002 a PI3-K inhibitor (square, grey solid line); pre-treated in vivo with CYT-C and treated in vitro with 
U0126 an Erk inhibitor (white triangle, dotted line).
Table 5.5 sum m arises the level o f  significance resulted from inhibition o f  either ERK or 
PI3-K pathway on the late treatm ent group o f  neurons.
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p-VALUES
LATE TREATMENT GROUP
NGF CYT-C
UNTREATED vs. LY294002 0.0009 0.0000008
UNTREATED vs. U0126 0.001 0.000004
LY294002 vs. U0126 Not significant (0.06) 0.01
LY294002 (NGF) vs. LY294002 
(CYT-C)
0.0001
U0126 (NGF) vs.U0126 (CYT-C) 0.0212
NGF vs. CYT-C 0.0002
Table 5.5: Sum m ary o f  the p-value results for the late treatm ent group
5.2.6 A cross ages pharm acological inhibition o f  PI3-Kinase and ERK  signaling 
pathway, and regulation o f  the survival induced by N G F or A-NGF pre-treatm ent in 
vivo
Results o f  pharm acological inhibition o f  PI3-K  (LY294002), on SCG neurons, pre­
treated w ith  N G F is show n in  figure 5.13. There is significant differences between 
groups (p <  0.05) the 18 m onths group has the low est lt, w ith the exception o f  the 8 
m onths group during phase one. The acute group seem s to  be the one less affected by 
the pharm acological inhibition, excluding the 24 m onths group in phase three.
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SC G  NEURONS PRE-TREATED IN VIVO WITH NGF AND TREATED IN
VITRO WITH LY294002
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Figure 5.13: In vitro survival across ages o f SCG neurons from animals pre-treated in vivo at 3-7 weeks old 
with NGF and treated in vitro with LY294002 a PI3-K inhibitor; acute group (black diamond); 8 months old 
group (grey square); 18 months old group (white triangle); 24 months old group (black dotted line).
Figure 5.14 shows the effect o f  the ERK inhibitor, U 0126, in vitro when neurons have 
been pre-treated in vivo with NGF. There is significant difference between groups (p < 
0.01) even though ERK  inhibitor seems to have a reverse effect compared to PI3-K 
inhibitor. The acute group seems to be the one m ost negatively affected while the 8 
months is interm ediate. Eighteen months seems to be affected negatively only during 
phase three.
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Figure 5.14: In vitro survival across ages of SCG neurons from animals pre-treated in vivo at 3-7 weeks old 
with NGF and treated in vitro with U 0126  an ERK inhibitor; acute group (black diamond); 8 months old 
group (grey square); 18 months old group (white triangle); 24 months old group (black dotted line).
Figure 5.15 shows results o f  neurons treated in vitro with LY294002 and pre-treated in 
vivo w ith CYT-C. There is significant difference between groups (p < 0 .0 1 ) and results 
show behaviour sim ilar to N GF pre-treatment with the exception that the effect is more 
drastic. PI3-K  inhibition affects mainly the 8 months group as for the NGF pre-treated 
groups but the negative effect continues in phase 2.
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Figure 5.15: In vitro survival across ages of SCG neurons from animals pre-treated in vivo at 3-7 weeks old 
with CYT-C and treated in vitro with LY294002 a P13-K inhibitor; acute group (black diamond); 8 months 
old group (grey square); 18 months old group (white triangle); 24 months old group (black dotted line).
Figure 5.16 shows results o f neurons pre-treated in vivo with CYT-C and in vitro with 
ERK inhibitor. There is significant difference between groups (p < 0.01), and, as 
resulted from NGF pre-treated neurons, the ERK inhibition causes a reverse effect 
compared to PI3-K inhibition. The acute group is negatively affected throughout each 
phase.
Table 5.6 shows the ANOVA exact p-value results comparing groups between in vivo 
pre-treatment and in vitro treatment.
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SCG  NEURONS PRE-TREATED IN VIVO WITH CYT-C AND TREATED
IN VITRO WITH U0126
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Figure 5.16: In vitro survival across ages o f SCG neurons from animals pre-treated in vivo at 3-7 weeks old 
with CYT-C and treated in vitro with U 0126  an ERK inhibitor; acute group (black diamond); 8 months old 
group (grey square); 18 months old group (white triangle); 24 months old group (black dotted line).
P-VALUE 
ACROSS AGES
NGF CYT-C
LY294002 0.02 0.00008
U0126 0.005 0.004
Table 5.6: Summary o f the p-value results across ages
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5,2.7 In vitro p-Akt and GSK-3B upregulation following ‘early’ and ‘late’ pre-treatment
in vivo
In vitro phospho-Akt regulation: p-Akt upregulation following early pre-treatment in 
vivo of 24 months old SCG neurons (figure 5.17). There is no significant difference 
between early pre-treatments in vivo.
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Figure 5.17: Phospho-A kt regulation o f  24 months old group o f  SCG neurons from animals pre-treated in vivo 
at 3-7 w eeks old w ith N G F, A -NG F or CYT-C (control); results on immunostained sections o f SCG.
Results for the 24 month group are consistent with the results of chapter 4 and previous 
results in this chapter, showing that vulnerable neurons have died by this age and we are 
not expecting any significant difference between in vivo pre-treatments.
Figure 5.18 shows that NGF late pre-treatment in vivo down regulates p-Akt. There is 
significant difference between grey values of neurons pre-treated with NGF compared 
with the control (p < 0.05).
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Figure 5.18: Phospho-A kt regulation o f  the late treatm ent group of SCG neurons from animals pre-treated in 
vivo at 3 months old w ith N G F or CYT-C (control); results on immunostained sections o f SCG.
In vitro GSK-3p regulation:
In the 24 months group GSK-3p immunoreactivity there is no significance when it is 
down-regulated as a consequence o f pre-treatment with NGF, compared with CytC (see 
figure 5.19). There are no significant differences in GSK-3b immunoreactivity between 
the anti-NGF and CYT-C or between the NGF and anti-NGF pre-treated groups. This 
result is expected because it indicates a that vulnerable neurons have already died, by 18 
months according to previous data, and there is no significant effect of NGF pre­
treatment on SCG neurons.
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Figure 5.19: GSK-3[J regulation of the 24 months group of SCG neurons from animals pre-treated in vivo at 3- 
7 weeks old with NGF, A-NGF or CYT-C (control). Measurements of grey values obtained from MAP1B 
immunostaining with BUGS.
In the late treatment group GSK-3p is significantly down regulated as an effect of NGF 
treatment, see figure 5.20 (p < 0.05). These results show comparable results with 
previous survival pathways experiments, where the late treatment group showed 
significant decrease in survival following NGF pre-treatment in vivo.
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Figure 5.20: GSK-3P regulation of the late treatment group of SCG neurons from animals pre-treated in vivo 
at 3 months old with NGF or CYT-C (control). Measurements of grey values obtained from MAPIB 
immunostaining with BUGS.
Table 5.7 shows a summery of the results of section 5.7 in this chapter, comparing NGF 
in vivo pre-treatment to control, as well as 24 months control to late treatment control.
P-VALUE 
P-Akt and GSK-30
p-Akt GSK-3P
24 m Not significant Not significant
Late treatment P < 0.05 P < 0.05
24 m vs. late treatment Not significant Not significant
Table 5.7: Summery of cell grey value significance results of p-Akt and GSK-3P in 24 m and late treatment 
neurons.
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53 Discussion
Extracellular stimuli, such as NGF, are transmitted intracellularly by signaling cascades 
that involve the interaction o f macromolecules and the generation o f second messenger 
molecules that pass signals between the origin and the target o f the signal. The principal 
pathways involved in survival o f sympathetic and other neurons are described in the 
Introduction, but to summarise, one class of second messenger is generated by 
phosphorylation o f PI3-K , while ERK/MAP-kinase are the principal mediators of a 
second survival pathway.
My hypothesis is that pre-treatment during early postnatal life with NGF or A-NGF 
would permanently affect survival pathways of SCG neurons in later life by 
upregulating one or both o f these pathways. Mutually the general introduction and the 
chapter introduction describe the hypothesis that the pre-treatment in vivo is affecting 
both survival pathway causing differential results.
If this hypothesis is proved, can altered availability of NGF in later (adult) life have 
similar effects?
The questions are very similar to those raised in chapter IV: Are we looking at a 
maturational phenomenon, or at a lifetime neuroprotective programme? And, is early 
life4re-setting’ o f neuron survival equally effective with different pre-treatments, and do 
the effects change with age?
Inhibition o f PI3-kinase and ERK survival pathways in vitro had very different effects 
in the different age and treatment groups (acute, 8m, 18m, 24m and late treatment). As 
described in Chap. IV, effects of NGF in vivo pre-treatment resulted in a marked 
enhancement o f neuron survival in vitro in the acute and 8m groups, with smaller 
effects at 18m and no effect at 24m. I attributed the age-related decline in the effect of
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NGF to the death o f vulnerable neurons around the 18m stage (Gatzinsky et al. 2004). 
The results o f  inhibition o f PI3-kinase and ERK appear to demonstrate that long-term 
NGF-induced upregulation o f PI3-kinase is the principal mechanism underlying the 
enhanced survival that I have shown. This effect is most clearly demonstrated in the 
acute and 8m groups and has largely disappeared by 18m and 24m. According to the 
results in this chapter Erk inhibitor seems to affect neurons differently compared to PI3- 
K inhibitor. ERK seems to kill neurons quicker (shorter survival time t to t+1) 
suggesting not only that PI3-K and ERK have different developmental timetables (PI3- 
K acting more on 8, 18, and 24 months; ERK acting on the acute and late treatment 
mainly), but that they might act on different populations of neurons. A preliminary 
experiment was carried out to see if adding both inhibitors together had an additive 
effect, this resulted in a total death before the counting time, suggesting that further 
more articulated research needs to be done in order to answer this question.
Acute group: in the acute group, the determinant phase, in showing neurons’ responses 
to pathway inhibition, is phase one (in fact in vitro survival pathways inhibition act 
within few hours o f application). In this age-group, when neurons are pre-treated with 
CYT-C, ERK1/2 inhibition (achieved by application of U0126) has a major effect on 
cell survival, particularly during this early phase of the cultures compared to PI3-K 
inhibition (achieved by application of LY294002). Furthermore, when neurons are pre- 
treated with NGF in vivo, PI3-K inhibition is ineffective; it is only in phase 1 that 
substantial reduction in neuron survival shows that PI3-K inhibition becomes effective, 
again. ERK inhibition remains overall significantly more effective than PI3-K inhibition 
and its effects are not altered by the NGF pre-treatment regime. Orike et a l  (2001) 
shows that LY is effective in inhibiting in vitro survival of SCG neurons at 12 weeks,
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therefore my results from studies o f neurons at 7wks following CYT-C in vivo pre­
treatment is evidence that PI3-K is upregulated during the postnatal period, between 7 
and 12 weeks o f age. Furthermore Crowder and Freeman (1998) showed that perinatal 
neurons are responsive to PI3-K in the presence of NGF, this may be due to the fact that 
the half life o f  the signaling NGF-Phospho-TrkA complex in adult sympathetic neurons 
is about 2 days, indicating that in my experiments even in the early age, the effect of 
NGF pre-treatment on subsequent survival in vitrois a ‘conditioning’ response to NGF 
and not just an ongoing direct effect of the NGF treatment (Tsui-Pierchala and Ginty, 
1999).
Comparison o f the LY and UO curves shows that both have similar curve in NGF and 
CYT-C graphs although survival level is different, statistical analysis shows some 
difference between LY for NGF and LY for CYT-C, indicating that NGF pre-treatment 
in vivo upregulates the PI3-K survival pathway but not the ERK 1/2 survival pathway in 
the acute group. This suggests either a survival threshold below which neuron survival 
is controlled by ERK and above which is controlled by PI3-K, or alternatively, different 
subpopulations o f neurons may be preferentially responsive to the two pathways.
8 months group: particularly interesting is the switch in the dependence of the 8 months 
group on PI3-K. In contrast to the acute group, the control (Cyt-C) group now shows 
PI3-K as the major survival pathway. This is in agreement with Orike et al. (2001) 
suggesting that there is a maturational increase in the role of PI3-K in neuron survival in 
the absence o f NGF.
NGF pre-treatment in vivo markedly enhances survival in vitro (in agreement with the 
results o f chapter IV). Both LY and UO seem to inhibit survival in NGF in vivo pre- 
treated neurons to similar extents. However, LY inhibition of PI3-K depresses survival
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significantly less in the NGF pre-treated group compared to CYT-C, while the effect of 
UO is unchanged in the two groups. Again this suggests that the rescue is the result of 
an intrinsic upregulation o f PI3-K signaling since it occurs in the absence of ongoing 
NGF signaling. Furthermore at this particular age UO inhibition seems to be unaffected 
by NGF pre-treatment in vivo.
18 months group: 16 months after termination o f treatment neurons are old and seem to 
show both pathways, PI3-K and ERK1/2, to be equally inhibited with PI3-K creating 
more vulnerability for neurons when inhibited in phase one and two; despite the 
rescuing effect o f NGF pre-treatment. These results suggest the idea that at this stage 
there is an ‘attrition mechanism’, on one side there is the ageing effect and on the other 
side the intrinsic elevation o f PI3-K which keeps the NGF responsive neurons alive has 
been reduced to a point where LY and UO effects are no longer different. In turn, this 
suggests that the vulnerable neurons are now close to their survival threshold, in fact 
according to Gatzinsky et a l  (2004) by 18 months many of the sympathetic neurons of 
the rat SCG which are vulnerable to ageing have already died.
The 24 months group: this shows a similar effect on survival when either of the 
pathways are inhibited. With age both pathways react similarly to inhibition therefore 
we might be looking at an additive effect of age and survival pathway inhibition. As 
expected, the responses o f  this group are closely similar to the 18 months group, there is 
no rescue effect o f NGF, or depressive effect of A-NGF (as seen in chapter IV) and no 
difference between the inhibitory effects o f LY and UO. Once again, this indicates that 
those neurons lifted above a ‘survival threshold’ by NGF pre-treatment in early life 
have already been lost.
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Late treatment group: results are similar to those found in chapter IV; these latest results 
show that inhibitors in the late treatment group have a similar effect to the acute group 
(of this chapter) as far as the inhibitory pathways are concerned but an opposite effect 
with the NGF in vivo pre-treatment. In fact NGF in vivo pre-treatment is significantly 
decreasing survival (p < 0.05) possibly due to a dependence effect. Neurons treated at 3 
months of age, after termination o f development, may be dependent on extra exogenous 
NGF supplied by in vivo pre-treatment and possibly neurons become more vulnerable 
to external insults, which in this case are the pathway inhibitors. Late pre-treatment in 
vivo with NGF had significant effect on ERK survival compared with CYT-C. While in 
neurons pre-treated in vivo with CYT-C, ERK inhibition was principally affecting 
survival, neurons pre-treated in vivo with NGF seems to be equally affected by ERK 
inhibition and PI3-K inhibition. We may assume that we are intervening in a 
maturational programme with a limited time window of sensitivity, which acts through 
a long-lasting intrinsic upregulation of PI3-K activity.
It is also interesting to observe the effect of inhibition across ages as there seems to be a 
different effect according to the age stage considered. Neurons pre-treated in vivo with 
NGF show marked inhibition o f survival in vitro with LY at 8 and 18 months, and a 
switching o f survival pathways for the acute group and late treatment (i.e. UO inhibition 
affecting survival significantly more compared to LY inhibition); while UO is most 
effective on the acute group. For all groups NGF pre-treatment in vivo increased 
survival.
These data suggest, as I have argued previously, that PI3-K becomes the principal 
survival pathway in adult sympathetic neurons, while ERK 1/2 is more important during 
earlier stages o f development. In addition, altering availability of NGF during early
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postnatal life appears to enhance survival o f adult sympathetic neurons through an 
intrinsic upregulation o f PI3-kinase activity which can be maintained in the adult 
neuron in the absence o f NGF. The significance o f this observation will be discussed 
below in chapter VI.
PI3-K is a key enzyme for regulating neuronal cell survival; the downstream signalling 
partner o f PI3-K is Akt. However, there is still some debate about the role of Akt 
following NGF stimulations. Yano et a l  (1998) and Virdee et a l  (1999) reported that 
Akt can promote survival independently o f PI3-K activity, and this may be driven by 
anti-apoptotic second messengers such as calcium or cAMP (Filippa et a l , 1999). 
Philpott et a l  (1997) reports questioned the role o f Akt in NGF mediated survival of 
SCG neurons. My results shows that PI3-K mediates survival of SCG neurons in 
response to NGF and some preliminary results (see chapter VI) show that Akt is 
upregulated following in vivo NGF pre-treatment. We therefore deduce that both Akt 
and PI3-K are upregulated following NGF in vivo pre-treatment.
My results show that for both the 24 months group and the late treatment group there is 
no significant difference in the p-Akt regulation.
There is a possibility that the survival pathway may change according to the age of the 
neurons, in fact my signalling pathway experiments showed that the two survival 
pathways (PI3-K and ERK 1/2) shifted in relative importance according to the age group 
of the neurons; in addition to the effect of cell loss due to ageing.
Neurotrophins were originally identified as survival factors only, but recent studies 
reveals how th ey elicit many biological effects, including proliferation, synaptic 
modulation, and axonal pathfinding; specifically the nature of the signaling cascade and
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the biological responses that is elicited are specified by the ligand, the temporal pattern 
and the special location of the stimulation. Hetman and Xia review (2000) extensively 
how both ERK and PI3-K can mediate anti-apoptotic signaling of neurotrophins; 
suggesting that in most cases of trophic deprivation PI3-K is the main player, whereas 
ERK dominates as the major neuroprotective mechanism in damaged cells.
The strength o f this experiment is to examine the relation of a treatment effect applied 
in vivo (i.e. manipulation o f NGF availability) to the inhibition of specific survival 
pathways in vitro; therefore we look at an effect in the animal and we observe the 
changes at different developmental stages in vivo but we consider specific pathways in 
vitro.
According to Franke et al. (1997) although multiple responses are not probably 
explained by the action o f a single downstream target, the signaling pathway from PI3- 
K to Akt may mediate some cellular responses of PI3-K (Burgering and Coffer, 1995; 
Cross et al., 1995; Franke et al., 1995; Kohn et al., 1995) such as protection from 
apoptosis (Dudek et al., 1997; Kauffrnann-Zeh et al., 1997; Khwaja et al., 1997; Kulik 
e ta l ,  1997).
Downstream of PI3-K there are both Akt and GSK-3p, both produced some interesting 
preliminary results in this study. Results form the 24 months group showed, as 
expected, no significant difference when pre-treated in vivo with NGF, according 
previous data, the vulnerable neurons have probably already died by this age and we 
are dealing with a subset o f ‘super neurons’ that are masking the effect of NGF. 
Particularly interesting are the results for the late treatment group, where the effect of 
NGF pre-treatment in vivo significantly downregulates p-Akt and GSK-3p. These 
results show that PI3-K provoked a ‘dependence effect’ where neurons that have been
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receiving NGF in vivo after termination of development die once exogenous NGF 
supply stops. GSK-3P resuction in phosphorylayion causes a decrease in apoptosis, 
possibly as an effect o f the secondary survival pathway, ERK. Dozza et al. (2004) 
showed how both PI3-K and ERK are causing down regulation of GSK-3p in 
neuroblastoma cells, it can be hypothesized that a similar mechanisms is affecting SCG 
neurons. Bhat et al. (2000) studied the effect of NGF withdrawal from differentiated 
PC 12 cells which lead to phosphorylation at Y216, a GSK-3p regulatory site, leading to 
GSK-3p activity and cell death. Crowder and Freeman (2000) pointed out how in 
sympathetic neurons PI3-K and Akt are important mediators in cell survival and how 
GSK-3p is inhibited upon phosphorylation by Akt. According to Wagner et al. (1996) 
and Lovestone et al. (1994), GSK-3P in addition to a role in apoptosis it 
hyperphosphorylates the microtubule-associated protein t,  a mechanism implicated in 
paired helical filament formation in Alzheimer’s disease. The link with Alzheimer’s 
disease rises interest for future research.
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CHAPTER VI 
GENERAL DISCUSSION
6.1 Brief discussion of results
This thesis shows how pre-treatment in vivo with NGF at a specific point during 
development affects SCG neurons (see section 6.2). In summary, results show that 
following pre-treatment in vivo there is an effect on neuronal number, with differential 
effect on different subpopulations of neurons (MCA versus iris projecting neurons). MCA 
projecting neurons (a vulnerable subpopulation of SCG neurons) increase in number (acute 
group), growth and innervation of specific target tissues following NGF pre-treatment in 
vivo, showing a maintained plasticity after termination of development and therefore a 
potential target site for future therapeutics.
NGF pre-treatment in vivo also increases neuronal survival time throughout life in vitro, 
showing that the limited supply of NGF, in real life, primes neurons to a reduced potential. 
The results on survival also show a difference in the mode of action between the two major 
survival pathways (PI3-K and ERK), with PI3-K being the predominant in adult life and 
ERK acting mainly in early life. This shows a double survival mechanism which is both 
plastic and capable of shifting predominance according to factors such as NGF stimuli 
and/or ageing.
Furthermore if the NGF pre-treatment in vivo is applied after termination of development, 
neurons show plasticity by developing an ‘addiction’/dependance to NGF; pre-treatment 
termination results in death of the neurons.
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Preliminary results show upregulation of Akt which is downstream of PI3-K (see figure 5 . 1  
in chapter V), and is activated in NGF-dependent survival of SCG neurons (Pierchala et al 
2004). Biological consequences o f Akt activation are survival, increase in cell number and 
growth, which are all characteristics relevant to cancer-cell growth. In fact Hanahan and 
Weinberg (2000) observations of human cancers and animal models indicate that tumour 
development proceeds via a process formally analogous to Darwinian evolution, in which a 
succession of genetic changes, each conferring one or another type of growth advantage, 
leads to the progressive conversion of normal human or animal cells into cancer cells. 
Further preliminary results show reduction of the GSK-3p phosphorylation (see figure 5 . 1  
in chapter V), which inhibits and is determinant for cytoskeletal rearrangement, glucose 
metabolism and cell survival; regulation of GSK-3p has been widely studied in relation to 
Alzheimer’s disease. Alzheimer’s disease is associated, among other histological changes 
in the brain, with an intracellular deposition of neurofibrillary tangles that are composed of 
the microtubule-associated protein Tau; GSK-3(3 phosphorylates Tau and is therefore 
implicated in the progression of Alzheimer’s disease (Teter and Ashford, 2002).
6.2 Detailed discussion
6.2.1 Chapter III: neuron numbers and growth
Results from chapter III showed an increase in SCG neuronal number (ex vivo) due to NGF 
pre-treatment in vivo, as opposed to control where neurons which have not been pre-treated 
in vivo with NGF showed a decrease in neuronal number with age ex vivo (significant for 
the MCA-projecting neurons and less significant for the iris-projecting neurons). Increased 
survival in SCG neurons by NGF pre-treatment in vivo is thought to have been achieved by 
rescuing neurons that would otherwise have undergone atrophy due to loss of axon 
branches and dendrites and neuronal death would have caused neighbouring neurons to die
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too (Thrasivoulou and Cowen, 1995; Andrews et al., 1996). Understanding the effect of 
altered neurotrophin on the ageing of the nervous system will have important implications 
in understanding age-related neurodegenerative diseases. According to Kudwa et al. 
(2002), accumulation of exogenous NGF decreases with age in target tissues of SCG 
neurons following intracerebroventricular infusions of NGF.
A further interesting result is the plasticity of young MCA-projecting neurons compared to 
iris-projecting neurons: results showed that MCA-projecting neurons are very responsive to 
the availability of NGF, and with NGF antibodies there was a significant decrease in 
survival of MCA-projecting neurons in vitro.
Additionally, growth o f axons and dendrites has been shown as a consequence of 
exogenous NGF supply on NGF neurons both in vivo and in vitro (Gavazzi and Cowen, 
1993; Andrews and Cowen, 1994; Thrasivoulou and Cowen, 1995; Isaacson and Crutcher, 
1998; Orike et al., 2001). Previous studies have not investigated the permanent effect of 
NGF on SCG neurons across ages, while this research examined such effect at several age 
points and it is important to remember that there are high levels of NGF only during the 
treatment but it returns to normal levels shortly after termination of the treatment. Chapter 
III results showed an increase in neurite numbers and lengths following NGF pre-treatment 
in vivo. It is clear in this case that NGF was stimulating growth of neurons in early age, but 
not at 24 months when the effect of NGF was not stimulating growth anymore, while anti- 
NGF was clearly decreasing growth. These results show plasticity in young age which 
disappear some time before 18 months o f age. Further results of chapter III show an 
increase of innervation in specific target tissues, following pre-treatment in vivo with NGF. 
MCA target tissue shows an increased innervation compared to control, in accordance with 
previous results showing an increased number in MCA-projecting neurons. This supports
the idea that the limited amount of NGF available in early development causes MCA- 
projecting neurons to be more plastic compared to iris-projecting ones, in order to survive. 
Iris neurons may be already maximally stimulated and therefore have no further capacity 
for plasticity. Kuchel et al. (1997) showed that MCA-projecting neurons are more 
vulnerable to atrophy specifically with age causing a decrease of innervation of the specific 
target tissue.
The late treatment group showed a decrease in innervation which also reflects results in 
chapter IV, where an addiction effect is hypothesized: a large availability of NGF supplied 
by the pre-treatment in vivo and a sudden lack of extra NGF caused neurons to have an 
increased vulnerability and die and therefore a decreased innervation of the target tissues.
As we now understand the extent of the effect of in vivo pre-treatment with NGF, future 
research should investigate the mode of action (maybe) by looking at receptors.
Miller et al. (1991, 1994), Wyatt and Davies (1995) studied NGF receptors (trkA, p75) and 
specifically trkA and showed that trkA receptors of SCG neurons of rats and mice before or 
after birth do not respond to NGF treatment. However, according to Horton et al. (1997), 
p75 receptors do increase after NGF treatment. More specifically, the ratio of trkA and p75 
determines the SCG response to exogenous NGF. In this research, observing the 
differential effect that pre-treatment with NGF in vivo has on survival compared to growth 
of SCG neurons, it would be interesting, for future research, to investigate how exactly 
TrkA and p75 are regulated in response to NGF pre-treatment in vivo.
6.2.2 Chapter IV: survival and mortality in vitro and external factors 
Orike et a l (2001) showed how 12 weeks old SCG neurons in culture survive in the 
absence of neurotrophins, while retaining their growth dependency on these neurotrophins. 
Furthermore if NGF is administered in vivo, as it is done in this PhD research, rather than
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in vitro (Orike et al.,2001; Price et al., 2005), and at a crucial time before termination of 
development, there is a permanent upregulation of PI3-K/Akt pathway which increases 
survival and is detected up to 15 months after termination of treatment.
Results in chapter IV showed that the effect of NGF pre-treatment in vivo on neuronal 
survival in vitro when, at the time of culturing, there were no abnormal levels of NGF. 
Chapter IV results reported a significant increase in survival and a decrease in mortality 
which were not only a result of the acute group but were clearly present in the 8 months 
group as well. More precisely, the acute group results delayed the onset of cell death in 
vitro causing also a change in the survival pattern, while the 8 months group, despite the 
NGF pre-treatment in vivo, caused an increased number of neurons to survive, but for a 
shorter time. Possibly the treatment was causing precocious ageing of the neurons: results 
from the mortality assays revealed an unexpectedly higher vulnerability of NGF pre-treated 
neurons compared to controls. Early ageing in the 8 months group was possibly due to a 
variation of the activity of the tumour suppressor p53 which can upset the balance of 
neuronal turnover by affecting the rate of cell proliferation. Medrano and Scrable (2005) 
showed in genetically engineered mice in which p53 activity was increased, that premature 
loss of neurogenic capacity is linked to accelerate organismal ageing.
Results from chapter IV showed that while at 18 months NGF in vivo pre-treated neurons 
tended to retain the positive effect of NGF and were affected negatively by anti-NGF, at 24 
months the effect of the pre-treatment in vivo was no longer distinguishable from the effect 
of ageing cells. At 24m neurons pre-treated with anti-NGF or NGF had either different 
survival mechanisms or their ‘survival threshold’ was set at a different level so that they 
were unaffected by pre-treatment.
169
The increased survival phenomenon appears to resemble the numerous examples of a 
retained memory, a kind of conditioning stimulus in neural, immune and other cells 
indicating a long term NGF effect (Dutton et aL, 1998; Kamimura and Murakami, 2005). 
Results from chapter IV, on neurons from the late treatment group, showed that if treatment 
is applied late, after termination of development, neurons were not primed, showing again 
that priming may be related to a long-term memory of the cells by resetting the survival 
pathway through treatment.
There is a developmental programme involving local differences in availability of 
neurotrophins which has 'knock-on* or pleiotropic effects on survivability in vitro, and 
perhaps in vivo. What is the purpose of this programme? Clearly, if it were only to regulate 
neuronal survival in adult life, selective pressure would ensure that all neurons were 
exposed to maximum levels of NGF. According to the results on subpopulations of chapter 
IV, iris neurons already survive maximally, while MCA neuron survival can still be 
boosted as a result of different levels of neurotrophins. Low levels of NGF are ‘adaptive’ 
for MCA-projecting neurons (related perhaps to the small size, relative simple axonal and 
dendritic arbors, Andrews et al., 1996) and the pleiotropy is that these adaptive feature 
become a hazard in ageing. These results are in accordance with findings by Gatzinsky et 
al. (2004), and therefore propose another link to the hypothesis that the capacity of NGF 
uptake in later life is linked to the age-related vulnerability of specific neurons.
NGF is not the only neurotrophin affecting survival of SCG neurons; therefore, the 
preliminary results o f chapter IV on the effect of external factors (insulin, IGF, BDNF and 
GDNF) on survival and mortality are particularly interesting. Insulin and IGF-1 are growth 
promoting peptides (LeRoith and Roberts, 1993); in the nervous system IGF-1 appears to 
regulate tissue growth, supporting differentiation of fatal neurons in culture, stimulating
170
protein synthesis and promoting neurite outgrowth (Recio-Pinto et al., 1984; Ishii and 
Recio-Pinto, 1987; Werner et al., 1989; 1994; Mozell and McMorris, 1991; Heidenreich, 
1993), while insulin regulates and restores IGF-1 levels in rats (Taylor et al., 1987).
Results from chapter IV showed that neurons which were pre-treated with NGF in vivo 
were significantly affected by in vitro addition of insulin or IGF-1, by increasing neuronal 
survival in controls and decreasing survival with NGF pre-treatment, suggesting there may 
be an optimal survival threshold which neurotrophic factors such as insulin and IGF-1 tend 
to re-establish when altered by NGF pre-treatment in vivo. Therefore it can be hypothesized 
that neurotrophic factors are the result of a homeostatic mechanism controlling survival 
(and perhaps growth) which prevents a synergistic effect of growth factors which could 
cause either too many neurons to survive (during development), or those neurons that do 
survive to grow too large (during adulthood) and hence force the neuron out of its ‘proper’ 
phenotypic shape. Kimpinski and Mearow (2001) showed that IGF-1 can elicit extensive 
neurite extension in adult sensory neurons and this can potentiate NGF-induced 
neuritogenesis.
According to Foukas et al. (2004) insulin has an important effect in NT signalling; insulin 
has been shown to stimulate PI3-K (Rondinone et al., 2000).
Therefore, while IGF-1 is related to Akt activity, insulin affects the PI3-K/Akt signaling 
pathway through phosphorylation of the insulin receptor substrate-1 (IRS-1), (Foukas et al.,
2004).
6.2.3 Chapter V: neuronal survival pathways in vitro
Results from chapter V revealed some interesting information on the main survival 
pathways in SCG neurons: PI3-K/Akt which were recently extensively reviewed by
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Sofroniew et al. (2001) and Vivanco and Sawyers (2002) and the ERK pathway recently 
reviewed by Segal (2003). Altering availability of NGF during early postnatal life appeared 
to enhance survival of adult sympathetic neurons through an intrinsic upregulation of PI3- 
kinase activity which was maintained in the adult neuron in the absence of NGF. In fact, 
PI3-K activates phosphatidylinositol (3, 4, 5) in a wide range of tumours which in turn 
activates Akt, triggering responses that drive tumour progression such as cell growth, 
proliferation, survival and mortality. Akt results are preliminary and may be used as base 
for future research possibly using Western blot to quantify the qualitative Akt results in this 
thesis.
It has never been reported before that survival signaling pathways (PI3-K and ERK) in 
SCG neurons, pre-treated with NGF in vivo before the end of development, work together, 
shifting importance with age: ERK being the major survival pathway before the end of 
development and PI3-K in adulthood and during ageing. As expected, late treatment (after 
termination of treatment) did not affect significantly PI3-K survival pathway (results form 
chapter V). What causes the neurons to die? It appears that at a certain stage in 
development, about the time that neuronal axons reach their targets, neurons begin to shift 
to an apoptotic state, and unless something happens, they die. This suggest that they receive 
a ‘signal’ that counteracts the apoptotic self-destruction programme, and that signal comes 
from trophic factors binding to trophic factor receptors in the neurons’ plasma membrane, 
activating various internal signaling pathways involving protein kinases.
Earlier studies showed ERK, as the main survival pathway regulating cell proliferation and 
survival (Xia et a l, 1995; Mazzoni et al., 1999). Nevertheless, in recent years new 
discoveries regarded PI3-K as an important regulator in mammalian cells (Hlobilkova et al.,
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2003, Pierchala et al., 2004). On the contrary, Lentzsch et al. (2004) reported that some 
survival pathway, including PI3-K/Akt and MAPK/ERK, are redundantly stimulated to 
independently promote proliferation and survival of multiple myeloma cells. The present 
research shows that both survival pathways might be working together to promote survival, 
shifting predominance with age, possibly due to a redundancy of survival pathways.
Results from chapter V showed interesting effects of ‘NGF dependence’ in the late 
treatment group, where neurons pre-treated in vivo with NGF tended to be negatively 
affected by lack of NGF in culture and therefore showed a decreased Akt activity. This is 
possibly due to the fact that adult neurons supplied with large amounts of NGF might be 
developing dependence to NGF. Eichler et al. (1992) described the dependence between 
intracellular calcium and NGF in dorsal root ganglion (DRG) in culture, explaining that a 
variation in calcium channels activation may affect survival in adult neurons.
Results from chapter V showed a decreased activation of GSK-3(3 following pre-treatment 
in vivo with NGF in all groups (young and ageing neurons as well as in the late treatment 
group). One downstream target of Akt is GSK-3(3 which, among other functions, associates 
with presenilin and phosphorylates the microtubule-associated protein tau, implicating 
GSK-3 in the progression of Alzheimer’s disease (Harwood, 2001).
Active Akt phosphorylates and inactivates GSK-3p as well as mediating cell survival. 
According to Bhat et al. (2000) GSK-3|3 increases in neurons susceptible to degeneration 
but its pathway exerts a pro-apoptotic effect independently in response to NGF deprivation. 
GSK-3p is also a downstream target of insulin stimulation and regulates glycogen synthase, 
the protein translation initiation factor elF2B, and the transcription factor C/EBPa (Cohen,
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1999). GSK-3p is involved in the Wnt signaling pathway, influencing pattern formation 
during embryonic development and regulation of cell proliferation (Dale, 1998).
Cordes and Beuningen (2004) provided molecular insight into the importance of 
extracellular-matrix (ECM)-dependent cell survival; where they suggested a novel pathway 
that makes direct phosphorylation of GSK-3(3 by the integrin-linked kinase (ILK), showing 
that ILK, Akt and GSK-3p are involved in modulation of the cell cycle. Since integrin and 
growth factor receptors are colocalised at the source of integrin signalling, which are called 
focal adhesions, convergence and mutual modification between these networks are highly 
likely to occur. This crosstalk could result in differentiated regulative schemes of cellular 
functions such as cell growth and survival.
Therefore results in chapter V of down regulation of GSK-3p in all groups might be due to 
an upregulation of Akt (see also figure 5.1 chapter V). Differently in the late treatment 
group the decreased activation of GSK-3p could be hypothesized as an effect of ERK 
(Dozza et al., 2004) which acts in the same way as PI3-K in blocking GSK-3p and 
therefore increasing survival.
6.3 Future research and alternative treatments
The results of Ruit et a l (1990) showed that sympathetic ganglion cells remain dependant 
on NGF for survival and maintenance of dendritic geometry even in maturity and old age. 
According to my initial results, neurons are NGF independent but benefit from high level of 
NGF availability by changing their response during survival. It seems that NGF availability 
early in life results in more independency from NGF later; with the exception of neurons 
which have been pre-treated with NGF ‘later in life’ and develop dependence.
NGF might have caused intrinsic altered regulation not dependent on PI3-K receptors so 
that NGF acts on survival, through down regulation of PTEN.
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Ruit and Snider (1991) repeated a similar treatment in the 2-3 postnatal weeks showing a 
marked effect on survival, size and arborisation 6 months after completion of treatment, 
when number, size and branching of cells changed considerably in SCG neurons. Ruit and 
Snider (1991) suggest number, size and branching of cells remain malleable throughout 
postnatal life, and they also sustained the idea that primary dendrites, a fundamental 
determinant of organization within sympathetic ganglia, were permanently altered. A 
further hypothesis for future research is that NGF treatments might have influenced 
integrins, which affect survival and growth, interacting with laminin and also with PI3-K. 
According to my results, on 7 weeks old rats, no permanent alteration on neurites in vitro 
was visible yet. This might also be due to the difference in the injected quantities of 
neurotrophic factor and antibodies, which were ten times lower in my experiment compared 
to Ruit et al, the emerging idea was that NGF influences primary dendrites only during the 
critical development period, while in maturity NGF acts as ‘maintenance’ factor, but 
neurons lose the capacity to respond with wholesale rearrangements of dendritic 
architecture.
According to Orike et al (2001) SCG neurons acquire NGF-independent survival by week 
12, but they remain still dependent on neurotrophins for growth. On the other hand my 
results show survival independence already at week 7 of age with NGF treatment 
increasing both time as well as number of surviving cells, suggesting that NGF treated cells 
might have retained higher survivability.
The present research is a comprehensive investigation on the effect of NGF pre-treatment 
in vivo which raises numerous questions on potential future research which explores 
mechanisms of survival into details. For example PTEN, a major tumour suppressor
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protein, causes dephosphorylation of PIP3  (a second intracellular messenger produced by 
PI3-K) and therefore deactivation of PI3-K (Leslie and Downes, 2002). PTEN is one of the 
most common targets of mutation in human cancer; its cellular functions have been 
reported using different experimental model organisms; regulation of cell division, cell 
survival, apoptosis and cell migration in human and mouse cells, involvement in dauer 
formation in Caenorhabditis elegans, and regulation of cell size in Drosphila eye (Huang et 
a l , 1999).
The pre-treatment in vivo, used in this research, is not resulting in deactivation of PI3-K, as 
Akt resulted in being upregulated following the treatment in vivo; consequently, as an 
investigator should always raise questions for future research, the natural question for 
future studies is: how is the antagonistic effect of PTEN acting on PI3-K signaling?
Graff (2002) suggested that functional loss of PTEN and subsequent activation of the Akt 
pathway have been implicated in the progression of prostatic adenocarcinoma; the Akt 
pathway can suppress the apoptotic response, undermine cell cycle control and enhance 
production of key growth and survival factors.
Akt and Erk regulate caspase-mediated apoptosis in prostate cancer cells via p53 (Hu et a l,
2005); p53 is a proapoptotic pathway which is suppressed by activation of PI3-K, therefore 
future research might concentrate in understanding how p53 causes cells to arrest or die in 
case of DNA damage, hypoxia, oxidative stress, excessive mitogenic stimuli, or telomerase 
shortening (reviewed in Hahn and Weinberg, 2002). At the same time excess p53 activity 
causes ageing (Sharpless and DePinho, 2002) in response to increased metabolism, ROS 
and DNA damage.
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At the moment there are no studies linking autophagy and diet restriction to PI3-K 
activation. Autophagy, meaning ‘’self-eating’, is activated during gross developmental 
changes and times of nutrient deprivation and wanes with age, it is a key mechanisms in 
modulation of insulin signaling and caloric restriction, promoting longevity. Insulin, 
binding its receptor on the plasma membrane, activates PI3-K. Genetic interaction studies 
by Rusten et al. (2004) on Drosophila showed that PI3-K signaling represses programmed 
autophagy, and that there is a link between hormonal induction of autophagy and regulatory 
function of the PI3-K signaling pathway in vivo.
In order to target specific groups of cells precisely, a variation in treatment regimes may be 
appropriate as these may give more specific results: a change of regime of treatment where 
synthetic NGF instead of NGF 2.5 S Murine may be used. The synthetic NGF having a 
smaller molecular weight will be easily absorbed through the blood-brain barrier and 
therefore less likely to create inflammation.
Xie and Longo (2000) studied neurotrophic mimetic strategies. They identified specific 
neurotrophin protein domains likely to modulate receptor interaction, guiding synthesis of 
neurotrophin small-molecule peptidomimetics corresponding to individual domains and 
functioning via selected receptors to trigger neurotrophic-like signal transduction. They 
also suggested the possibility to design neurotrophin antagonists that would inhibit 
neurotrophin action in the context of neurotrophin-induced cell death, aberrant sprouting, 
and growth in general. Mahoney and Saltzman (1999) studied an alternative effective local 
delivery of NGF by implanting small polymer pellets that slowly release NGF; illustrating
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pharmacotectonics a drug-delivery system arranged spatially in tissues to create a 
concentration field which enhance the action of potent agents.
6.4 Summary
The main points summarizing the effect of NGF pre-treatment in vivo on SCG neurons 
across ages, as established in chapter III to V are as follows:
■ Increased number of neurons in the ganglia;
■ Vulnerable subpopulation of neurons increased in numbers;
■ Increased neurite growth both in early as well as late treatment;
■ Increased innervation in target tissues;
■ Increased survival time of single neurons and decreased mortality;
■ Constitutively activated survival pathways.
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APPENDIX
GLOSSARY
■ A-NGF: Anti NGF antibody;
■ BDNF: Brain derived neurotrophic factor;
■ CYT-C: Cytochrome-c used as a control for its similarity to NGF in structure and 
molecular weight;
■ GDNF: Glial derived neurotrophic factor;
■ GSK-3p: glycogen synthase kinase-3p;
■ IGF: Insulin-like growth factor;
■ MCA: Middle cerebral artery;
■ NGF: Nerve Growth Factor first discovered by Rita Levi-Montalicini;
■ PI3-K: phosphatidylinositol 3-kinase;
■ SCG: Superior cervical ganglia;
■ Terms from survival analysis for describing survival of cells in culture:
o Nt: Number of live cells;
o t to t+1: Total period in culture;
o dt: Number of dead cells;
o It: Cumulative proportion of surviving cells;
o qt: Specific mortality per unit time (period) in culture;
o pt: Period-specific survival (pt = 1- qt);
o ut: Mortality rate (per period);
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